UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a)
of the
Securities Exchange Act of 1934
Filed by the Registrant þ
Filed by a Party other than the Registrant ¨
Check the appropriate box:
|
¨
|
Preliminary Proxy Statement
|
|
¨
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
þ
|
Definitive Proxy Statement
|
|
¨
|
Definitive Additional Materials
|
|
¨
|
Soliciting Material Pursuant to §240.14a-12
|
IOVANCE BIOTHERAPEUTICS,
INC.
(Name of Registrant as Specified in Its Charter)
Payment of Filing Fee (check the appropriate box);
|
¨
|
Fee computed on table below per Exchange Act Rules 14a(i)(1) and 0-11.
|
|
(1)
|
Title of each class of securities to which transaction applies:
|
|
(2)
|
Aggregate number of securities to which transaction applies:
|
|
(3)
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on
which the filing fee is calculated and state how it was determined):
|
|
(4)
|
Proposed maximum aggregate value of transaction:
|
|
¨
|
Fee paid previously with preliminary materials.
|
|
¨
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the
offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and
the date of its filing.
|
|
(1)
|
Amount Previously Paid:
|
|
(2)
|
Form, Schedule or Registration Statement No.:
|
999 Skyway Road, Suite 150
San Carlos, California 94070
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
To Be Held at 11:00 a.m. Eastern Daylight
Savings Time on Monday, June 8, 2020
Dear Stockholders of Iovance Biotherapeutics, Inc.:
The 2020 Annual Meeting of Stockholders
(the “Annual Meeting”) of Iovance Biotherapeutics, Inc., a Delaware corporation (the “Company”), will be
held on Monday, June 8, 2020 at 11:00 a.m. Eastern Daylight Savings Time. In light of the public health impact of the coronavirus
outbreak, and in order to help protect the health and well-being of our shareholders and employees, the Annual Meeting will be
held virtually, via live webcast. Stockholders will be able to attend the Annual Meeting, and submit questions and vote their shares
during the Annual Meeting, from any location that has internet connectivity. There will be no physical in-person meeting. You or
your proxyholder will be able to participate and vote by visiting www.cstproxy.com/iovance/2020 and using your control number assigned
by Continental Stock Transfer. To register and receive access to the virtual meeting, registered stockholders and beneficial stockholders
(those holding shares through a stock brokerage account or by a bank or other holder of record) will need to follow the instructions
applicable to them provided in the enclosed proxy statement. The Annual Meeting will be held for the following purposes, as more
fully described in the accompanying proxy statement:
|
1.
|
To elect seven directors named in the proxy statement
accompanying this notice to serve until the 2021 Annual Meeting of Stockholders;
|
|
2.
|
To approve, by non-binding advisory vote, the compensation
of our named executive officers;
|
|
3.
|
To approve, by non-binding advisory vote, the frequency of future votes on the compensation of our named executive officers;
|
|
4.
|
To approve an amendment to our 2018 Equity Incentive
Plan (the “2018 Plan”) to increase the number of shares of common stock authorized for issuance thereunder from 6,000,000
shares to 14,000,000 shares;
|
|
5.
|
To approve our 2020 Employee Stock Purchase Plan (“2020 ESPP”); and
|
|
6.
|
To ratify the appointment of Marcum LLP as our independent
registered public accounting firm for our fiscal year ending December 31, 2020.
|
We will also consider and act upon other
business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
Our Board of Directors has fixed the close
of business on April 16, 2020 as the record date for the Annual Meeting. Only stockholders of record on April 16, 2020 are entitled
to notice of and to vote at the Annual Meeting. Further information regarding voting rights and the matters to be voted upon is
presented in the accompanying proxy statement.
This proxy statement and our 2019 Annual
Report can be accessed directly at the following internet address: http://www.cstproxy.com/iovance/2020.
YOUR VOTE IS IMPORTANT. Whether or not you
plan to attend the Annual Meeting, we urge you to submit your vote via the internet, telephone or mail.
We appreciate your continued support of
Iovance Biotherapeutics, Inc. and look forward to either greeting you personally at the Annual Meeting or receiving your proxy.
|
By order of the Board of Directors
|
|
|
|
Maria Fardis, Ph.D., M.B.A.
|
|
President and Chief Executive Officer
|
|
April 27, 2020
|
TABLE OF CONTENTS
PROXY STATEMENT
FOR 2020 ANNUAL MEETING OF STOCKHOLDERS
To Be Held at 11:00 a.m. Eastern Daylight
Savings Time on Monday, June 8, 2020
This proxy statement and the enclosed form
of proxy are furnished by Iovance Biotherapeutics, Inc., a Delaware corporation (“we,” “our,” “us,”
or the “Company”), in connection with the solicitation of proxies by our Board of Directors for use at our 2020 Annual
Meeting of Stockholders, and any postponements, adjournments or continuations thereof (the “Annual Meeting”). The Annual
Meeting will be held on Monday, June 8, 2020 at 11:00 a.m. Eastern Daylight Savings Time. In light of the public health impact
of the coronavirus outbreak (“COVID-19”), and in order to help protect the health and well-being of our shareholders
and employees, the Annual Meeting will be held virtually, via live webcast. Stockholders will be able to attend the Annual Meeting,
and submit questions and vote their shares during the Annual Meeting, from any location that has internet connectivity. There will
be no physical in-person meeting. You or your proxyholder will be able to participate and vote by visiting www.cstproxy.com/iovance/2020
and using your control number assigned by Continental Stock Transfer (“Continental”). Please see pages 3 – 5
of this proxy statement for further instructions on how to attend and vote your shares at the Annual Meeting. Stockholders can
attend the meeting via the Internet at www.virtualshareholdermeeting.com/IOVA2020 by using the 16-digit control number which appears
on your proxy card (printed in the box and marked by the arrow) and the instructions that accompanied your proxy materials. The
Notice of Internet Availability of Proxy Materials (the “Notice”) containing instructions on how to access this proxy
statement and our 2019 Annual Report is first being mailed on or about May 1, 2020 to all stockholders entitled to vote at the
Annual Meeting.
IMPORTANT NOTICE REGARDING THE INTERNET
AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING: This proxy statement, the accompanying proxy card or voting instruction
card and our 2019 Annual Report are also available at http://www.cstproxy.com/iovance/2020.
The information provided in the “question
and answer” format below is for your convenience only and is merely a summary of the information contained in this proxy
statement. You should read this entire proxy statement carefully. Information contained on, or that can be accessed through, our
website is not intended to be incorporated by reference into this proxy statement and references to our website address in this
proxy statement are inactive textual references only.
QUESTIONS AND ANSWERS ABOUT THE PROXY
MATERIALS AND OUR ANNUAL MEETING
What matters am I voting on at the Annual Meeting?
You will be voting:
|
·
|
To elect seven directors to serve until the 2021 Annual Meeting of Stockholders;
|
|
·
|
To approve, by non-binding advisory vote, the compensation of our named executive officers;
|
|
·
|
To approve, by non-binding advisory vote, the frequency of our future votes on the compensation of our named executive officers;
|
|
·
|
To approve an amendment to our 2018 Equity Incentive Plan (the “2018 Plan”) to increase the number of shares of the Company’s common stock authorized for issuance thereunder from 6,000,000 shares to 14,000,000 shares;
|
|
·
|
To approve our 2020 Employee Stock Purchase Plan (the “2020 ESPP”);
|
|
|
|
|
·
|
To ratify the appointment of Marcum LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020; and
|
|
·
|
Upon any other business as may properly come before the Annual Meeting.
|
How does the Board of Directors recommend I vote on these proposals?
Our Board of Directors recommends a vote:
|
·
|
Proposal No. 1 - “FOR” election of the nominees for directors named in this proxy statement;
|
|
·
|
Proposal No. 2 - “FOR” the approval of the compensation of our named executive officers as disclosed in this proxy statement;
|
|
·
|
Proposal No. 3 - “FOR” an annual advisory vote on the compensation of our named executive officers;
|
|
|
|
|
·
|
Proposal No. 4 - “FOR” the approval of an amendment to our 2018 Plan to increase the number of shares of the Company’s common stock authorized for issuance thereunder from 6,000,000 shares to 14,000,000 shares;
|
|
·
|
Proposal No. 5 - “FOR” the approval of our 2020 ESPP; and
|
|
|
|
|
·
|
Proposal No. 6 - “FOR” the ratification of the appointment of Marcum LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020.
|
Who is entitled to vote?
Holders of our common stock as of the close
of business on April 16, 2020 (the “Record Date”) may vote at the Annual Meeting. As of the Record Date, there were
126,846,818 shares of our common stock outstanding. At the Annual Meeting, the stockholders will be entitled to one vote for each
share of our common stock held by them on the Record Date. We do not have cumulative voting rights for the election of directors.
On the Record Date, 194 shares of our Series A Convertible Preferred Stock (the “Series A Preferred”) were outstanding,
which shares of Series A Preferred were convertible into 97,000 shares of common stock, and 3,581,119 shares of our Series B Convertible
Preferred Stock (the “Series B Preferred”) were outstanding, which shares of Series B Preferred were convertible into
3,581,119 shares of common stock. However, except as otherwise required by law, the holders of shares of Series A Preferred and
Series B Preferred do not have the right to vote on matters that come before the stockholders. Accordingly, the holders of the
Series A Preferred and Series B Preferred do not have the right to vote at the Annual Meeting in their capacities as holders of
preferred stock.
Registered Stockholders. If shares
of our common stock are registered directly in your name with our transfer agent, you are considered the stockholder of record
with respect to those shares, and the Notice was provided to you directly by us. As the stockholder of record, you have the right
to grant your voting proxy directly to the individuals listed on the proxy card or to vote in person at the Annual Meeting by using
the online meeting website.
Street Name Stockholders. If shares
of our common stock are held on your behalf in a stock brokerage account or by a bank or other nominee, you are considered the
beneficial owner of those shares held in “street name,” and the Notice was forwarded to you by your broker or nominee,
who is considered the stockholder of record with respect to those shares. As the beneficial owner, you have the right to direct
your broker or nominee how to vote your shares. Beneficial owners are also invited to attend the Annual Meeting. However, since
a beneficial owner is not the stockholder of record, you may not vote your shares of our common stock in person at the Annual Meeting
unless you follow the instructions under the next section, “How do I register for and attend the virtual-only Annual Meeting?”
Throughout this proxy, we refer to stockholders who hold their shares through a broker, bank or other nominee as “street
name stockholders.”
How do I register for and attend the virtual-only Annual Meeting?
There will be no in-person annual meeting
of the stockholders in 2020. The Annual Meeting will be held virtually over the Internet by means of a live audio webcast. Only
stockholders who own common stock as of the close of business on April 16, 2020 will be entitled to attend the virtual meeting.
Any stockholder wishing to attend the virtual Annual Meeting should register for the meeting by June 7, 2020. To register for the
virtual meeting, please follow these instructions as applicable to the nature of your ownership of our common stock:
Registered Stockholders. If your
shares are registered in your name with Continental and you wish to attend the online-only virtual meeting, go to www.cstproxy.com/iovance/2020,
enter the control number you received on your proxy card or Notice and click on the “Click here to preregister for the online
meeting” link at the top of the page. Just prior to the start of the meeting you will need to log back into the meeting site
using your control number. Pre-registration is recommended but is not required in order to attend.
Street Name Stockholders. Street
name stockholders who wish to attend the online-only virtual meeting must obtain a legal proxy by contacting their account representative
at the bank, broker, or other nominee that holds their shares and e-mail a copy (a legible photograph is sufficient) of their legal
proxy to proxy@continentalstock.com. Street name stockholders who e-mail a valid legal proxy will be issued a meeting control number
that will allow them to register to attend and participate in the online-only meeting. After contacting Continental, a street name
stockholder will receive an e-mail prior to the meeting with a link and instructions for entering the virtual meeting. Street name
stockholders should contact Continental at least 5 business days prior to the meeting date.
Stockholders participating in the virtual
meeting will be in a listen-only mode and will not be able to speak during the webcast. However, in order to maintain the interactive
nature of the virtual meeting, virtual attendees are able to:
|
·
|
Vote using the online meeting website; and
|
|
·
|
Submit questions or comments to the Company’s officers during
the meeting via e-mail or the virtual meeting webcast.
|
Starting June 1, 2020, stockholders may
submit questions or comments before or during the meeting through the virtual meeting portal by typing in the “Submit a question”
box.
Stockholders will also have the option to
call in to the virtual meeting and listen by telephone by calling -
Optional telephone access (listen-only):
Within the U.S. and Canada: +1-877-770-3647
(toll-free)
Outside of the U.S. and Canada: +1-312-780-0854
(standard rates apply)
Passcode for telephone access:
45262131#
How many votes are needed for approval of each proposal?
The representation, in person or by proxy,
of at least a majority of the outstanding shares of common stock entitled to vote at the Annual Meeting is necessary to constitute
a quorum for the transaction of business. Virtual attendance at the Annual Meeting constitutes presence in person for purposes
of a quorum at the Annual Meeting. Shares represented by proxies pursuant to which votes have been withheld from any nominee for
director, or which contain one or more abstentions or broker “non-votes,” are counted as present or represented for
purposes of determining the presence or absence of a quorum for the Annual Meeting. A “non-vote” occurs when a broker
or other nominee holding shares for a beneficial owner votes on one proposal but does not vote on another proposal because the
broker does not have discretionary voting power and has not received instructions from the beneficial owner.
Election of Directors (Proposal No. 1).
Directors are elected by a plurality of the votes cast, in person or by proxy, at the Annual Meeting. The seven nominees who receive
the highest number of affirmative votes of the shares present or represented and voting on the election of directors at the Annual
Meeting will be elected to our Board of Directors. Shares present or represented and not so marked as to withhold authority to
vote for a particular nominee will be voted in favor of a particular nominee and will be counted toward such nominee’s achievement
of a plurality. Shares properly withheld for a nominee by a stockholder, whether that stockholder is (i) present at the meeting
or (ii) represented by proxy at the meeting, and broker “non-votes,” will not be counted toward such nominee’s
achievement of plurality.
Advisory Vote on the Compensation of
our Named Executive Officers (Proposal No. 2). For the advisory vote on the compensation of our named executive officers,
the affirmative vote of the majority of shares present, in person or represented by proxy, and voting on that matter is required
for approval. Shares voted to abstain are included in the number of shares present or represented and voting on each matter. Shares
subject to broker “non-votes” are considered to be not entitled to vote for the particular matter and have the practical
effect of reducing the number of affirmative votes required to achieve a majority for such matter by reducing the total number
of shares from which the majority is calculated.
Advisory Vote on the Frequency of the
Advisory Vote on the Compensation of our Named Executive Officers (Proposal No. 3). For the advisory vote on the frequency
of the advisory vote on the compensation of our named executive officers, the affirmative vote of the majority of shares present,
in person or represented by proxy, and voting on that matter is required for approval. Shares voted to abstain are included in
the number of shares present or represented and voting on each matter. Shares subject to broker “non-votes” are considered
to be not entitled to vote for the particular matter and have the practical effect of reducing the number of affirmative votes
required to achieve a majority for such matter by reducing the total number of shares from which the majority is calculated.
Approval of an Amendment to our 2018
Plan to increase the number of shares of the Company’s common stock authorized for issuance thereunder from 6,000,000 shares
to 14,000,000 shares (Proposal No. 4). For the approval of an amendment to our 2018 Plan to increase the number of shares of
our common stock authorized for issuance thereunder from 6,000,000 shares to 14,000,000 shares, the affirmative vote of the majority
of shares present, in person or represented by proxy, and voting on the matter is required for approval. Shares voted to abstain
are included in the number of shares present or represented and voting on each matter. Shares subject to broker “non-votes”
are considered to be not entitled to vote for the particular matter and have the practical effect of reducing the number of affirmative
votes required to achieve a majority for such matter by reducing the total number of shares from which the majority is calculated.
Approval of our 2020 ESPP (Proposal No.
5). For the approval of our 2020 ESPP, the affirmative vote of the majority of shares present, in person or represented by
proxy, and voting on the matter is required for approval. Shares voted to abstain are included in the number of shares present
or represented and voting on each matter. Shares subject to broker “non-votes” are considered to be not entitled to
vote for the particular matter and have the practical effect of reducing the number of affirmative votes required to achieve a
majority for such matter by reducing the total number of shares from which the majority is calculated.
Ratification of Independent Accountants
(Proposal No. 6). For the ratification of the appointment of Marcum LLP as our independent registered public accounting firm
for the fiscal year ending December 31, 2020, an affirmative vote of a majority of the shares present, in person or represented
by proxy, and voting on such matter is required for approval. Shares voted to abstain are included in the number of shares present
or represented and voting. Brokers are entitled to vote on this matter without direction from you, and therefore are included in
the number of affirmative votes required to achieve a majority.
Other Matters. The Board of Directors
knows of no other matters to be presented at the Annual Meeting. If any other matter should be presented at the Annual Meeting
upon which a vote properly may be taken, the persons named on the enclosed proxy will have discretionary authority to vote the
shares represented by such proxies in accordance with their best judgment.
How do I vote?
If you are a stockholder of record, there
are four ways to vote:
|
·
|
By Internet — You may submit your proxy from any location in the world by following the internet voting instructions on the proxy card or voting instruction card sent to you.
|
|
·
|
By Telephone — You may submit your proxy by following the telephone voting instructions on the proxy card or voting instruction card sent to you.
|
|
·
|
By Mail — You may do this by marking,
dating and signing your proxy card or, for shares held in street name, the voting instruction card provided to you by your broker
or nominee, and mailing it in the enclosed, self-addressed, postage prepaid envelope. No postage is required if mailed in the United
States. Please note that you will be mailed a printed proxy card or printed voting instruction card only if you request that
such printed materials be sent to you by following the instructions in the Notice of Internet Availability for requesting paper
copies of the proxy materials.
|
|
·
|
In Person — You may vote at the Annual Meeting by using the online website, if you are a stockholder of record.
|
If you are a street name stockholder, you
will receive voting instructions from your broker, bank or other nominee. You must follow the voting instructions provided by your
broker, bank or other nominee in order to instruct your broker, bank or other nominee on how to vote your shares. Street name stockholders
should generally be able to vote by returning an instruction card, or by telephone or on the internet. However, the availability
of telephone and internet voting will depend on the voting process of your broker, bank or other nominee. As discussed above, if
you are a street name stockholder, you may not vote your shares in person at the Annual Meeting unless you follow the instructions
under the section “How do I register for and attend the virtual-only Annual Meeting?”
Can I change my vote?
Yes. If you are a stockholder of record,
you can change your vote or revoke your proxy any time before the Annual Meeting by:
|
·
|
entering a new vote by internet;
|
|
·
|
returning a later-dated proxy card;
|
|
·
|
notifying the Corporate Secretary, in writing, at Iovance Biotherapeutics, Inc., 999 Skyway Road, Suite 150, San Carlos, California 94070; or
|
|
·
|
voting at the Annual Meeting by using the online website.
|
If you are a street name stockholder, your
broker, bank or other nominee can provide you with instructions on how to change your vote.
What is the effect of giving a proxy?
Proxies are solicited by and on behalf of
our Board of Directors. Maria Fardis, Ph.D. and Timothy E. Morris, or either of them, have been designated as proxies by our Board
of Directors. When proxies are properly dated, executed and returned, the shares represented by such proxies will be voted at the
Annual Meeting in accordance with the instructions of the stockholder. If no specific instructions are given, however, the shares
will be voted in accordance with the recommendations of our Board of Directors as described above. If any matters not described
in this proxy statement are properly presented at the Annual Meeting, the proxy holders will use their own judgment to determine
how to vote the shares. If the Annual Meeting is adjourned, the proxy holders can vote the shares on the new Annual Meeting date
as well, unless you have properly revoked your proxy instructions, as described above.
Why did I receive a Notice of Internet Availability of Proxy
Materials instead of a full set of proxy materials?
In accordance with the rules of the Securities
and Exchange Commission (“SEC”), we have elected to furnish our proxy materials, including this proxy statement and
our annual report, primarily via the internet. The Notice containing instructions on how to access our proxy materials is first
being mailed on or about May 1, 2020 to all stockholders entitled to vote at the Annual Meeting. Stockholders may request to receive
all future proxy materials in printed form by mail or electronically by e-mail by following the instructions contained in the Notice.
We encourage stockholders to take advantage of the availability of our proxy materials on the internet to help reduce the environmental
impact of our annual meetings of stockholders.
How are proxies solicited for the Annual Meeting?
Our Board of Directors is soliciting proxies
for use at the Annual Meeting. All expenses associated with this solicitation will be borne by us. We will reimburse brokers or
other nominees for reasonable expenses that they incur in sending our proxy materials to you if a broker or other nominee holds
shares of our common stock on your behalf.
How may my brokerage firm or other intermediary vote my shares
if I fail to provide timely directions?
Brokerage firms and other intermediaries
holding shares of our common stock in street name for customers are generally required to vote such shares in the manner directed
by their customers. In the absence of timely directions, your broker will have discretion to vote your shares on our sole “routine”
matter, the proposal to ratify the appointment of Marcum LLP as our independent registered public accounting firm for our fiscal
year ending December 31, 2020. Your broker will not have discretion to vote on the election of directors or any of the other proposals,
which are “non-routine” matters, absent direction from you. Absent direction from you, shares not voted for our “non
routine” matters will result in broker non-votes.
Who will bear the cost of soliciting votes for the Annual Meeting?
We will bear all expenses of this solicitation,
including the cost of preparing and mailing these proxy materials, as well as hosting the virtual-only Annual Meeting. We may reimburse
brokerage firms, custodians, nominees, fiduciaries and other persons representing beneficial owners of common stock for their reasonable
expenses in forwarding solicitation material to such beneficial owners. Directors, officers and employees of our Company may also
solicit proxies in person or by other means of communication. Such directors, officers and employees will not be additionally compensated
but may be reimbursed for reasonable out-of-pocket expenses in connection with such solicitation. We may engage the services of
a professional proxy solicitation firm to aid in the solicitation of proxies from certain brokers, bank nominees and other institutional
owners. Our costs for such services, if retained, will not be significant. You are responsible for any internet access charges
you may incur in connection with viewing our proxy materials or voting over the internet.
Is my vote confidential?
Proxy instructions, ballots, and voting
tabulations that identify individual stockholders are handled in a manner that protects your voting privacy. Your vote will not
be disclosed either within our Company or to third parties, except as necessary to meet applicable legal requirements, to allow
for the tabulation of votes and certification of the vote, or to facilitate a successful proxy solicitation.
Where can I find the voting results of the Annual Meeting?
We will announce preliminary voting results
at the Annual Meeting. We will also disclose voting results on a Current Report on Form 8-K that we will file with the SEC within
four business days after the Annual Meeting. If final voting results are not available to us in time to file a Current Report on
Form 8-K within four business days after the Annual Meeting, we will file a Current Report on Form 8-K to publish preliminary results
and will provide the final results in an amendment to this Current Report on Form 8-K as soon as they become available.
I share an address with another stockholder, and we received
only one paper copy of the proxy materials. How may I obtain an additional copy of the proxy materials?
We have adopted a procedure called “householding,”
which the SEC has approved. Under this procedure, we deliver a single copy of the Notice and, if applicable, our proxy materials
to multiple stockholders who share the same address unless we have received contrary instructions from one or more of the stockholders.
This procedure reduces our printing costs, mailing costs, and fees, and is also environmentally friendly. Stockholders who participate
in householding will continue to be able to access and receive separate proxy cards. Upon written or oral request, we will deliver
promptly a separate copy of the Notice and, if applicable, our proxy materials to any stockholder at a shared address to which
we delivered a single copy of any of these materials. To receive a separate copy, or, if a stockholder is receiving multiple copies,
to request that we only send a single copy of the Notice and, if applicable, our proxy materials, such stockholder may contact
us at the following address:
Iovance Biotherapeutics, Inc.
Attention: Corporate Secretary
999 Skyway Road, Suite 150
San Carlos, California 94070
Stockholders who beneficially own shares
of our common stock held in street name may contact their brokerage firm, bank, broker-dealer or other similar organization to
request information about householding.
What is the deadline to propose actions for consideration at
next year’s Annual Meeting of Stockholders or to nominate individuals to serve as directors?
Stockholders may present proper proposals
for inclusion in our proxy statement and for consideration at the next Annual Meeting of Stockholders by submitting their proposals
in writing to our Corporate Secretary in a timely manner. For a stockholder proposal to be considered for inclusion in our proxy
statement for our Annual Meeting, our Corporate Secretary must receive the written proposal at our principal executive offices
not later than December 26, 2020, which is 120 days prior to the first anniversary of the mailing date of this proxy. In addition,
stockholder proposals must comply with the requirements of Rule 14a-8 regarding the inclusion of stockholder proposals in company-sponsored
proxy materials. Stockholder proposals should be addressed to:
Iovance Biotherapeutics, Inc.
Attention: Corporate Secretary
999 Skyway Road, Suite 150
San Carlos, California 94070
In addition, our bylaws establish an advance
notice procedure for stockholders who wish to present certain matters before an Annual Meeting of Stockholders. In general, nominations
for the election of directors may be made by our Board of Directors or any committee thereof or any stockholder, who is a stockholder
of record on the date of the giving of such notice and on the record date for the determination of stockholders entitled to vote
at such meeting, who is entitled to vote at such meeting and who has delivered Timely Notice (as defined below) to our Corporate
Secretary, which notice must contain specified information concerning the nominees and concerning the stockholder proposing such
nominations, as specified in our bylaws.
Our bylaws also provide that the only business
that may be conducted at an annual meeting is business that is (1) specified in the notice of meeting (or any supplement thereto)
given by or at the direction of our Board of Directors, (2) otherwise properly brought before the meeting by or at the direction
of our Board of Directors (or any committee thereto) or (3) properly brought before the meeting by a stockholder who has delivered
Timely Notice (as defined below) to our Corporate Secretary.
“Timely Notice” is defined in
our amended and restated bylaws as that date which is not less than 90 days nor more than 120 days prior to the one-year anniversary
of the previous year’s Annual Meeting of Stockholders. As a result, in order for a stockholder to bring an item of business
before the 2021 Annual Meeting of Stockholders, that item must be provided to our Corporate Secretary between February 6, 2021
and March 8, 2021 in accordance with the applicable provisions of our bylaws.
You may recommend candidates to our Board
of Directors for consideration by our nominating and governance committee by following the procedures set forth below in “Board
of Directors and Corporate Governance — Director Nominations Process — Nomination of Directors by Stockholders.”
If a stockholder who has notified us of
his, her or its intention to present a proposal at an annual meeting does not appear to present his, her or its proposal at such
annual meeting, we are not required to present the proposal for a vote at such annual meeting.
How may I obtain a copy of the bylaw provisions regarding stockholder
proposals and director nominations?
A copy of the full text of the bylaw provisions
discussed above may be obtained by writing to our Corporate Secretary. In addition, this and other information about our
Company may be obtained at the web site maintained by the SEC that contains reports, proxy and information statements and other
information regarding registrants that file electronically with the SEC. The address of the SEC’s website is www.sec.gov.
All notices of proposals by stockholders, whether or not included in our proxy materials, should be sent to our principal
executive offices, Attention: Corporate Secretary.
PROPOSAL NO. 1 - ELECTION OF DIRECTORS
The following is information concerning
the nominees for election as directors. We believe that each nominee will be able to serve as a director. In the event that a nominee
is unable to serve, the proxy holder will vote the proxies for such other nominee as he or she may determine. Each nominee currently
serves as a director of the Company. The term of office of each director will expire at next year’s Annual Meeting of Stockholders.
Nominees
Our Nominating and Corporate Governance
Committee has recommended, and our Board of Directors has approved, as nominees the following individuals for election as directors
at the Annual Meeting.
Iain Dukes, D. Phil.
Maria Fardis, Ph.D.
Athena Countouriotis, M.D.
Ryan Maynard
Merrill A. McPeak
Wayne P. Rothbaum
Michael Weiser, M.D., Ph.D.
For information concerning the nominees,
please see the section titled “Board of Directors and Corporate Governance” below.
If you are a stockholder of record and you
sign your proxy card or vote by telephone or over the internet but do not give instructions with respect to the voting of directors,
your shares will be voted “FOR” the re-election of the above-mentioned nominees.
We expect that all of the foregoing nominees
will accept such nomination; however, in the event that a director nominee is unable or declines to serve as a director at the
time of the Annual Meeting, the proxies will be voted for any nominee who shall be designated by our Board of Directors to fill
such vacancy. If you are a street name stockholder and you do not give voting instructions to your broker or nominee, your broker
will leave your shares unvoted on this matter.
BOARD OF DIRECTORS AND CORPORATE GOVERNANCE
Our business affairs are managed under the
direction of our Board of Directors, which is currently composed of seven members. The following table sets forth the names, ages
as of the Record Date, and certain other information for the seven directors whose terms are expiring at the annual meeting and
who are also nominees for election as a director at the Annual Meeting.
Directors with Terms
expiring at the Annual
Meeting/Nominees
|
|
Age
|
|
Position
|
|
Director
Since
|
Iain Dukes, D.Phil.
|
|
61
|
|
Chairman of the Board of Directors
|
|
2016
|
Maria Fardis, Ph.D.
|
|
52
|
|
President, Chief Executive Officer and Director
|
|
2016
|
Athena Countouriotis, M.D.
|
|
48
|
|
Director
|
|
2019
|
Ryan Maynard
|
|
50
|
|
Director
|
|
2015
|
Merrill A. McPeak
|
|
84
|
|
Director
|
|
2011
|
Wayne P. Rothbaum
|
|
52
|
|
Director
|
|
2016
|
Michael Weiser, M.D., Ph.D.
|
|
57
|
|
Director
|
|
2018
|
Nominees for Director
Iain Dukes, D. Phil. Dr. Dukes joined
our Board of Directors on August 4, 2016 and was appointed Chairman of the Board on August 16, 2016. Dr. Dukes is a Venture Partner
at OrbiMed Advisors LLC, which he joined in 2016. He previously served as Senior Vice President and Head of Business Development
and Licensing for Merck Research Laboratories through May 2016. He joined Merck in August 2013. Prior to joining Merck, Dr. Dukes
was Vice President of External Research & Development at Amgen from August 2010 to August 2013. From 2007 to 2010, Dr. Dukes
was the President and Chief Executive Officer, and a member of the board of directors, of Essentialis Therapeutics, a clinical
stage biotechnology company focused on the development of breakthrough medicines for the treatment of rare metabolic diseases.
From 2000 to 2007, Dr. Dukes was Vice President of Scientific and Technology Licensing at GlaxoSmithKline, and prior to that, from
1990 to 1999, he held various positions at Glaxo Wellcome, including Head of Exploratory Development for Metabolic and Urogenital
Diseases and Head of Ion Channel Drug Discovery Group. Dr. Dukes serves on the Board of Directors of Themis Biosciences, Ikena
Oncology, KaNDy Therapeutics (previously as Chairman), NeRRe Therapeutics, ReViral Limited, and ENYO Therapeutics. He co-founded
and is Chief Executive Officer of Theseus Pharmaceuticals, co-founded and serves on the Board of Directors of Kartos Therapeutics,
and co-founded Telios Pharma where he serves as President. Dr. Dukes holds Master of Jurisprudence and Doctor of Philosophy degrees
from the University of Oxford, a Master of Science degree in Cardiovascular Studies from the University of Leeds and a Bachelor
of Science degree in Pharmacology from the University of Bath.
Our Board of Directors believes that Dr.
Dukes is highly qualified to serve as a member of the Board of Directors because of his extensive experience in the pharmaceutical
industry, including his service in senior management roles.
Maria Fardis, Ph.D. Dr. Fardis joined
the Company as President and Chief Executive Officer on June 1, 2016 and was appointed to our Board of Directors on June 7, 2016.
Since joining, the Company has been transformed from an early-stage development company to a company with multiple late-stage programs
involving lifileucel and LN-145 for treatment of multiple solid tumors. Dr. Fardis served as the Chief Operating Officer of Acerta
Pharma B.V., a clinical-stage biopharmaceutical company, from January 2015 to March 2016, where she worked on the development of
Calquence® until the company’s acquisition by AstraZeneca. From 2011 to 2014, she worked at Pharmacyclics, Inc., where
she was a key contributor in the creation of a broad clinical program leading to global approvals for Imbruvica® in multiple
hematologic malignancies, and where she served as Chief of Oncology Operations and Alliances. Prior to joining Pharmacyclics, from
August 2001 to April 2011, Dr. Fardis held increasingly senior positions in Medicinal Chemistry and the project and portfolio management
department at Gilead Sciences, Inc., where she was involved with multiple therapeutic areas including antivirals, oncology, and
cardiovascular therapeutics and worked on the development and life cycle management of Letairis®. Dr. Fardis received her Ph.D.
in Organic Chemistry from the University of California, Berkeley and her B.S. summa cum laude, in chemistry from the University
of Illinois, Urbana-Champaign. Dr. Fardis holds an M.B.A., with highest honors, from Golden Gate University.
Our Board of Directors believes that Dr.
Fardis is highly qualified to serve as a member of the Board of Directors because of her experience as an executive of multiple
prior biopharmaceutical companies, extensive experience in drug development, and strong scientific background.
Athena Countouriotis, M.D. Dr. Countouriotis
joined our Board of Directors in June 2019. Dr. Countouriotis is the President and Chief Executive Officer of Turning Point Therapeutics
and was named to its board of directors in September 2018. Dr. Countouriotis has also served as the Chief Medical Officer for multiple
public biotechnology companies, including Adverum Biotechnologies, Halozyme Therapeutics and Ambit Biosciences. Earlier in her
career, Dr. Countouriotis led development of products for Pfizer and Bristol-Myers Squibb, including Sutent®, Mylotarg®,
Bosulif® and Sprycel®. She serves on the board of directors at Turning Point Therapeutics and Passage Bio. Dr. Countouriotis
holds an undergraduate degree from the University of California, Los Angeles and an M.D. from the Tufts University School of Medicine.
She received training at the University of California, Los Angeles and at the Fred Hutchinson Cancer Research Center in the Pediatric
Hematology-Oncology Program.
Our Board of Directors believes that Dr.
Countouriotis is highly qualified to serve as a member of the Board of Directors because of her medical and business background
and education, her experience as an executive of several biotechnology companies, and her experience in drug development.
Ryan Maynard. Mr. Maynard joined
our Board of Directors in February 2015. Mr. Maynard is currently the Chief Financial Officer of Paulus Holdings Ltd. d/b/a LetsGetChecked,
a position to which he was appointed in October 2019. Mr. Maynard previously was the Chief Financial Officer of Blade Therapeutics,
Inc., a privately held biotechnology company, from February 2018 to June 2019. Until December 2017, he was the Executive Vice President
and Chief Financial Officer of Rigel Pharmaceuticals, Inc., a public commercial-stage drug development company. He joined Rigel
in September 2001 as Corporate Controller and was appointed as an Assistant Secretary in October 2001. In June 2006 he became Rigel’s
Vice President of Finance and Acting Chief Financial Officer and became its Vice President and Chief Financial Officer in January
2007. Prior to joining Rigel, Mr. Maynard was Corporate Controller and Director of Finance and Accounting for Personify, Inc.,
an e-commerce software company, from November 1999 to April 2001. From July 1998 to October 1999 he served as Controller of General
Magic, Inc. and from July 1994 to June 1998 he held various positions at Siliconix, Inc., most recently as Senior Finance Manager.
He previously worked at Ernst & Young LLP. Mr. Maynard holds a B.S. in Commerce - Accounting from Santa Clara University.
Our Board of Directors believes that Mr.
Maynard is highly qualified to serve as a member of the Board of Directors because of his extensive experience as the Chief Financial
Officer of a publicly traded pharmaceutical company, as well as his expertise in auditing and financial and other related matters
pertaining to the operation of publicly traded pharmaceutical companies.
Merrill A. McPeak. General (Ret.)
McPeak joined our Board of Directors in July 2011. From February 2015 until the appointment of Dr. Dukes as our new Chairman, General
McPeak was the lead director on our Board of Directors. General McPeak also served as our unpaid, interim Chief Executive Officer
from January 14, 2013 until July 24, 2013. General McPeak currently is the President of McPeak and Associates, a consulting
firm that he founded in 1995. He has previously served as a director of several public companies, including Tektronix, Inc., Trans
World Airlines, Inc., and ECC International Corp., where he was for many years the chairman of the board. General McPeak has served
as a director of Research Solutions, Inc., a company engaged in developing systems to reuse published content, since November 2010,
and of Aerojet Rocketdyne, an aerospace and defense contractor, from March 2013 to May 2019. He also served on the board of directors
of Lilis Energy, an independent oil and gas producer, from January 2015 to April 2018. He was Chairman of the Board of Coast Plating,
Inc., a privately held turnkey provider of metal processing and metal finishing services, from January 2009 until the company was
acquired by Trive Capital and renamed Valence Surface Technologies. He continued to be a director of Valence Surface Technologies,
which became the country’s largest independently owned aerospace and defense metal processing company, until the company
was acquired by a private equity firm in June 2019. He helped found, and from December 2003 to February 2012 was Chairman of the
Board of EthicsPoint, Inc., a provider of risk management and compliance software-as-a-service that was acquired in 2012 and restyled
Navex Global. General McPeak remained a member of the board of directors of Navex Global until that company was sold in 2014.
From 1990 until his retirement from active
military service in late 1994, General McPeak was Chief of Staff of the United States Air Force. As a member of the Joint Chiefs
of Staff, General McPeak was a military advisor to the Secretary of Defense and the President of the United States. General McPeak
received a Bachelor of Arts degree in economics from San Diego State College and a Master of Science degree in international relations
from the George Washington University, and is a member of the Council on Foreign Relations. From July 2010 to December 2017, General
McPeak was Chairman of the American Battlefield Monuments Commission.
Our Board of Directors believes that General
McPeak is highly qualified to serve as a member of the Board of Directors because of his extensive leadership experience, including
his experience in the military and as a director serving on numerous public and private company boards of directors.
Wayne P. Rothbaum. Mr. Rothbaum joined
our Board of Directors on June 7, 2016. Mr. Rothbaum is currently the President of Quogue Capital LLC, a life sciences investment
fund he founded in 2001. Beginning in 2012, Mr. Rothbaum served as the co-founder and largest investor of Acerta Pharma, B.V.,
a Dutch biotech focused on developing selective, covalent small molecules to treat cancer and inflammation. Acerta Pharma was sold
to AstraZeneca in February 2016. From February 2013 until its sale in February 2016, Mr. Rothbaum served as the executive chairman
of Acerta Pharma. From 1993 until 2001, Mr. Rothbaum led the biotechnology practice at the strategic consulting firm The Carson
Group. Mr. Rothbaum graduated Phi Beta Kappa from Binghamton University in 1990 with a dual major in political science and psychology
and received his master’s degree in international economics from the George Washington University.
Our Board of Directors believes that Mr.
Rothbaum is highly qualified to serve as a member of the Board of Directors on the basis of his business background and education,
his investment experience as the manager of an investment fund focused on the life sciences industry, and his experience serving
in a leadership capacity with other biotechnology companies.
Michael Weiser, M.D., Ph.D. Dr. Weiser
joined our Board of Directors in March 2018. He is the founder and has been a principal of Actin Biomed LLC since 2006. Actin Biomed
is a healthcare investment firm focused on the discovery and development of novel treatments for unmet medical needs. Prior to
joining Actin Biomed, Dr. Weiser was the Director of Research at Paramount BioCapital, Inc., a pharmaceutical development and healthcare
investment firm. Dr. Weiser currently serves on the board of directors of Emisphere Technologies, Inc., a pharmaceutical and drug
delivery company. Dr. Weiser previously served as the chairman of the board of directors of Chelsea Therapeutics International,
Ltd., a development stage pharmaceutical company that was acquired by H. Lundbeck A/S in 2014, and served on the board of directors
of Ziopharm Oncology, Inc., a publicly traded biopharmaceutical company focused on immunotherapies in oncology. Dr. Weiser holds
a B.A. in Psychology from the University of Vermont, received his M.D. from New York University School of Medicine and completed
his Ph.D. in Molecular Neurobiology at Cornell University Medical College.
Our Board of Directors believes that Dr.
Weiser is highly qualified to serve as a member of the Board of Directors because of his medical and business background and education,
his experience serving on boards of directors, and his investment experience as the manager of an investment fund focused on biotechnology
companies.
Corporate Governance Highlights at a Glance
What we do
|
·
|
Annually Elected Directors
|
|
·
|
Robust Independent Director Role
|
|
·
|
Majority of Independent Directors
|
|
·
|
Non-Executive Chairperson
|
|
·
|
Regular Non-Executive Director Executive Sessions
|
|
·
|
Proactive Stockholder Engagement
|
|
·
|
Annual Say on Pay Vote
|
What we do not do
|
·
|
No Poison Pill
|
|
·
|
No Supermajority Voting Provisions
|
|
·
|
No Classified Board
|
Director Nominations Process
The Nominating and Corporate Governance
Committee administers our director nominations process and establishes criteria for Board of Directors member candidates and the
process by which candidates for inclusion in our recommended slate of director nominees are selected. The Committee’s charter
is available under the “Investors” section of our website at www.iovance.com, under “Corporate Governance
– Governance Highlights.”
Minimum Criteria for Board of Directors
Members. Under the director nominations process, each Board of Directors candidate must possess at least the following specific
minimum qualifications:
|
·
|
He or she shall be prepared to represent the best interests of all of our stockholders and not just one particular constituency.
|
|
·
|
He or she shall be an individual who has demonstrated integrity and ethics in his or her personal and professional life and established a record of professional accomplishment in his or her chosen field.
|
|
·
|
Neither the candidate nor any family member (as defined in the Nasdaq Stock Market Rules) or affiliate or associate (each as defined in SEC rules) shall have any material personal, financial or professional interest in any of our current or potential competitors.
|
|
·
|
He or she shall be prepared to participate fully in Board of Directors activities, including, if eligible, active membership on at least one committee and attendance at, and active participation in, meetings of the Board of Directors and any committee of which he or she is a member, and not have other personal or professional commitments that would, in the Nominating and Corporate Governance Committee’s sole judgment, interfere with or limit his or her ability to do so.
|
Desirable Qualities and Skills. The
Nominating and Corporate Governance Committee also considers it desirable that each candidate should:
|
·
|
Contribute to our Board of Directors’ overall diversity — diversity being broadly construed to mean a variety of opinions, perspectives, personal and professional experiences and backgrounds, as well as other differentiating characteristics.
|
|
·
|
Contribute positively to the collaborative culture among Board of Directors members.
|
|
·
|
Possess professional and personal experiences and expertise relevant to our goal of being a leading biopharmaceutical company. At this stage of our development, relevant experiences might include, among other things, large biotechnology or pharmaceutical company chief executive officer or senior management experience, senior-level management experience in medical research or clinical development activities in the fields of oncology, immunology or molecular biology within a public company or large university setting, and relevant senior-level expertise in one or more of finance, accounting, sales and marketing, organizational development and public relations.
|
Internal Process for Identifying Candidates.
The Nominating and Corporate Governance Committee has two primary methods for identifying Board of Directors candidates. On a periodic
basis, the Nominating and Corporate Governance Committee may solicit suggestions for possible candidates from a number of sources,
which may include members of the Board of Directors, our senior executives, individuals personally known to members of the Board
of Directors, and independent research by either members of the Board of Directors or our senior executives. The Nominating and
Corporate Governance Committee may also use its authority under its Charter to retain at the Company’s expense one or more
search firms to identify candidates. If a search firm is used, it may be asked to identify possible candidates who meet minimum
and desired qualifications; interview and screen candidates, and conduct appropriate background and reference checks; act as a
liaison among the Board of Directors, the Nominating and Corporate Governance Committee, and the candidate during the screening
and evaluation process; and be available for consultation as needed by the Nominating and Corporate Governance Committee. The Nominating
and Corporate Governance Committee has the authority under its Charter to approve such firms’ fees and other retention terms.
Nomination of Directors by Stockholders.
The Nominating and Corporate Governance Committee will also consider properly submitted stockholder nominations for candidates
for membership on the Board of Directors. Any of our stockholders may recommend one or more eligible persons for election as a
director at an Annual Meeting of Stockholders if the stockholder provides the recommendation to our Corporate Secretary at our
principal executive offices not less than 120 days prior to the anniversary of the date of the proxy statement released to stockholders
in connection with the previous year’s annual meeting. In the event that we set an annual meeting date that is not within
30 days before or after the date of the immediately preceding annual stockholders meeting, the stockholder’s recommendation
must be received no later than the close of business on the tenth day following the day on which notice of the date of the annual
meeting was mailed or public disclosure of that date was made, whichever occurs first. To be eligible for consideration, a candidate
proposed by a stockholder must be independent of the stockholder providing the nomination in all respects, as determined by the
Nominating and Corporate Governance Committee or by applicable law, qualify as an “independent director” under the
Nasdaq Stock Market Rules and meet the Minimum Criteria for Board of Directors Members set forth above.
Evaluation of Candidates. The Nominating
and Corporate Governance Committee will consider all candidates identified through the processes described above, and will evaluate
each of them, including incumbents, based on the same criteria. If, based on the Nominating and Corporate Governance Committee’s
or other director’s initial evaluation, a candidate continues to be of interest, the Nominating and Corporate Governance
Committee Chair or one or more other directors will interview the candidate and communicate the interviewer(s)’ evaluation
to the other Nominating and Corporate Governance Committee member(s), the Chairman of the Board of Directors, the Chief Executive
Officer, and the independent members of the Board of Directors. Later reviews will be conducted by other members of the Nominating
and Corporate Governance Committee, the Board of Directors and senior management. Ultimately, background and reference checks will
be conducted, and the Nominating and Corporate Governance Committee will meet to finalize its list of recommended candidates for
the Board of Directors’ consideration.
Timing of the Identification and Evaluation
Process. Our fiscal year is the calendar year. The Nominating and Corporate Governance Committee expects generally to meet
one or more times to consider, among other things, candidates to be recommended to the Board of Directors for inclusion in our
recommended slate of director nominees for the next annual meeting and our Proxy Statement. The Board of Directors usually meets
each March or early April and at that meeting approves, among other things, the slate of director nominees to be submitted to and
recommended for election by stockholders at the annual meeting, which is typically held in May or June. All candidates, whether
identified internally or by a nomination received from a stockholder, who after evaluation are recommended by the Nominating and
Corporate Governance Committee and the independent members of the Board of Directors, and approved by the Board of Directors, will
be included in our recommended slate of director nominees in our Proxy Statement.
Meetings of the Board of Directors
The property, affairs and business of our
Company are conducted under the supervision and management of our Board of Directors, as called for under the laws of Delaware
and our bylaws. Pursuant to our bylaws, our Board of Directors may establish committees of one or more directors from time to time,
as it deems appropriate.
Our common stock currently is listed on
the Nasdaq Global Market. A majority of our directors currently are “independent directors” as defined under the Nasdaq
Stock Market Rules, which define an “independent director” as “a person other than an executive officer or employee
of the Company or any other individual having a relationship which, in the opinion of the Company’s board of directors, would
interfere with the exercise of independent judgment in carrying out the responsibilities of a director.” The definition further
provides that, among others, employment of a director by us (or any parent or subsidiary of ours) at any time during the past three
years is considered a bar to independence regardless of the determination of our Board of Directors.
Our Board of Directors has determined that,
with the exception of Dr. Fardis and Dr. Dukes, for the purposes of serving on our Board of Directors, all of our other directors
are “independent” under the Nasdaq Stock Market Rules.
Our Board of Directors held eight meetings
during the fiscal year ending December 31, 2019. Each director attended at least 75% of the aggregate of the total meetings of
the Board of Directors that were held during the portion of the 2019 fiscal year in which he/she served as a director.
Executive Sessions
During the fiscal year ended December 31,
2019, the non-executive directors of the Board of Directors met in executive session on five occasions, the members of the Audit
Committee met in executive session on five occasions, the members of the Nominating and Corporate Governance Committee met in executive
session on one occasion, and the members of the Compensation Committee met in executive session on one occasion.
Committees of the Board of Directors
Our Board of Directors has a standing Audit
Committee, Nominating and Corporate Governance Committee, and Compensation Committee.
Current committee memberships are as follows:
Audit Committee
The Audit Committee currently consists of:
Ryan Maynard (Chair)
Merrill A. McPeak
Michael Weiser, M.D., Ph.D.
The Audit Committee operates pursuant to
a written charter. Among other things, the Audit Committee is responsible for:
|
·
|
appointing, approving the compensation of, and assessing the independence of our independent registered public accounting firm;
|
|
·
|
overseeing the work of our independent registered public accounting firm;
|
|
·
|
reviewing and discussing with management and the independent registered public accounting firm our annual and quarterly financial statements and related disclosures;
|
|
·
|
monitoring our internal control over financial reporting, disclosure controls and procedures and Code of Conduct and Ethics;
|
|
·
|
overseeing our internal audit function;
|
|
·
|
meeting independently with our internal auditing staff or consultants, independent registered public accounting firm and management;
|
|
·
|
reviewing and approving or ratifying any related person transactions;
|
|
·
|
periodically reviewing and assessing the adequacy of our insurance programs, including directors’ and officers’ insurance programs, and recommending any changes to such programs to our Board of Directors; and
|
|
·
|
preparing the Audit Committee Report required by SEC rules (which is included on page 16 of this proxy statement).
|
As of the date of this proxy statement,
Mr. Maynard, Dr. Weiser, and General McPeak constitute all of the members of the Audit Committee. All of the members of the Audit
Committee are non-employee directors and independent as defined under the Nasdaq Stock Market Rules. Mr. Maynard is a former chief
financial officer of a public company, Rigel Pharmaceuticals, Inc., where he served in that role for more than 10 years. Because
of his knowledge of financial, audit and accounting matters, our Board of Directors has designated him as the “audit committee
financial expert” of the Audit Committee.
The Audit Committee operates pursuant to
a written charter, which is available on our website, www.iovance.com, under “Corporate Governance – Governance Highlights”.
Compensation Committee
The Compensation Committee currently consists
of:
Michael Weiser, M.D., Ph.D. (Chair)
Athena Countouriotis, M.D.
Merrill A. McPeak
Wayne P. Rothbaum
The Compensation Committee is responsible
for the compensation of our executives and directors. As part of its responsibilities, the Compensation Committee has the following
duties and responsibilities:
|
·
|
Establish peer group, annual base salary and annual incentive compensation amounts for executive officers and, based upon discussions with the Chief Executive Officer, annual incentive levels and the operational and any other goals to be met to earn annual and long-term incentive awards.
|
|
·
|
Review and evaluate the performance and leadership of the Chief Executive Officer and determine the amounts of annual and any long-term incentive awards and any adjustment to the annual salary and annual incentive compensation amounts based upon such performance and other factors as the Compensation Committee deems appropriate.
|
|
·
|
Review with the Chief Executive Officer his/her evaluation of the performance of the other executive officers and either approve or recommend Board of Directors approval of, the amounts of annual and any long-term incentive awards and any adjustments to the annual salary and annual incentive compensation amounts based upon such performance and other factors as the Compensation Committee deems appropriate.
|
|
·
|
Review the compensation of non-employee directors and recommend to the Board of Directors, for its approval, the components and amounts of compensation for non-employee directors.
|
As part of its other responsibilities, the
Compensation Committee reviews and approves any reports required by the SEC for inclusion in the annual report and proxy statement,
provides general oversight of our compensation structure, and, if deemed necessary, retains and approves the terms of the retention
of compensation consultants and other compensation experts. Other specific duties and responsibilities of the Compensation Committee
include reviewing the performance of executive officers; reviewing and approving objectives relevant to executive officer compensation;
administering our equity-based and incentive compensation plans; and establishing compensation policies and practices for service
on our Board of Directors and its committees and for the Chairman of our Board of Directors.
In the Compensation Committee’s sole
discretion, the Committee has the authority to retain or obtain the advice of a compensation consultant, legal counsel or other
advisor after taking into consideration the independence of such compensation consultant, legal counsel or other advisor. Our Compensation
Committee requires any compensation consultant, legal counsel or other advisor retained by the Compensation Committee, or who otherwise
provides advice to the Compensation Committee, to be independent.
Our Board of Directors has granted our Chief
Executive Officer the authority to grant options to (i) newly hired non-executive employees, and (ii) non-executive employees as
part of our annual performance review. The Compensation Committee has established certain parameters within which non-executive
options could be granted by our Chief Executive Officer.
The Board of Directors is responsible for
developing employment compensation policies for our Company, including ensuring that the policies are sufficiently attractive to
retain our Company’s existing employees and to incentivize prospective employees. For a description of the processes and
procedures used by the Compensation Committee for the consideration and determination of executive and director compensation, see
“Executive Compensation-Compensation Discussion and Analysis.”
Our Board of Directors has determined that
each of the current members of the Compensation Committee is “independent” under the current independence standards
of the Nasdaq Stock Market Rules.
Nominating and Corporate Governance Committee
The Nominating and Corporate Governance
Committee currently consists of:
Merrill A. McPeak (Chair)
Athena Countouriotis, M.D.
Michael Weiser, M.D., Ph.D.
The Nominating and Corporate Governance
Committee recommends candidates to be nominated for election as directors at our annual meeting, consistent with criteria approved
by our Board of Directors; develops and regularly reviews corporate governance principles and related policies for approval by
our Board of Directors; oversees the organization of our Board of Directors to discharge its duties and responsibilities properly
and efficiently; and sees that proper attention is given and effective responses are made to stockholder concerns regarding corporate
governance. The Nominating and Corporate Governance Committee also oversees an annual assessment by the Board of Directors of its
performance. In addition, the Nominating and Corporate Governance Committee oversees succession planning for executive officers
in conjunction with the Board of Directors.
Usually, nominees for election to our Board
of Directors are proposed by our existing directors. In identifying and evaluating individuals qualified to become Board of Directors
members, our current directors will consider such factors as they deem appropriate to assist in developing a Board of Directors
and committees thereof that are diverse in nature and comprised of experienced and seasoned advisors. Our Board of Directors has
not adopted a formal policy with regard to the consideration of diversity, other than as may be prescribed by law, when evaluating
candidates for election to our Board of Directors. However, our Board of Directors believes that membership should reflect diversity
in its broadest sense, but should not be chosen nor excluded based on race, color, gender, national origin or sexual orientation.
In this context, our Board of Directors does consider a candidate’s experience, education, industry knowledge, history with
the Company, independence, and differences of viewpoint when evaluating his or her qualifications for election to our Board of
Directors. In evaluating such candidates, our Board of Directors seeks to achieve a balance of knowledge, experience and capability
in its composition. In connection with this evaluation, our Board of Directors determines whether to interview the prospective
nominee, and if warranted, one or more directors interview prospective nominees in person or by telephone.
Report of the Audit Committee of the Board of Directors
The Audit Committee provides assistance
to our Board of Directors in fulfilling its oversight responsibility to the Company’s stockholders, potential stockholders,
the investment community, and others relating to our financial statements and the financial reporting process, the systems of internal
accounting and financial controls, the internal audit function, the annual independent audit of our financial statements and the
ethics programs when established by our management and our Board of Directors. The Audit Committee has the sole authority (subject
to stockholder ratification) to appoint or replace the outside auditors and is directly responsible for determining the compensation
of the independent auditors. In discharging its oversight role, the Audit Committee is empowered to investigate any matter brought
to its attention, with full access to all of our books, records, facilities and personnel, and to retain its own legal counsel
and other advisers as it deems necessary or appropriate.
As part of its oversight of our financial
statements, the Audit Committee reviewed and discussed with both management and our outside auditors our interim financial statements
and annual audited financial statements that are included in our Quarterly Reports on Form 10-Q and Annual Report on Form 10-K,
respectively. The Audit Committee held six meetings during the fiscal year ended December 31, 2019, including regular meetings
in conjunction with the close of each fiscal quarter, during which the Audit Committee reviewed and discussed the Company’s
financial statements with management and Marcum LLP. These Audit Committee meetings routinely include executive sessions of the
committee, as well as private sessions with Marcum LLP. Our management advised the Audit Committee in each case that all such financial
statements were prepared in accordance with accounting principles generally accepted in the United States of America and reviewed
significant accounting issues with the Audit Committee. These reviews included discussion with the outside auditors of matters
required to be discussed by Auditing Standard 1301, “Communications with Audit Committees,”
issued by the Public Company Accounting Oversight Board.
During the fiscal year ended December 31,
2019, Marcum LLP served as our independent registered public accounting firm and audited our financial statements for the year
ended December 31, 2019. Marcum LLP did not have any financial interest, direct or indirect, in our Company, and did not have any
connection with our Company except in its professional capacity as our independent auditors. As discussed in Proposal No. 6 below,
the Audit Committee has engaged Marcum LLP as our independent registered public accountants for the fiscal year ending December
31, 2020.
The Audit Committee discussed with Marcum
LLP, the auditors of our 2019 annual financial statements, matters relating to its independence, including a review of audit and
non-audit fees and the letter and written disclosures made by Marcum LLP to the Audit Committee pursuant to Public Company Accounting
Oversight Board (United States) Rule 3526.
Audit and non-audit services to be provided
by Marcum LLP are subject to the prior approval of the Audit Committee. In general, the Audit Committee’s policy is to grant
such approval where it determines that the non-audit services are compatible with maintaining the independent registered public
accounting firm’s independence and there are cost or other efficiencies in obtaining such services from the independent registered
public accounting firm as compared to other possible providers.
Taking all of these reviews and discussions
into account, the Audit Committee recommended to our Board of Directors that our Board of Directors approve the inclusion of our
audited financial statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which was deemed filed
with the SEC on February 25, 2020.
AUDIT COMMITTEE OF THE BOARD OF DIRECTORS
Ryan Maynard (Chair)
Merrill McPeak
Michael Weiser, M.D., Ph.D.
Board Leadership Structure and Role in Risk Oversight
Our Board of Directors believes it is important
to select the Company’s Chairman and Chief Executive Officer in the manner it considers in the best interests of the Company
at any given time. Our Chairman and Chief Executive Officer positions are filled by two different individuals, allowing for greater
independence between the Board of Directors and management.
Our Board of Directors is currently comprised
of a majority of individuals who are independent from the management of the Company and, assuming that the nominees are elected
at the Annual Meeting, five of the seven members of our Board of Directors will continue to be independent directors. Our Board
of Directors and its committees meet regularly throughout the year to assure that the independent directors are well briefed and
informed with regard to the Company’s affairs. Each of the independent directors has access to the executive officers of
the Company. In this fashion, we seek to maintain well informed, independent directors who are prepared to make informed decisions
regarding our business affairs.
Management is responsible for the day-to-day
management of risks the Company faces, while our Board of Directors as a whole plays an important role in overseeing the identification,
assessment and mitigation of such risks. Our Board of Directors reviews information regarding the Company’s finances and
operations, as well as the risks associated with each. For example, the oversight of financial risk management lies primarily with
the Audit Committee, which is empowered to appoint and oversee our independent auditors, monitor the integrity of our financial
reporting processes and systems of internal controls and provide an avenue of communication among our independent auditors, management
and our Board of Directors. The Compensation Committee is responsible for overseeing the management of risks relating to the Company’s
compensation plans and arrangements. In fulfilling its risk oversight responsibility, our Board of Directors, as a whole and acting
through any established committees, consults with management to evaluate and, when appropriate, modify our risk management strategies.
Stockholder Communication with Members of the Board of Directors
Stockholders who wish to communicate with
members of our Board of Directors may contact us at our principal executive office at 999 Skyway Road, Suite 150, San Carlos, California
94070. Written communications specifically marked as a communication for our Board of Directors, or a particular director, except
those that are clearly marketing or soliciting materials, will be forwarded unopened to Dr. Dukes, currently the Chairman of our
Board of Directors, or to the particular director to whom they are addressed, or presented to the full Board of Directors or the
particular director at the next regularly scheduled Board of Directors meeting.
Board of Directors Members’ Attendance at Annual Meetings
It is the Company’s policy to have
each director and director nominee attend the Annual Meeting of Stockholders. Six of our current directors attended our 2019 Annual
Meeting of Stockholders either as a director or as a director nominee. In light of the public health impact of COVID-19, virtual
attendance of our directors at our Annual Meeting is permitted in 2020.
Code of Ethics
Our Board of Directors has adopted a Code
of Conduct and Ethics that applies to our officers, directors and employees (“Code of Ethics”). A copy of our Code
of Ethics will be furnished without charge to any person upon written request. Requests should be sent to: Secretary, Iovance Biotherapeutics,
Inc., 999 Skyway Road, Suite 150, San Carlos, California 94070. Our Code of Ethics is also available under the “Investors”
section of our website at www.iovance.com, under “Corporate Governance – Governance Highlights”.
Director Compensation
We believe that a combination of cash and
equity compensation is appropriate to attract and retain the individuals we desire to serve on our board of directors and that
this approach is comparable to the policies of our peer companies. Our cash compensation policies are designed to encourage frequent
and active interaction between directors and our executives both during and between formal meetings as well as compensate our directors
for their time and effort. Further, we believe it is important to align the long-term interests of our non-employee directors with
those of the Company and its stockholders, and that awarding equity compensation to, and thereby increasing ownership of our common
stock by, our non-employee directors is an appropriate means to achieve this alignment.
In 2019, our non-employee directors received
an annual cash retainer for Board of Directors and committee service in addition to equity compensation, as set forth in further
detail in the table below. We expect non-employee director compensation to remain the same in 2020, except that the Chair of the
Compensation Committee is expected to receive an additional 15,000 options for his additional service to the Board of Directors.
|
|
|
|
Annual Cash
Retainer (1)
|
|
|
Annual Equity
Compensation (2)
|
|
Board of Directors membership
|
|
|
|
$
|
35,000
|
|
|
|
35,000
|
|
Chairman of the Board of Directors (Extra Retainer)
|
|
|
|
$
|
25,000
|
|
|
|
35,000
|
|
Audit Committee
|
|
Chair
|
|
$
|
15,000
|
|
|
|
|
|
|
|
Member
|
|
$
|
7,500
|
|
|
|
|
|
Compensation Committee
|
|
Chair
|
|
$
|
15,000
|
|
|
|
|
|
|
|
Member
|
|
$
|
7,500
|
|
|
|
|
|
Nominating and Corporate Governance Committee
|
|
Chair
|
|
$
|
15,000
|
|
|
|
|
|
|
|
Member
|
|
$
|
7,500
|
|
|
|
|
|
|
(1)
|
The annual cash retainers are payable in quarterly installments.
|
|
(2)
|
Represents number of shares underlying options granted annually to the directors. These options are exercisable in four equal
quarterly installments following the date of grant. If the individual’s service with the Board of Directors is terminated
before the option expiration date, the options will be exercisable for two years following termination of service (or until the
expiration of the option) unless the director is terminated for cause, in which case the options are terminated.
|
The table below shows the compensation received
by each of our non-employee directors during 2019 for serving on the Board of Directors and on its committees. Our non-employee
directors do not receive fringe or other benefits.
Director Compensation Table
Name
|
|
Fees
Earned or Paid in Cash
|
|
|
Options Awards
($) (1)
|
|
|
Total ($)
|
|
Athena Countouriotis, M.D.
|
|
$
|
27,885
|
|
|
$
|
450,363
|
|
|
$
|
478,248
|
|
Iain Dukes, D.Phil.
|
|
$
|
60,000
|
|
|
$
|
900,725
|
|
|
$
|
960,725
|
|
Ryan Maynard
|
|
$
|
50,000
|
|
|
$
|
450,363
|
|
|
$
|
500,363
|
|
Merrill A. McPeak
|
|
$
|
65,000
|
|
|
$
|
450,363
|
|
|
$
|
515,363
|
|
Wayne P. Rothbaum (2)
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
Michael Weiser, M.D., Ph.D.
|
|
$
|
65,000
|
|
|
$
|
643,375
|
|
|
$
|
708,375
|
|
|
(1)
|
Represents the grant date value computed in accordance with FASB ASC Topic 718. These amounts do not reflect the actual economic
value that will be realized by the directors upon the vesting of the stock options, the exercise of the stock options, or the sale
of the common stock underlying such stock options.
|
|
(2)
|
To date, Mr. Rothbaum has declined to receive any compensation, whether cash or options.
|
OUR BOARD OF DIRECTORS RECOMMENDS A VOTE
“FOR” EACH OF THE DIRECTOR NOMINEES NAMED ABOVE.
* * *
PROPOSAL NO. 2 - ADVISORY VOTE ON THE
COMPENSATION OF
THE COMPANY’S NAMED EXECUTIVE OFFICERS
Section 951 of the Dodd-Frank Wall Street
Reform and Consumer Protection Act of 2010 (the “Dodd-Frank Act”), as set forth in Section 14A(a) of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), provides the Company’s stockholders with the opportunity
to vote to approve, on an advisory, non-binding basis, the compensation of our named executive officers as disclosed in this proxy
statement in accordance with SEC rules. At the 2014 Annual Meeting of Stockholders, our stockholders approved an advisory measure
that the stockholders’ advisory votes on executive compensation be held on an annual basis. Our Board of Directors determined
to follow our stockholders’ recommendations and to include an annual stockholders advisory vote on the compensation of the
Company’s named executive officers. Please refer to the discussion under “Executive Compensation-Compensation Discussion
and Analysis” for a description of the compensation of our named executive officers.
We are asking for stockholder approval of
the compensation of our named executive officers as disclosed in this proxy statement in accordance with SEC rules, which include
the disclosures under “Executive Compensation - Compensation Discussion and Analysis,” the compensation tables and
the narrative discussion following the compensation tables. This vote is not intended to address any specific item of compensation,
but rather the overall compensation of our named executive officers and the compensation policies and practices described in this
proxy statement. Accordingly, we are asking you to approve the following resolution:
RESOLVED, that the compensation paid to the named executive
officers of Iovance Biotherapeutics, Inc., as disclosed in the 2020 Proxy Statement of Iovance Biotherapeutics, Inc. pursuant to
Item 402 of SEC Regulation S-K, including the compensation tables and narrative discussion, hereby is approved.
This proposal, commonly known as a “Say-on-Pay”
proposal, gives our stockholders the opportunity to express their views on our named executive officers’ compensation as
a whole. This vote is advisory in nature and therefore is not binding on us, our Compensation Committee or our Board of Directors.
Our Board of Directors and our Compensation Committee, however, value the opinions of our stockholders. To the extent there is
any significant vote against the named executive officer compensation as disclosed in this proxy statement, we will consider the
stockholders’ concerns, and our Compensation Committee will evaluate whether any actions are necessary to address those concerns.
Vote Required
The affirmative vote of a majority of the
shares of our common stock present in person or represented by proxy and entitled to vote on this proposal at the Annual Meeting
is required for advisory approval of the proposal.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE
"FOR" THE APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
MANAGEMENT NAMED EXECUTIVE OFFICERS
Named Executive Officers
The following table sets forth information
regarding our named executive officers as of the Record Date.
Name
|
|
Age
|
|
Position
|
Maria Fardis, Ph.D.
|
|
52
|
|
President and Chief Executive Officer
|
Timothy E. Morris
|
|
58
|
|
Chief Financial Officer
|
Friedrich Graf Finckenstein, M.D.
|
|
53
|
|
Chief Medical Officer
|
Frederick G. Vogt, Ph.D., Esq.
|
|
46
|
|
General Counsel and Corporate Secretary
|
Maria Fardis, Ph.D. Dr. Fardis has
served as our President and Chief Executive Officer since her appointment effective June 1, 2016. See, “Proposal No. 1: Election
of Directors — Nominees for Director,” above.
Timothy E. Morris. Mr. Morris joined
the Company as our Chief Financial Officer on August 14, 2017. Mr. Morris thereafter became our principal accounting officer on
November 8, 2017. Prior to joining us, Mr. Morris was the Chief Financial Officer and Head of Business Development for AcelRx Pharmaceuticals,
Inc., a publicly traded biopharmaceutical company focusing on the development and commercialization of sublingual therapies for
the treatment of acute pain, from March 2014 until June 2017. From November 2004 to December 2013, Mr. Morris served as the Chief
Financial Officer and Global Head of Corporate Development for VIVUS, Inc., a publicly traded biopharmaceutical company focused
on the development and commercialization of therapies to treat obesity and restore sexual health. Prior to joining VIVUS, he served
as Chief Financial Officer and Senior Vice President of Finance, Manufacturing and Administration at Questcor Pharmaceuticals,
Inc. from September 2001 to November 2004. Prior thereto, Mr. Morris also served as Chief Financial Officer of Interpro Business
Solutions, Inc., Utility.com, and RiboGene, Inc. Mr. Morris currently serves as a non-executive director of Humanigen, Inc. Mr.
Morris is a Certified Public Accountant (inactive) and received a bachelor’s degree in business with emphasis in accounting
from California State University, Chico.
Friedrich Graf Finckenstein, M.D.
Dr. Graf Finckenstein joined the Company as our Chief Medical Officer on July 18, 2019. Dr. Graf Finckenstein is a physician-scientist
with decades of experience in clinical medicine, laboratory cancer research, and drug development in the biopharmaceutical industry.
Prior to joining Iovance he was Global Head of Oncology Translational Medicine at Roche Pharma Research and Early Development in
Basel, Switzerland, where he led all clinical development aspects in the Oncology Discovery and Translational Area, including the
design and conduct of clinical trials, exploratory development studies and translational medicine, biomarker and personalized healthcare
strategy. Prior to that, Dr. Graf Finckenstein held multiple clinical leadership roles at Bristol-Meyers Squibb Company, where
he worked on an array of products from early clinical development to late stage, including key contributions to the approval of
Opdivo® in lung cancer. Dr. Graf Finckenstein has a medical degree from the University of Hamburg in Germany. He holds a German
medical license, a pediatric board certification, and has conducted basic cancer research at the Ludwig Institute, San Diego Branch,
the Children’s Hospital Los Angeles and the University of Hamburg.
Frederick G. Vogt, Ph.D., Esq. Dr.
Vogt joined the Company on September 30, 2016 as our Vice President, Intellectual Property. Dr. Vogt was promoted to General Counsel
on July 1, 2017. From May 2013 until he joined the Company, Dr. Vogt practiced law at the international law firm of Morgan, Lewis
& Bockius LLP, focusing on intellectual property and business law in the life sciences and representing clients in patent strategy,
transactional, and litigation matters. Prior to joining Morgan, Lewis & Bockius LLP, he served in numerous scientific, management,
and legal roles of increasing responsibility over a period of 13 years at GlaxoSmithKline plc., where he focused primarily on oncology
and cardiovascular drug development. Dr. Vogt holds a B.S. in Chemistry from Ursinus College, a Ph.D. in Chemistry from the Pennsylvania
State University, and a J.D. from Temple University. He is admitted to practice in Pennsylvania and before the U.S. Patent and
Trademark Office and the U.S. District Court for the Eastern District of Pennsylvania.
EXECUTIVE COMPENSATION — COMPENSATION
DISCUSSION AND ANALYSIS
Overview of Executive Compensation Program
This section explains the objectives of
our named executive officer compensation program, the compensation decisions we made with respect to compensation for our fiscal
year ended December 31, 2019, and the factors we considered in making those decisions, and focuses on the compensation of officers
who are listed as our “named executive officers” in this proxy statement. The named executive officers include the
following four officers who are currently employed with us:
Maria Fardis, Ph.D., our President and Chief Executive
Officer,
Timothy E. Morris, our Chief Financial Officer,
Friedrich Graf Finckenstein, M.D., our Chief Medical
Officer, and
Frederick G. Vogt, Ph.D., Esq., our General
Counsel.
At our 2019 Annual Meeting of Stockholders,
on an advisory basis, approximately 98% of the stockholders who voted on this matter approved the compensation of our named executive
officers as disclosed in our 2019 proxy statement. Based on our continued engagement with our shareholders as well as the results
of the 2019 stockholder advisory vote, the Compensation Committee has determined to follow the stockholders’ recommendation
and to continue to follow our historical compensation policies and procedures, subject to recommendations received from our independent
compensation consulting firm.
2019 Performance Highlights
2019 was a year of significant progress
for us. Over the course of 2019, our stock price increased in value by 213%. The following are some of our performance highlights
for 2019:
|
·
|
In advancing our tumor infiltrating lymphocyte (“TIL”) therapy in melanoma, in March 2019, we initiated patient dosing in our melanoma program, cohort 4 of our C-144-01 clinical trial, using lifileucel, our TIL therapy produced using our 22-day second generation manufacturing process. We completed patient dosing in cohort 4 in January 2020, three months ahead of schedule.
|
|
·
|
We continued to present clinical data to demonstrate the efficacy and safety of lifileucel in metastatic melanoma and for our TIL therapy LN-145 in recurrent, metastatic, or persistent cervical cancer, including presentations at the 2019 Meeting of the American Society of Clinical Oncology and the 34th Meeting of the Society for Immunotherapy in Cancer.
|
|
·
|
In progressing our TIL therapy in cervical cancer, we received Fast Track designation and Breakthrough Therapy Designation for LN-145 in recurrent, metastatic or persistent cervical cancer with disease progression on or after chemotherapy from the U.S. Food and Drug Administration (“FDA”), and we held an End-of-Phase 2 meeting with the FDA where the FDA agreed that data from our ongoing clinical trial of LN-145, C-145-04, may be supportive of registration for treatment of patients with advanced cervical cancer.
|
|
·
|
To expand our TIL therapy to earlier line patients and new indications, we initiated patient dosing in our IOV-COM-202 clinical trial, which includes cohorts where TIL therapy is combined with pembrolizumab in immune checkpoint inhibitor naïve melanoma, squamous cell carcinoma of the head and neck, and non-small lung cancer (“NSCLC”), and a cohort where TIL therapy is offered to relapsed/refractory NSCLC patients.
|
|
·
|
Our investigational new drug (“IND”) application for our internally-developed peripheral blood lymphocyte therapy, IOV-2001, was accepted by the FDA in a blood cancer indication, relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, and the first patient was dosed with IOV-2001 in our Phase 1/2 study, IOV-CLL-01.
|
|
·
|
We began construction of our commercial manufacturing facility in Philadelphia, Pennsylvania.
|
Compensation Policies and Practices at a Glance
What we do
|
·
|
Practice pay-for-performance, under which a significant percentage of our named executive officer compensation is at-risk and may not be realized if corporate and individual performance goals are not achieved
|
|
·
|
Set challenging incentive award goals
|
|
·
|
Maintain an industry-specific peer group for benchmarking compensation
|
|
·
|
Target named executive officer compensation based on market norms
|
|
·
|
Offer market-competitive benefits for named executive officers that are consistent with the rest of our employees
|
|
·
|
Do not guarantee annual bonus or guarantee salary increases
|
|
·
|
Have a pre-established grant date practice for approving executive officers’ equity awards
|
|
·
|
Maintain an independent Compensation Committee
|
|
·
|
Consult with an independent compensation advisor on compensation levels and practices
|
What we do not do
|
·
|
Executives are prohibited from hedging or pledging our stock
|
|
·
|
Compensation Committee’s independent consultant performs no other work for the Company
|
|
·
|
No re-pricing of stock options
|
|
·
|
Provide excessive personal perquisites, such as automobile leases, country club memberships or personal use of aircraft
|
|
·
|
Provide supplemental executive retirement plans
|
Compensation Objectives and Philosophy
Our named executive officer compensation
program is designed to meet the following key objectives:
|
·
|
Attract, Motivate and Retain Talented and Dedicated Executive Officers. We strive to offer competitive compensation opportunities with both annual and significant long-term components that support management development and continuity of leadership.
|
|
·
|
Performance-Driven Pay: Align executive officer compensation with the achievement of our short- and long-term business objectives and strategies with the long-term interests of our stockholders through the use of performance-based and variable compensation elements.
|
|
·
|
Long-Term Focus on Stockholder Value: Provide our executive officers with long-term incentives that are directly aligned to the enhancement of stockholder value, as well as facilitate long-term executive retention.
|
Elements of Executive Officer Compensation
Our 2019 compensation program is made up
of the following three direct compensation elements:
Compensation Element
|
Purpose
|
Base Salary
|
· Fixed cash compensation that is reviewed annually and adjusted as appropriate based on individual performance and internal
and external practices and levels.
·
Attracts and retains executives by offering fixed compensation that is competitive with market opportunities and that recognizes
each executive’s position, role, responsibility, and experience.
|
Annual Incentives
|
·
Variable cash compensation based on performance versus pre-established annual goals as well as individual performance.
·
Designed to motivate and reward the achievement of our key annual performance objectives, which for 2019 were generally
based on clinical, manufacturing, regulatory, financial, and research and development performance.
|
Long-Term Incentives
|
·
Variable long-term compensation payable in the form of time-vesting stock options.
· Generally, employees receive an initial stock option grant upon joining the Company. Annually thereafter, employees are
eligible for grants based on a combination of company and individual performance.
·
Intended to align our executives’ interests with the interests of our stockholders through equity-based compensation where
value to the participants is directly tied to stockholder value.
·
Promotes the long-term retention of our executives and employees.
·
Promotes an ownership culture among our employees.
|
Mix of Executive Officer Compensation
Our Compensation Committee does not have
any formal policies for allocating compensation among our three primary compensation elements. Rather, our Compensation Committee
uses its judgment to determine the appropriate level and mix of compensation on an annual basis with the goal to balance current
cash compensation with equity awards to reward both short-term and long-term performance. In addition, we believe that our executive
officer compensation programs should be focused on performance- and stock price-variable compensation elements. For 2019, the mix
of compensation at target for our executive officers was as follows:(1)
|
(1)
|
The 2019 mix of compensation is based on the compensation provided to Dr. Fardis (“CEO”)
and Mr. Morris, and Dr. Vogt (“Other NEOs”). The exhibits above exclude Dr. Graf Finkenstein, who was not employed
by us at the beginning of the year.
|
Role of the Board of Directors, the Compensation Committee,
Management and Consultant
Our Compensation Committee is charged with,
among other things, the responsibility of reviewing executive officer compensation policies and practices to ensure adherence to
our compensation philosophy and objectives and that the total compensation paid to our executive officers is consistent with our
performance, fair, reasonable and competitive with companies within our industry. Our Compensation Committee’s primary responsibilities
with respect to determining executive compensation are (i) setting performance targets under our annual bonus plan; (ii) verifying
that performance targets used for any performance-based compensation plan have been met before payment of any executive bonus or
compensation; (iii) approving all amendments to, and terminations of, all compensation plans and any awards under such plans; (iv)
granting any awards under any performance-based annual bonus, long-term incentive compensation and equity compensation plans to
executive officers; (v) approving which executive officers and other employees receive awards under our equity and incentive compensation
plan(s); and (vi) conducting an annual review of all compensation plans. In some cases, the Compensation Committee makes recommendations
that our Board approve these items or grant equity awards.
The Compensation Committee reviews and considers
our Chief Executive Officer’s recommendations with respect to compensation decisions for our named executive officers, other
than herself. The Compensation Committee believes it is valuable to consider the recommendations of our Chief Executive Officer
with respect to these matters because, given her knowledge of our operations, the biotechnology industry and the day-to-day responsibilities
of our executive officers, she is in the best position to provide the Compensation Committee perspective into the performance of
our executive officers. Our Board of Directors (without the participation of our Chief Executive Officer), after considering the
recommendations of the Compensation Committee, makes the final determination with respect to the compensation of our Chief Executive
Officer.
As part of the 2019 and 2020 executive compensation
process, the Compensation Committee engaged Haigh & Company (“Haigh”) as its compensation consultant. Haigh provides
us advisory services only with respect to executive and director compensation and works with management only with the approval
and under the direction of the Compensation Committee. Haigh assisted in the development of our 2019 peer group, reviewed the compensation
components of our 2019 program for our named executive officers and advised the Compensation Committee regarding the components
and levels of the executive compensation program, including our incentive and equity-based compensation plans. Haigh continues
to make itself available on an ongoing basis to provide guidance to the Compensation Committee on compensation issues as they arise.
The Compensation Committee has assessed Haigh’s independence pursuant to SEC rules and concluded that no conflict of interest
exists that would prevent Haigh from independently advising the Compensation Committee.
Compensation Determination Process and the Role of Named
Executive Officers in Compensation Decisions
We conduct an annual review of named executive
officer compensation with a presentation by our Chief Executive Officer to our Board of Directors and Compensation Committee regarding
each element of our executive compensation arrangements. Our Compensation Committee met on December 15, 2019 to establish year-end
compensation for the fiscal year ended December 31, 2019. At the Compensation Committee’s direction, our Chief Executive
Officer, in consultation with Haigh, typically prepares an executive compensation review for each named executive officer which
includes reviews of, and recommendations for:
|
·
|
the Company’s goals and objectives and their weighting for the purposes of making compensation determinations;
|
|
·
|
a proposed year-end cash bonus, if any, (i) payable under the terms of each named executive officer’s employment agreement or (ii) under our discretionary cash bonus program, in each case based on the achievement of individual and/or corporate objectives and the applicable terms of the employment agreements;
|
|
·
|
a proposed increase, if any, in base salary for the upcoming year; and
|
|
·
|
an award, if any, of stock options or stock awards for the year under review.
|
As part of the compensation review, our
Compensation Committee also considers changes to an executive officer’s compensation. The Compensation Committee in its discretion
may revise our Chief Executive Officer’s recommendations or make its own recommendations to our Board of Directors, which
may in turn suggest further revisions. The Compensation Committee, in consultation with our Chief Executive Officer, reviews each
performance goal and determines the extent to which we achieved such goals. For a description of some of the goals established
for 2019, see “2019 Named Executive Officer Compensation - Annual and Special Cash Bonuses,” below.
In accordance with Nasdaq requirements,
the Compensation Committee also meets in an executive session without the Chief Executive Officer to consider and make recommendations
to our Board of Directors regarding the Chief Executive Officer’s compensation, including base salary and cash bonus. The
Compensation Committee recommends to our Board of Directors year-end annual stock option grants to our Chief Executive Officer.
The Compensation Committee also grants year-end stock options to other named executive officers based on, among other factors,
recommendations by our Chief Executive Officer.
Peer and Industry Data
For purposes of determining the competitiveness
of 2019 compensation and setting compensation for 2020, our Compensation Committee, with the advice of Haigh, examined our 2019
peer group in light of our continued growth throughout 2019, which is anticipated to continue in 2020, the stage of development
of our clinical programs, the growth in our headcount and changes in our market capitalization. With reference to these and other
key business metrics, companies whose market capitalization and/or whose number of employees that were at the low end, below, or
significantly above our targeted range were removed and new companies were added to the peer group for 2020. Based on its discussions
with Haigh, the Compensation Committee identified the following 18 peer companies for determining the competitiveness of 2019 compensation
and setting compensation for 2020 that were selected from among publicly-held U.S. pharmaceutical and biotechnology companies with
comparable operations in the U.S. based on the following criteria: number, stage and indication of development programs, total
R&D spending, number of employees, and market capitalization:
Acceleron Pharma, Inc.
Aimmune Therapeutics, Inc.
AnaptysBio, Inc.
Atara Biotherapeutics, Inc.
Audentes Therapeutics, Inc.
Blueprint Medicines Corp.
ChemoCentryx, Inc.
Cytokinetics, Inc.
Editas Medicine, Inc.
|
Epizyme, Inc.
Fate Therapeutics, Inc.
Five Prime Therapeutics, Inc.
Mirati Therapeutics, Inc.
MyoKardia, Inc.
Portola Pharmaceuticals, Inc.
Sangamo Therapeutics, Inc.
Xencor, Inc.
Zogenix, Inc.
|
In 2019, Audentes Therapeutics, MyoKardia,
and Xencor were added as peer companies based primarily on comparable headcount and market capitalization at the time of our Compensation
Committee’s review. Location, expertise and field of drug development of the peer companies were also considered, because
of the similarities between the talent pools accessible by these companies and by our Company. Aduro BioTech, Calithera Biosciences,
CytomX Therapeutics, ImmunoGen, and Kura Oncology were removed from our prior year’s peer group primarily based on their
stage of development and their market capitalization, which was below the low-end of our targeted range.
In addition to the compensation data of
our peer group, our Compensation Committee and Haigh review industry specific, broad-based compensation surveys. In 2019, the Radford
Global Life Science survey was used to supplement the peer company market data.
Benchmarking in the Context of Our Other Executive Compensation
Principles
Our Compensation Committee and our Board
of Directors use market data as one means of evaluating and establishing executive pay. In instances where an executive officer
is believed to be especially suited to our Company or important to our success, the Compensation Committee may establish or recommend
compensation that deviates from industry averages or other specific benchmarks. Upward or downward variations in total cash compensation
and long-term incentives may also occur as a result of the individual’s experience level, the nature and level of the individual’s
specific job responsibilities, the balance of the individual’s different elements of compensation, market factors and other
strategic considerations.
Our Compensation Committee believes that,
given the competitiveness of our industry and our corporate culture, our base compensation, annual cash bonuses and equity programs
are flexible enough to reward the achievement of clearly defined corporate goals and are sufficient to retain our existing executive
officers and to hire new executive officers with the appropriate qualifications and experience.
2019 Named Executive Officer Compensation
Base Salaries
The Compensation Committee considers salary
increases for our named executive officers generally on an annual basis, setting salaries based on market compensation levels and
the recommendations of our Chief Executive Officer after assessing each executive’s performance. A similar process is used
by the Board of Directors in setting our Chief Executive Officer’s salary. The Chief Executive Officer does not provide recommendations
on her own salary.
At its February 26, 2019 meeting, our Compensation
Committee approved the following base salary actions:
Name and Position (1)
|
|
2018
Salary
|
|
|
2019
Salary
|
|
|
% Increase
from Final 2018
Base Salary
|
|
|
|
|
|
|
|
|
|
|
|
Maria Fardis, Ph.D., President and Chief Executive Officer
|
|
$
|
600,000
|
|
|
$
|
600,000
|
|
|
|
0
|
%
|
Timothy E. Morris, Chief Financial Officer
|
|
$
|
450,000
|
|
|
$
|
460,000
|
|
|
|
2.22
|
%
|
Friedrich Graf Finckenstein, M.D., Chief Medical Officer
|
|
$
|
--
|
|
|
$
|
450,000
|
|
|
|
(1
|
)
|
Frederick G. Vogt, Ph.D., Esq., General Counsel and Corporate Secretary
|
|
$
|
375,000
|
|
|
$
|
400,000
|
|
|
|
6.67
|
%
|
|
(1)
|
Dr. Graf Finckenstein became an employee of the Company on July 18, 2019.
|
The Compensation Committee did not increase
the salary of Dr. Fardis from her 2018 base salary level based on its determination that Dr. Fardis’ salary was already competitive
with our peer group. In recognition of their performance, the Compensation Committee increased the 2019 base salaries of Mr. Morris
to $460,000 and Dr. Vogt to $400,000 over their 2018 base salary levels. Dr. Graf Finckenstein became an employee of the Company
on July 18, 2019 and received a 2019 base salary of $450,000.
Annual Incentive Bonuses
The corporate goals and objectives for fiscal
year 2019 were based on meeting certain goals with respect to the Company’s operational performance as follows: (i) enrolling
a specified number of patients in the Company’s clinical program including C-144-01 and C-145-04 clinical trials of its TIL
therapies; (ii) ensuring that the Company’s second generation TIL manufacturing process is prepared for product registration;
(iii) selecting a location and commencing work on a commercial manufacturing facility; (iv) completing certain regulatory interactions
and submissions; ; (v) completing certain preclinical work to support IND applications in the U.S. for new Company products; (vi)
achieving specified goals relating to submission of Company data for presentations at medical conferences; and (vii) managing the
Company’s budget.
At its December 15, 2019 meeting, the Compensation
Committee determined that the Company met 100% of its 2019 corporate goals and paid the following bonuses for 2019 performance.
Mr. Morris did not receive a performance bonus for fiscal year 2019.
Name and Position
|
|
Hire Date
|
|
Annual
Incentive
Target % (1), (3)
|
|
|
2019 Target
Bonus
Opportunity
|
|
|
2019 Actual
Bonus
Payment (2)
|
|
|
2019 Actual
Bonus
Payment (%
of Target
Award
Opportunity)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maria Fardis, Ph.D., President and Chief Executive Officer
|
|
6/1/2016
|
|
|
100
|
%
|
|
$
|
600,000
|
|
|
$
|
600,000
|
|
|
|
100
|
%
|
Timothy E. Morris, Chief Financial Officer
|
|
8/14/2017
|
|
|
40
|
%
|
|
$
|
184,000
|
|
|
$
|
-
|
|
|
|
0
|
%
|
Friedrich Graf Finckenstein, M.D., Chief Medical Officer (4)
|
|
7/18/2019
|
|
|
40
|
%
|
|
$
|
81,863
|
|
|
$
|
82,500
|
|
|
|
101
|
%
|
Frederick G. Vogt, Ph.D., Esq., General Counsel and Corporate Secretary
|
|
9/30/2016
|
|
|
40
|
%
|
|
$
|
160,000
|
|
|
$
|
160,000
|
|
|
|
100
|
%
|
|
(1)
|
The annual cash bonus target is a percentage of base salary.
|
|
(2)
|
Bonus amounts were paid on March 13, 2020.
|
|
(3)
|
The annual cash bonus target will remain the same for 2020.
|
|
(4)
|
Bonus amount prorated based on Dr. Graf Finckenstein’s date of hire.
|
The Compensation Committee retains the right
to make discretionary cash bonus payments in excess of the target cash bonus levels to the named executive officers if in its opinion
a named executive officer’s performance justifies such excess payment. No excess payments were made for 2019.
2019 Initial and Annual Stock Option Awards
Our Board of Directors and Compensation
Committee generally make annual stock option grants to our named executive officers in recognition of their performance, potential
and the critical impact of their roles following our fiscal year. Dr. Graf Finckenstein was granted stock options upon becoming
an employee with us.
At its February 26, 2019 meeting, our Compensation
Committee approved the following stock option awards that were granted on March 4, 2019, except that Dr. Graf Finckenstein’s
award was approved by our Board of Directors and was made in connection with his hiring:
Name
|
|
Grant Date
|
|
Number of
Securities
Underlying
Options (1)
|
|
|
Exercise
Price of
Option
Awards
($/Share)
|
|
|
Grant Date
Fair Value of
Stock and
Option Awards
($) (2)
|
|
Maria Fardis, Ph.D.
|
|
3/4/2019
|
|
|
400,000
|
(3)
|
|
$
|
11.26
|
|
|
$
|
2,907,960
|
|
Timothy E. Morris
|
|
3/4/2019
|
|
|
100,000
|
(3)
|
|
$
|
11.26
|
|
|
$
|
726,990
|
|
Friedrich Graf Finckenstein, M.D. (4)
|
|
7/18/2019
|
|
|
160,000
|
(3)
|
|
$
|
25.78
|
|
|
$
|
2,655,440
|
|
Frederick G. Vogt, Ph.D., Esq.
|
|
3/4/2019
|
|
|
200,000
|
(3)
|
|
$
|
11.26
|
|
|
$
|
1,453,980
|
|
|
(1)
|
Represents shares of our common stock underlying options awarded, each of which vest over time.
|
|
(2)
|
Represents the fair value of each equity award on the date of grant, as computed in accordance with FASB ASC 718.
|
|
(3)
|
The option awards vest as to 33% of the shares underlying the options on the first anniversary, with remaining option awards vesting in equal quarterly installments over the two-year period following such first anniversary.
|
|
(4)
|
Dr. Graf Finckenstein joined the Company on July 18, 2019.
|
2020 Named Executive Officer Compensation
At its December 15, 2019 meeting, our Compensation
Committee approved a 5% salary increase for Dr. Vogt resulting in a base salary for 2020 of $420,000. The Compensation Committee
also approved the following stock option awards that were granted on January 3, 2020. Even though these awards are granted in part
based on 2019 performance, these stock option values will not be disclosed in our executive compensation tables until our 2021
proxy:
Name
|
|
Grant Date
|
|
Number of
Securities
Underlying
Options (1)
|
|
|
Exercise
Price of
Option
Awards
($/Share)
|
|
|
Grant Date
Fair Value of
Stock
Option Awards
($) (2)
|
|
Maria Fardis, Ph.D.
|
|
1/03/2020
|
|
|
500,000
|
(3)
|
|
$
|
25.54
|
|
|
$
|
8,139,400
|
|
Friedrich Graf Finckenstein, M.D.
|
|
1/03/2020
|
|
|
75,000
|
(3)
|
|
$
|
25.54
|
|
|
$
|
1,220,910
|
|
Frederick G. Vogt, Ph.D., Esq.
|
|
1/03/2020
|
|
|
150,000
|
(3)
|
|
$
|
25.54
|
|
|
$
|
2,441,820
|
|
|
(1)
|
Represents shares of our common stock underlying options awarded.
|
|
(2)
|
Represents the fair value of each equity award on the date of grant, as computed in accordance with Financial Accounting Standards ASC Topic 718.
|
|
(3)
|
The option awards vest as to one third of the shares underlying the options on the first anniversary, with remaining option awards vesting in equal quarterly installments over the two-year period following such first anniversary.
|
Other Compensation Elements
Retirement Plans, Perquisites and Other Personal Benefits
Our named executive officers are eligible
to participate in the employee benefit plans on the same terms and conditions as they are available to our other regular employees.
These benefits include medical, dental, vision, disability and life insurance, flexible spending accounts, and a 401(k) plan.
Under the tax-qualified employee savings
and retirement plan, our 401(k) plan, all eligible U.S. employees, including our named executive officers, may elect to defer a
percentage of their eligible compensation in our 401(k) plan, subject to the annual IRS limit. In 2019, we matched 100% of the
employee contributions up to 4% of annual eligible compensation. The 2019 matching contributions made under the Safe Harbor Matching
Contribution are fully vested.
We do not provide perquisites or other personal
benefits to our named executive officers other than those that we provide to our employees. We do not provide any tax reimbursement
payments (including “gross-ups”) on any personal benefits, except in the case of certain relocation benefits.
Discretionary Cash Bonuses
From time to time, we may pay cash bonuses
to employees upon the successful completion of certain projects and we may also pay sign-on bonuses to aid in recruiting certain
key employees.
Employment Agreements and Termination Benefits.
We have entered into written employment
agreements with each of our current and former named executive officers. The main purpose of these agreements is to protect our
Company from business risks such as competition for each named executive officer’s service, loss of confidential information
or trade secrets, solicitation of our other employees, and to define our respective rights to terminate the employment relationship.
Each of these employment agreements can be terminated by either party at any time. Each employment agreement was individually negotiated,
so there are some variations in the terms among named executive officers. Generally speaking, however, the employment agreements
provide for termination and severance benefits that the Compensation Committee believes are consistent with industry practices
for similarly situated executives. The Compensation Committee believes that the termination and severance benefits help the Company
retain the named executive officers by providing them with a competitive employment arrangement and compensation for termination
of their employment by us without “cause.”
In the event of termination of a named executive
officer’s employment by us without “cause” or a resignation for “good reason,” the named executive
officers will be, entitled to a lump-sum payment, which payment is equal to twelve months of base salary in the case of Dr. Fardis,
and six months of base salary in the case of Mr. Morris, Dr. Graf Finckenstein, and Dr. Vogt. If a named executive officer’s
employment is terminated by us without “cause” in connection with a change of control of our Company, the named executive
officers will be entitled to a lump-sum payment equal to twelve months of base salary in the case of Dr. Fardis and Mr. Morris,
and six months of base salary in the case of Dr. Graf Finckenstein and Dr. Vogt, plus in each instance the pro-rated amount of
their respective minimum bonuses for those periods. In addition, if the employment agreements of Dr. Fardis, Dr. Graf Finckenstein,
or Dr. Vogt are terminated by us without “cause” or by them for “good reason,” their unvested stock options
vest immediately.
The specific terms of the termination and
change of control arrangements, as well as an estimate of the compensation that would have been payable had such provisions been
triggered as of the end of 2019, are described in detail in the section below entitled “Executive Compensation – Potential
Payments Upon Termination/Change of Control.”
Other Executive Compensation Considerations
Stock Ownership Guidelines
Although stock option grants encourage equity
ownership, we do not require our directors or executive officers to own a particular number of shares of our common stock. We believe
that stock and option holdings among our directors and named executive officers are adequate at this time to appropriately align
their interests with those of our stockholders.
Deductibility of Executive Compensation
The Compensation Committee takes into consideration
the tax consequences of compensation to the named executive officers, but tax considerations are not a significant part of our
Company’s compensation policy especially in light of the passage of the Tax Cuts and Jobs Act of 2017 (“TCJA”),
which limits the deductibility of certain compensation to highly compensated executives.
Accounting for Share-Based Compensation
We account for share-based compensation
in accordance with the requirements of FASB ASC Topic 718. This accounting treatment has not significantly affected our executive
compensation decisions.
Clawbacks
We are subject to the clawback provisions
of Section 304 of the Sarbanes-Oxley Act and Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act and any
rules or regulations promulgated thereunder (collectively, “SOX 304”). In addition, our 2018 Plan contains a “clawback”
provision whereby, to the extent required by applicable law (including, without limitation, SOX 304) and/or the rules and regulations
of Nasdaq or any other securities exchange or inter-dealer quotation service on which our common stock is listed or quoted, awards
issued under the 2018 Plan shall be subject (including on a retroactive basis) to clawback, forfeiture or similar requirements,
in the event our Company’s historical financial results are subsequently revised or restated.
Insider Trading Policy
Our insider trading policy expressly prohibits
short sales and derivative transactions of our stock by our named executive officers, directors and specified other employees,
including short sales of our securities, including short sales “against the box”; purchases or sales of puts, calls
or other derivative securities of the Company or any derivative securities that provide the economic equivalent of ownership of
any of our securities or an opportunity, direct or indirect, to profit from any change in the value of our securities; or other
hedging or monetization transactions accomplished through the use of prepaid variable forwards, equity swaps, collars and exchange
funds. In addition, our insider trading policy expressly prohibits our named executive officers, directors and specified other
employees from purchasing our securities on margin, borrowing against Company securities held in a margin account, or pledging
our securities as collateral for a loan.
The foregoing policies remained in place
through 2019, and, unless otherwise noted above, we expect to continue to follow them for the foreseeable future.
Compensation Committee Interlocks and Insider Participation
During 2019, no member of the Compensation
Committee served as one of our officers, former officers, or employees. During 2019, none of our named executive officers served
as a member of the compensation committee of any other entity, one of whose executive officers served as a member of our Board
of Directors or Compensation Committee, and none of our named executive officers served as a member of the Board of Directors of
any other entity, one of whose executive officers served as a member of our Compensation Committee.
2019 Stockholder Advisory Vote
Each year, we hold a non-binding advisory
stockholder vote on the compensation program for our named executive officers. At our annual stockholder meetings held in 2017,
2018 and 2019, our stockholders approved, on an advisory basis, the compensation of our named executive officers. In evaluating
our compensation arrangements in late 2018 (and most recently for 2019 year-end bonuses), we considered the support of our stockholders
of our compensation arrangements and objectives. As a result, our Compensation Committee retains our general approach to executive
compensation and continues to apply the same general principles and philosophy as in the prior fiscal years in determining executive
compensation. Our Compensation Committee values the opinions of our stockholders and will take our stockholders’ opinions
into account when making compensation decisions for the members of our executive team, including the named executive officers.
Report of the Compensation Committee on Executive Compensation
The Compensation Committee of our Board
of Directors has reviewed and discussed with management the foregoing “Compensation Discussion and Analysis” required
by Item 402(b) of Regulation S-K and, based on such review and discussions, the Compensation Committee recommended to our Board
of Directors that this “Compensation Discussion and Analysis” be included in this Proxy Statement.
COMPENSATION COMMITTEE OF THE BOARD OF
DIRECTORS
Michael Weiser, M.D., Ph.D. (Chair)
Athena Countouriotis, M.D.
Merrill A. McPeak
Wayne P. Rothbaum
Summary Compensation of Named Executive Officers
The following table sets forth all compensation
awards to, paid or earned by the following type of named executive officers for each of the Company’s last three years ended
December 31, 2019, 2018, and 2017: (i) individuals who served as, or acted in the capacity of, the Company’s principal executive
officer or principal financial officer for the year ended December 31, 2019; (ii) the Company’s most highly compensated executive
officers, other than the principal executive officer or principal financial officer, who were serving as executive officers at
the end of the year ended December 31, 2019; and (iii) up to two additional individuals for whom the disclosure would have been
provided but for the fact that the individual was not serving as an executive officer of the Company at the end of the year ended
December 31, 2019. We refer to these individuals collectively as our named executive officers.
Name and Principal
|
|
|
|
Salary (1)
|
|
|
Bonus
|
|
|
Stock
Awards
|
|
|
Stock
Options (2)
|
|
|
Non-Equity
Incentive Plan
Compensation (3)
|
|
|
All Other
Compensation
|
|
|
Total
|
|
Position
|
|
Year
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)(10)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current Officers:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maria Fardis, Ph.D.
|
|
2019
|
|
$
|
600,000
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
2,907,960
|
|
|
$
|
600,000
|
|
|
$
|
-
|
|
|
$
|
4,107,960
|
|
President and Chief
|
|
2018
|
|
$
|
600,000
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
8,284,600
|
(4)
|
|
$
|
510,000
|
|
|
$
|
-
|
|
|
$
|
9,394,600
|
|
Executive Officer
|
|
2017
|
|
$
|
500,000
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
350,000
|
|
|
$
|
-
|
|
|
$
|
850,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Timothy E. Morris (5)
|
|
2019
|
|
$
|
460,000
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
726,990
|
|
|
$
|
-
|
|
|
$
|
11,200
|
|
|
$
|
1,198,190
|
|
Chief Financial
|
|
2018
|
|
$
|
450,000
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
153,000
|
|
|
$
|
11,000
|
|
|
$
|
614,000
|
|
Officer
|
|
2017
|
|
$
|
172,212
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
1,262,500
|
|
|
$
|
65,130
|
(6)
|
|
$
|
-
|
|
|
$
|
1,499,842
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Friedrich Graf
Finckenstein, M.D. (7)
|
|
2019
|
|
$
|
204,807
|
|
|
$
|
160,000
|
(8)
|
|
$
|
-
|
|
|
$
|
2,665,440
|
|
|
$
|
82,500
|
|
|
$
|
11,200
|
|
|
$
|
3,113,947
|
|
Chief Medical Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Frederick G. Vogt,
|
|
2019
|
|
$
|
400,000
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
1,453,980
|
|
|
$
|
160,000
|
|
|
$
|
11,200
|
|
|
$
|
2,025,180
|
|
Ph.D., Esq. (9)
|
|
2018
|
|
$
|
375,000
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
127,500
|
|
|
$
|
11,000
|
|
|
$
|
513,500
|
|
General Counsel
|
|
2017
|
|
$
|
326,355
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
393,070
|
|
|
$
|
131,390
|
(9)
|
|
$
|
9,075
|
|
|
$
|
859,890
|
|
and Corporate Secretary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Includes amounts earned but deferred at the election of the named executive officer, such as salary deferrals under the Company’s 401(k) plan.
|
|
(2)
|
The Company’s share-based compensation program includes incentive and non-statutory stock options. The amounts set forth under this column represent the aggregate grant date fair value of stock options granted in each fiscal year for financial reporting purposes under Statement of Financial Accounting Standards ASC Topic 718, “Stock Compensation,” disregarding the estimate of forfeitures. The Company’s methodology, including its underlying estimates and assumptions used in calculating these values, is set forth in Note 6 to its audited financial statements included in its Form 10-K filed with the SEC for the year ended December 31, 2019. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options.
|
|
(3)
|
Amounts reported represent the annual cash performance-based bonuses earned pursuant to the achievement of certain corporate and individual performance objectives during 2019. Please see the descriptions of the annual performance bonuses in the prior sections entitled “Annual Cash Incentive Bonuses.”
|
|
(4)
|
The grant date fair value of stock options calculated using Black-Scholes calculations in accordance with Statement of Financial Accounting Standards ASC Topic 718, “Stock Compensation,” included the following inputs: volatility, 192%; expected term, 6 years; risk free interest rate, 2.58%; and dividend rate, 0%. The volatility was calculated using historical Company share prices which included the impact of a 100-to-1 reverse split which occurred subject to a restructuring effective May 22, 2013. Starting on January 1, 2019, the volatility calculation no longer included the impact of the unusual volatility observed in 2013 due in part to the 100-to-1 reverse split. During 2019, the volatility used in the Black-Scholes calculations ranged between 71.62% - 70.63%.
|
|
(5)
|
Mr. Morris became our Chief Financial Officer on August 14, 2017.
|
|
(6)
|
Amount represents a discretionary pro-rata annual bonus paid for the 2017 fiscal year.
|
|
(7)
|
Dr. Graf Finckenstein became our Chief Medical Officer on July 18, 2019, and the values shown here are pro-rated for the duration of his time at the Company.
|
|
(8)
|
Amount represents a sign-on bonus.
|
|
(9)
|
Dr. Vogt was promoted to General Counsel on July 1, 2017 and became a named executive officer on October 20, 2017. Amounts paid to Dr. Vogt prior thereto represent compensation he received after joining the Company on September 30, 2016 as Vice President, Intellectual Property.
|
|
(10)
|
Represents the Company matching portion of amounts
contributed to the Company’s 401(k) plan on behalf of the named executive officer.
|
Chief Executive Officer Pay Ratio
As a result of the recently adopted rules
under the Dodd-Frank Act, SEC rules now require companies to disclose the ratio of the total annual compensation of the principal
executive officer to the median employee’s total annual compensation. We identified the median employee by examining the
2019 total annual compensation for all individuals, excluding our Chief Executive Officer, who were employed by us on December
17, 2019. We included all employees. For all employees, we examined total compensation, which included base salary, incentive compensation
plan payments, equity awards consisting of stock options, and other compensation such as 401(k) matching contributions. We annualized
the compensation of all permanent employees who were not employed by us for all of 2019.
After identifying the median employee based
on total cash compensation, we calculated annual total compensation for that employee using the same methodology we use for our
named executive officers as set forth in the 2019 Summary Compensation Table above. We then updated the median employee’s
compensation to be stated in the same manner as our named executive officers. The total annual compensation of the median employee
for 2019 was $355,547. The total annual compensation including bonuses for our Chief Executive Officer for 2019 was $4,107,960.
The ratio of Chief Executive Officer total annual compensation to the median employee total annual compensation for 2019 was approximately
11.6 to 1.
Outstanding Equity Awards
The following table sets forth outstanding
stock options held by our named executive officers as of December 31, 2019. Options were granted in 2019 under the 2018 Plan and
the remaining options were granted under the 2014 Plan. In addition, the following table sets forth the restricted stock units
held by Dr. Fardis under a restricted stock unit agreement as of December 31, 2019.
Outstanding Equity Awards at Year Ended
December 31, 2019
|
|
Option Awards
|
|
Stock Awards
|
|
|
|
Grant Date
|
|
Number
of Securities Underlying Unexercised Options
(#)
Exercisable
|
|
|
Number
of Securities Underlying Unexercised Options
(#)
Unexercisable
|
|
|
Option Exercise Price
($)
|
|
|
Option Expiration
Date
|
|
|
Number of Shares or Units
of Stock That Have Not Vested
(#)
|
|
|
Market Value of Shares or
Units of Stock That Have Not Vested
($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maria Fardis, Ph.D.
|
|
3/4/2019
|
|
|
-
|
|
|
|
400,000
|
|
|
$
|
11.26
|
|
|
|
3/4/2029
|
|
|
|
-
|
|
|
|
-
|
|
|
|
2/9/2018
|
|
|
291,666
|
|
|
|
208,334
|
|
|
$
|
16.80
|
|
|
|
2/9/2028
|
|
|
|
-
|
|
|
|
-
|
|
|
|
6/1/2016
|
|
|
437,498
|
|
|
|
62,502
|
|
|
$
|
5.87
|
|
|
|
6/1/2026
|
|
|
|
-
|
|
|
|
-
|
|
|
|
6/1/2016
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
22,916
|
|
|
$
|
634,315
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Timothy E. Morris
|
|
3/4/2019
|
|
|
-
|
|
|
|
100,000
|
|
|
$
|
11.26
|
|
|
|
3/4/2029
|
|
|
|
-
|
|
|
|
-
|
|
|
|
8/14/2017
|
|
|
187,500
|
|
|
|
62,500
|
|
|
$
|
5.05
|
|
|
|
8/14/2027
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Friedrich Graf Finckenstein, M.D.
|
|
7/18/2019
|
|
|
-
|
|
|
|
160,000
|
|
|
$
|
25.78
|
|
|
|
7/18/2029
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Frederick G. Vogt, Ph.D., Esq.
|
|
3/4/2019
|
|
|
-
|
|
|
|
200,000
|
|
|
$
|
11.26
|
|
|
|
3/4/2029
|
|
|
|
-
|
|
|
|
-
|
|
|
|
12/29/2017
|
|
|
24,933
|
|
|
|
12,467
|
|
|
$
|
8.00
|
|
|
|
12/29/2027
|
|
|
|
-
|
|
|
|
-
|
|
|
|
3/16/2017
|
|
|
11,550
|
|
|
|
1,050
|
|
|
$
|
7.45
|
|
|
|
3/16/2027
|
|
|
|
-
|
|
|
|
-
|
|
|
|
11/14/2016
|
|
|
200,000
|
|
|
|
-
|
|
|
$
|
7.55
|
|
|
|
11/14/2026
|
|
|
|
-
|
|
|
|
-
|
|
Option Exercises and Restricted Stock Units Vested
The following table contains information
for our named executive officers concerning the option awards that were exercised and restricted stock units that vested during
the year ended December 31, 2019:
|
|
Option Awards
|
|
|
Stock Awards
|
|
Name
|
|
Number of
Shares
Acquired on
Exercise
|
|
|
Value
Realized on
Exercise ($)
|
|
|
Number of
Shares Acquired
on Vesting
|
|
|
Value Realized
on
Vesting ($) (1)
|
|
Maria Fardis, Ph.D.
|
|
|
-
|
|
|
$
|
-
|
|
|
|
45,833
|
|
|
$
|
768,998
|
|
|
(1)
|
Represents the closing price of our common stock on the vesting date multiplied by the number of restricted stock units that vested on that date.
|
Potential Payments Upon Termination/Change of Control
Our named executive officer employment agreements
have no specified term, and the employment relationship may be terminated by the named executive officers or by us at any time.
The following table sets forth information regarding payments that would have been made to our named executive officers if they
suffered an involuntary termination without cause not in connection with a change of control, or a termination without cause in
connection with a change of control, and such termination payments were triggered on December 31, 2019. The closing price per share
of our common stock on the Nasdaq Global Market on December 31, 2019 was $27.68. The amounts listed below do not include any taxes
due in connection with such payments, including any tax under Section 280G of the Internal Revenue Code of 1986, as amended (the
“Code”) that may be triggered by such payments. See the Employment Agreements section following the table for potential
additional benefits that may be awarded to the named executive officers as well as additional conditions that may apply to such
payments.
|
|
Change in Control/Acceleration
and Termination
|
|
|
Termination Without Cause
|
|
|
|
Salary and
|
|
|
Equity
|
|
|
Salary and
|
|
|
Equity
|
|
|
|
Bonus
|
|
|
Acceleration
|
|
|
Bonus
|
|
|
Acceleration
|
|
Name
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maria Fardis, Ph.D.
|
|
$
|
1,200,000
|
(1)
|
|
$
|
10,832,157
|
(2)
|
|
$
|
1,200,000
|
(1)
|
|
$
|
7,628,470
|
(3)
|
Timothy E. Morris
|
|
$
|
644,000
|
(4)
|
|
$
|
3,056,375
|
(5)
|
|
$
|
230,000
|
(6)
|
|
$
|
-
|
|
Friedrich Graf Finckenstein, M.D.
|
|
$
|
225,000
|
(6)
|
|
$
|
304,000
|
(5)
|
|
$
|
225,000
|
(6)
|
|
$
|
-
|
|
Frederick G. Vogt, Ph.D., Esq.
|
|
$
|
200,000
|
(6)
|
|
$
|
3,550,592
|
(5)
|
|
$
|
360,000
|
(7)
|
|
$
|
3,550,592
|
(5)
|
|
(1)
|
Dr. Fardis would have received one year of her annual base salary, and the target bonus for that year. In addition, Dr. Fardis may be entitled to additional severance payments under certain circumstances pursuant to her Executive Employment Agreement.
|
|
(2)
|
Upon a change of control, all of Dr. Fardis’ unvested time-based stock options and all unvested restricted stock units would vest immediately, and Dr. Fardis would have twelve months from the date of termination within which to exercise her vested options.
|
|
(3)
|
Upon termination, the vesting of Dr. Fardis’ stock options would accelerate by one year, Dr. Fardis would have twelve months from the date of termination within which to exercise her vested options, and the vesting of her time-based restricted stock units would have been accelerated by one year.
|
|
(4)
|
Mr. Morris would have received one year of his annual base salary, and his pro-rated target bonus for that year.
|
|
(5)
|
Upon termination, all equity awards would have vested and the named executive officer would have been given three months in which to exercise the equity awards.
|
|
(6)
|
The named executive officer would have received six months of his current annual base salary.
|
|
(7)
|
The named executive officer would have received six months of his annual base salary, and his pro-rated target bonus for that year assuming the bonus was earned in 2019.
|
Employment Agreements
The following is a summary of the employment
agreements we entered into with our four named executive officers, Dr. Fardis, Mr. Morris, Dr. Graf Finckenstein, and Dr. Vogt,
who continue to serve as executive officers as of the Record Date.
Maria Fardis, Ph.D. On June 1, 2016,
we entered into an Executive Employment Agreement with Maria Fardis, Ph.D., under which Dr. Fardis agreed to serve as our President
and Chief Executive Officer. In her employment agreement, we have agreed to pay Dr. Fardis an annual base salary of $500,000 and
a signing bonus of $150,000. In addition, on June 1, 2016, we granted to Dr. Fardis under our 2014 Plan stock options to purchase
an aggregate of 500,000 shares of our common stock and entered into a restricted stock unit agreement pursuant to which we granted
her 550,000 non-transferrable restricted stock units, outside the 2014 Plan, as an inducement of employment pursuant to the exception
to the Nasdaq Stock Market rules that generally require stockholder approval of equity incentive plans. Dr. Fardis’ stock
options have an exercise price per share of $5.87, vested 25% (125,000 shares) on June 1, 2017, with remaining options vesting
in equal monthly installments over the 36-month period following June 1, 2017. The restricted stock units vest in installments
as follows: (i) 137,500 restricted stock units vested upon the first anniversary of the effective date of her employment agreement;
(ii) 275,000 restricted stock units vested upon the satisfaction of certain clinical trial milestones; and (iii) 137,500 restricted
stock units vest in equal monthly installments over the 36-month period following the first anniversary of the effective date of
her employment, in each case, provided that Dr. Fardis has been continuously employed with us as of such vesting dates. Dr. Fardis
will also be eligible to participate in our annual incentive compensation program as approved by our Board of Directors, with target
potential annual incentive compensation of 50% of her base annual salary. On February 9, 2018, the Board of Directors increased
Dr. Fardis’ annual base salary from $500,000 to $600,000 and increased her annual cash bonus target as a percentage of her
annual base salary from 50% to 100% of her base salary.
If we terminate Dr. Fardis’ employment
agreement without “cause” (as defined in her employment agreement), or she terminates her employment for “good
reason,” Dr. Fardis will be entitled to receive her base salary through the date of termination, any incentive compensation
that was earned to the date of termination, and a severance payment equal to twelve months’ base annual salary and a full
year’s Incentive Compensation. In addition, Dr. Fardis may be entitled to additional severance payments under certain circumstances.
Further, there will be a twelve-month acceleration of her unvested stock options and unvested time-based restricted stock units,
and she will have twelve months from the date of termination within which to exercise her vested options.
In the event of a “change of control”
(as defined in her Executive Employment Agreement) of the Company, all of Dr. Fardis’ unvested time-based stock options and
all unvested restricted stock units will vest immediately, whether or not her employment is terminated. If, either before or after
a change in control, Dr. Fardis’ employment is terminated by us for any reason other than “cause” or she were
to terminate her employment for “good reason,” Dr. Fardis will be entitled to receive all of the cash payments she
would be entitled to receive in the event we were to terminate her employment without “cause.”
Timothy E. Morris. On August 4, 2017,
we entered into an Executive Employment Agreement with Mr. Morris pursuant to which agreed to serve as our Chief Financial Officer,
effective August 14, 2017. Under his employment agreement, we agreed to pay Mr. Morris an annual base salary of $450,000. In connection
with his employment, we granted Mr. Morris a ten-year incentive stock option to purchase up to an aggregate of 250,000 shares of
common stock at an exercise price of $5.05, which was equal to the closing trading price of our common stock on the date of his
employment. Provided that Mr. Morris is still employed with us on the following dates, the Option will vest in installments as
follows: (i) options for the purchase of one-third of the 250,000 shares shall vest on August 14, 2018; and (ii) the remaining
options shall vest as to one-twelfth of 250,000 shares at the end of each quarter over the next two years after August 14, 2018.
Mr. Morris will be eligible to participate in our annual cash bonus program applicable to executive employees, as approved annually
by the Board of Directors. The maximum potential amount payable to Mr. Morris under the bonus plan, if earned, is 40% of his base
salary earned during the applicable calendar year. Compensation under the bonus plan will be conditioned on the satisfaction of
individual and corporate objectives, as established in writing by our Compensation Committee, and on the condition that Mr. Morris
is still employed by us on the payment date of the bonus compensation. Mr. Morris’s annual salary was increased to $460,000,
effective February 15, 2019.
Mr. Morris’s employment is “at-will”
and not be for any pre-determined period of time. If the Company terminates Mr. Morris without cause, Mr. Morris will receive (i)
his base salary through the date of termination; (ii) a severance payment equal to six months of his then base salary, provided
he satisfies the severance conditions set forth in his employment agreement; and (iii) any benefits required to be paid in accordance
with applicable benefit plans through the date of termination. If Mr. Morris’ employment is terminated without cause in connection
with a “change of control” (as defined in his Executive Employment Agreement) of the Company, in addition to the foregoing
termination payments, Mr. Morris will receive a change of control severance payment equal to six months of his then base salary,
his prorated Incentive Compensation, and any of his time-based unvested stock options will become fully vested.
Friedrich Graf Finckenstein, M.D.
On May 18, 2019, we entered into an Executive Employment Agreement with Friedrich Graf Finckenstein, M.D., under which Dr. Graf
Finckenstein agreed to serve as our Chief Medical Officer. In his employment agreement, we agreed to pay Dr. Graf Finckenstein
an annual base salary of $450,000 and a signing bonus of $160,000, which included relocation expenses. In addition, effective as
of July 18, 2019, we granted him stock options to purchase an aggregate of 160,000 shares of our common stock. The stock options
have an exercise price of $25.78, equal to the fair market value of the common stock at the close of trading on the Nasdaq Global
Market as of the date of grant. The employment agreement provided that the foregoing stock options would vest in three installments
as follows: (i) options for the purchase of 53,333 shares vested on the one-year anniversary of the effective date of his employment;
and (ii) the remaining stock options vest as to 13,333 shares at the end of each quarter over the next two years. Dr. Graf Finckenstein
is eligible to participate in our annual incentive compensation program as approved by our Board of Directors, with target potential
annual incentive compensation of 40% of his base annual salary earned during the applicable calendar year.
Dr. Graf Finckenstein’s employment
is “at-will” and not be for any pre-determined period of time. If the Company terminates Dr. Graf Finckenstein without
cause, Dr. Graf Finckenstein will receive (i) his base salary through the date of termination; (ii) a severance payment equal to
six months of his then base salary, provided he satisfies the severance conditions set forth in his employment agreement; and (iii)
any benefits required to be paid in accordance with applicable benefit plans through the date of termination. If Dr. Graf Finckenstein’s
employment is terminated without cause in connection with a “change of control” (as defined in the employment agreement)
of the Company, in addition to the foregoing termination payments, Dr. Graf Finckenstein will receive a change of control severance
payment equal to six months of his then base salary, his prorated Incentive Compensation, and any of his time-based unvested stock
options will become fully vested.
Frederick G. Vogt, Ph.D., Esq. On
August 7, 2016, we entered into an Executive Employment Agreement with Frederick G. Vogt, Ph.D., Esq., under which Dr. Vogt agreed
to serve as our Vice President of Intellectual Property, effective September 30, 2016. In his employment agreement, we agreed to
pay Dr. Vogt an annual base salary of $300,000 and a signing bonus of $50,000. In addition, effective as of September 30, 2016,
we granted him stock options to purchase an aggregate of 200,000 shares of our common stock. The stock options have an exercise
price of $8.23, equal to the fair market value of the common stock at the close of trading on the Nasdaq Global Market as of the
date of grant. The employment agreement provided that the foregoing stock options would vest in three installments as follows:
(i) options for the purchase of 66,672 shares vested on the one-year anniversary of the effective date of his employment; and (ii)
the remaining stock options vest as to 16,672 shares at the end of each quarter over the next two years. Dr. Vogt is eligible to
participate in our annual incentive compensation program as approved by our Board of Directors, with target potential annual incentive
compensation of 30% of his base annual salary earned during the applicable calendar year, which was increased to 40% when he was
promoted to General Counsel on July 1, 2017. Dr. Vogt’s annual salary was increased to $375,000, effective February 1, 2018,
to $400,000, effective February 15, 2019, and to $420,000, effective February 14, 2020.
Dr. Vogt’s employment is “at-will”,
and either party can terminate the employment agreement and Dr. Vogt’s employment without cause at any time. If we terminate
Dr. Vogt’s employment without cause (as defined in his Executive Employment Agreement), whether or not in connection with
a “change of control” (as defined in the agreement), Dr. Vogt will receive a severance payment equivalent to six months
of his then-current base salary and all of Dr. Vogt’s unvested stock options will become fully vested, and he shall have
six months from the date of termination within which to exercise his vested options.
2010 Equity Compensation Plan
On March 29, 2010, our Board of Directors
adopted the 2010 Equity Compensation Plan (the “2010 Plan”) pursuant to which the Board of Directors reserved an aggregate
of 35,000 shares of common stock for future issuance. The 2010 Plan provided for awards of incentive stock options, non-qualified
stock options, rights to acquire restricted stock, rights to acquire unrestricted stock, and stock appreciation rights, or SARs,
but since we did not obtain stockholder approval of the 2010 Plan within twelve months after the date our Board of Directors adopted
the 2010 Plan, incentive stock options could not be granted thereunder. As of October 2011, options for the issuance of all 35,000
shares had been granted. As of December 31, 2019, 33,000 shares were available for grant under the 2010 Plan. However, we have
decided not to grant any awards under the 2010 Plan in the future.
2011 Equity Incentive Plan
As of October 14, 2011, we adopted our 2011
Equity Incentive Plan (the “2011 Plan”). Employees, directors, consultants and advisors of the Company are eligible
to participate in the 2011 Plan. The 2011 Plan initially had 180,000 shares of common stock reserved for issuance in the form of
incentive stock options, non-qualified options, common stock, and grant appreciation rights. The 2011 Plan was not approved by
our stockholders within the required one-year period following its adoption and, accordingly, no incentive stock options can be
granted under the 2011 Plan. In August 2013 our Board of Directors and a majority of our stockholders approved an amendment to
increase the number of shares available under the 2011 Plan from 180,000 shares to 1,900,000 shares, and an amendment to increase
the number options or other awards that can be granted to any one person during a twelve-month period from 50,000 shares to 300,000
shares. The foregoing amendment to the 2011 Plan became effective in September 2013. As of December 31, 2019, 151,240 shares were
available for future grant under the 2011 Plan.
2014 Equity Incentive Plan
On September 19, 2014, our Board of Directors
adopted the Iovance Biotherapeutics, Inc. 2014 Equity Incentive Plan (the “2014 Plan”). The 2014 Plan was approved
by our stockholders at the Annual Meeting of Stockholders held in November 2014. On June 10, 2016, our Board of Directors amended
the 2014 Plan to increase the total number of shares that can be issued under the 2014 Plan to 9,000,000 shares. The foregoing
increase in the number of shares available under the 2014 Plan was approved by our stockholders at the Annual Meeting of Stockholders
held on August 16, 2016. As of December 31, 2019, 174,292 shares were available for future grant under the 2011 Plan.
The 2014 Plan contains provisions that are
designed to protect our stockholders’ interests and to reflect strong corporate governance practices, including:
|
·
|
Continued broad-based eligibility for equity awards. We have granted stock options to our full-time employees. By doing so, we link employee interests with stockholder interests throughout the organization and motivate our employees to act as owners of the business.
|
|
·
|
Stockholder approval is required for additional shares. The 2014 Plan does not contain an annual “evergreen” provision. The 2014 Plan authorizes a fixed number of shares available under the plan, so that stockholder approval is required to issue any additional shares beyond those already approved under the 2014 Plan.
|
|
·
|
No discount stock options or stock appreciation rights. All stock options and stock appreciation rights are intended to have an exercise price equal to or greater than the fair market value of our common stock on the date the stock option or stock appreciation right is granted.
|
|
·
|
The Board is prohibited from taking action related to the 2014 Plan that would be treated as a repricing under generally accepted accounting principles without the approval of our stockholders. The 2014 Plan requires that the Board of Directors obtain the approval of our stockholders before taking actions that would be deemed to be a repricing under generally accepted accounting principles, including reducing the exercise price of any outstanding stock option and/or cancelling and re-granting any outstanding stock option to reduce the exercise price of the option.
|
General. The 2014 Plan provides for
awards of incentive stock options, non-statutory stock options, rights to acquire restricted stock, and stock appreciation rights,
or SARs. Incentive stock options (“ISOs”) granted under the 2014 Plan are intended to qualify as “incentive stock
options” within the meaning of Section 422 of the Code. Non-qualified stock options (NQSOs) granted under the 2014 Plan are
not intended to qualify as incentive stock options under the Code. See “Certain Federal Income Tax Consequences” below
for a discussion of the principal federal income tax consequences of awards under the 2014 Plan.
Purpose. Our Board of Directors adopted
the 2014 Plan to provide a means by which our employees, directors and consultants may be given an opportunity to benefit from
increases in the value of our common stock, to assist in attracting and retaining the services of such persons, to bind the interests
of eligible recipients more closely to our Company’s interests by offering them opportunities to acquire shares of our common
stock and to afford such persons stock-based compensation opportunities that are competitive with those afforded by similar businesses.
Administration. Our Board of Directors
has authorized our Compensation Committee to administer the 2014 Plan, although the Board of Directors also, from time to time,
participates in the administration of the 2014 Plan and the grant of options. Subject to the provisions of the 2014 Plan, our Compensation
Committee has the power to determine in its discretion: (a) to grant options and SARs and grant or sell restricted stock; (b) to
determine the fair market value of the shares of common stock subject to options or other awards; (c) to determine the exercise
price of options granted, which shall be no less than the fair market value of any common stock on the date of grant, the economic
terms of SARs granted, which shall provide for a benefit of the appreciation on common stock over not less than the value of our
common stock on the date of grant, or the offering price of restricted stock; (d) to determine the persons to whom, and the time
or times at which, options or SARs shall be granted or restricted stock granted or sold, and the number of shares subject to each
option or SAR or the number of shares of restricted stock granted or sold; (e) to construe and interpret the terms and provisions
of the 2014 Plan, of any applicable agreement and all options and SARs granted under the 2014 Plan, and of any restricted stock
award under the 2014 Plan; (f) to prescribe, amend, and rescind rules and regulations relating to the 2014 Plan; (g) to determine
the terms and provisions of each option and SAR granted and award of restricted stock (which need not be identical), including
but not limited to, the time or times at which options and SARs shall be exercisable or the time at which the restrictions on restricted
stock shall lapse; (h) with the consent of the grantee, to rescind any award or exercise of an option or SAR; (i) to modify or
amend the terms of any option, SAR or restricted stock (with the consent of the grantee or holder of the restricted stock if the
modification or amendment is adverse to the grantee or holder); (j) to accelerate or defer (with the consent of the grantee) the
exercise date of any option or SAR or the date on which the restrictions on restricted stock lapse; (k) to issue shares of restricted
stock to an optionee in connection with the accelerated exercise of an option by such optionee; (l) to authorize any person to
execute on behalf of our Company any instrument evidencing the grant of an option, SAR or award of restricted stock; (m) to determine
the duration and purposes of leaves of absence which may be granted to participants without constituting a termination of their
employment for the purpose of the 2014 Plan; and (n) to make all other determinations deemed necessary or advisable for the administration
of the 2014 Plan, any applicable agreement, option, SAR or award of restricted stock.
The Compensation Committee granted our Chief
Executive Officer the authority to grant options to (i) newly hired non-executive employees, and (ii) non-executive employees as
part of year-end bonus compensation. The Compensation Committee established a limit on the number of shares that may be granted
and certain other parameters within which non-executive options could be granted by our Chief Executive Officer.
Eligibility. Incentive stock options
may be granted under the 2014 Plan only to employees of our Company and its affiliates. Employees, directors and consultants of
our Company and its affiliates are eligible to receive all other types of awards under the 2014 Plan.
Terms of Options and SARs. The exercise
price of incentive stock options may not be less than the fair market value of our common stock subject to the option on the date
of the grant and, in some cases, may not be less than 110% of such fair market value. The exercise price of nonstatutory options
also may not be less than the fair market value of our common stock on the date of grant.
Options granted under the 2014 Plan may
be exercisable in increments, or “vest,” as determined by our Board of Directors. Our Board of Directors has the power
to accelerate the time as of which an option may vest or be exercised, with the consent of the optionee. The maximum term of options
and SARs under the 2014 Plan is ten years, except that in certain cases the maximum term is five years. Options and SARs awarded
under the 2014 Plan generally will terminate 90 days after termination of the participant’s service, subject to certain exceptions.
A recipient may not transfer an incentive
stock option otherwise than by will or by the laws of descent and distribution. During the lifetime of the recipient, only the
recipient may exercise an option or SAR. Our Board of Directors may grant nonstatutory stock options and SARs that are transferable
to the extent provided in the applicable written agreement.
Terms of Restricted Stock Awards.
Our Board of Directors or the Compensation Committee may issue shares of restricted stock under the 2014 Plan as a grant or for
such consideration, including services, and, subject to the Sarbanes-Oxley Act of 2002, promissory notes, as determined in its
sole discretion.
Shares of restricted stock acquired under
a restricted stock purchase or grant agreement may, but need not, be subject to forfeiture to us or other restrictions that will
lapse in accordance with a vesting schedule to be determined by our Board of Directors or the Compensation Committee. In the event
a recipient’s employment or service with our Company terminates, any or all of the shares of common stock held by such recipient
that have not vested as of the date of termination under the terms of the restricted stock agreement may be forfeited to our Company
in accordance with such restricted stock agreement.
Rights to acquire shares of our common stock
under the restricted stock purchase or grant agreement shall be transferable by the recipient only upon such terms and conditions
as are set forth in the restricted stock agreement, as our Board of Directors shall determine in its discretion, so long as shares
of common stock awarded under the restricted stock agreement remain subject to the terms of such agreement
Adjustment Provisions. If our common
stock is changed by reason of a stock split, reverse stock split, stock dividend, recapitalization, combination or reclassification,
then the number and class of shares of stock subject to each option and SAR outstanding under the 2014 Plan, and the exercise price
of each outstanding option and the base value of SAR, will be automatically and proportionately adjusted, except that our company
will not be required to issue fractional shares as a result of any such adjustments. Such adjustment in any outstanding option
or SAR will be made without change in the total price applicable to the unexercised portion of the option or SAR, but with a corresponding
adjustment in the price for each share covered by the unexercised portion of the option or SAR.
Effect of Certain Corporate Events.
Except as otherwise provided in an applicable employment agreement, in the event of (i) a liquidation or dissolution of our Company,
(ii) a merger or consolidation of our Company with or into another corporation or entity (other than a merger with a wholly-owned
subsidiary), or (iii) a sale of all or substantially all of the assets of our Company in a single transaction or a series of related
transactions, all options and SARs will terminate upon consummation of the transaction unless our Board of Directors determines
that they will survive. If our Board of Directors determines that outstanding options and SARs will survive, and if our Company
will not be the surviving entity in the transaction, our Board of Directors may provide that the outstanding options and SARs will
be assumed or an equivalent option or SAR substituted by an applicable successor entity or any affiliate of the successor entity.
If outstanding options and SARs are to terminate upon consummation of the corporate transaction, any options or SARs outstanding
immediately prior to the consummation of the corporate transaction will be deemed fully vested and exercisable immediately prior
to the consummation of the corporate transaction (provided that the option or SAR has not expired by its terms and that the grantee
takes all steps necessary to exercise the option or SAR prior to the corporate transaction as required by the agreement evidencing
the option or SAR).
Duration, Amendment and Termination.
Our Board of Directors may suspend or terminate the 2014 Plan without stockholder approval or ratification, subject to certain
restrictions, at any time or from time to time. Unless sooner terminated, the 2014 Plan will terminate ten years from the date
of its adoption by our Board of Directors, or on September 19, 2024.
Our Board of Directors may also amend the
2014 Plan at any time, and from time to time. However, except as relates to adjustments upon changes in common stock, no amendment
will be effective unless approved by our stockholders to the extent stockholder approval is necessary to preserve incentive stock
option treatment for federal income tax purposes. Our Board of Directors may submit any other amendment to the 2014 Plan for stockholder
approval in its discretion.
Certain Federal Income Tax Consequences of the 2014 Plan
Section 162(m). For the purposes
of complying with the requirements under Section 162(m) of the Code relating to the deductibility for federal income tax purposes
of employee expense associated with awards under the 2014 Plan of more than $1 million to “covered employees” within
the meaning of Section 162(m), the 2014 Plan as originally approved by our Board of Directors and our stockholders provided that
no eligible person shall be granted options or other awards during any twelve-month period covering more than 500,000 shares. This
so-called Section 162(m) limitation was increased to 550,000 by the amendment to the 2014 Plan adopted by our board of directors
on June 1, 2016. The amended limitation will not satisfy the requirements to Section 162(m) unless and until the limitation is
approved by our stockholders. We are not seeking stockholder approval of this recent amendment at the Annual Meeting, but our Board
of Directors may determine to present the amended Section 162(m) limitation for stockholder approval in the future.
Non-qualified Stock Options. There
will be no federal income tax consequences to either the Company or the participant upon the grant of a non-discounted NQSO. However,
the participant will realize ordinary income on the exercise of the NQSO in an amount equal to the excess of the fair market value
of the common stock acquired upon the exercise of such option over the exercise price, and the Company will receive a corresponding
deduction. The gain, if any, realized upon the subsequent disposition by the participant of the common stock will constitute short-term
or long-term capital gain, depending on the participant’s holding period.
Incentive Stock Options. There will
be no regular federal income tax consequences to either the Company or the participant upon the grant or exercise of an ISO. If
the participant does not dispose of the shares of common stock for two years after the date the option was granted and one year
after the acquisition of such shares of common stock, the difference between the aggregate option price and the amount realized
upon disposition of the shares of common stock will constitute long-term capital gain or loss, and the Company will not be entitled
to a federal income tax deduction. If the shares of common stock are disposed of in a sale, exchange or other “disqualifying
disposition” during those periods, the participant will realize taxable ordinary income in an amount equal to the excess
of the fair market value of the common stock purchased at the time of exercise over the aggregate option price (adjusted for any
loss of value at the time of disposition), and the Company will be entitled to a federal income tax deduction equal to such amount,
subject to the limitations under Section 162(m) of the Code.
While the exercise of an incentive stock
option does not result in current taxable income, the excess of (1) the fair market value of the option shares at the time of exercise
over (2) the exercise price, will be an item of adjustment for purposes of determining the participant’s alternative minimum
tax income.
SARs. A participant receiving an
SAR will not recognize income, and the Company will not be allowed a tax deduction, at the time the award is granted. When a participant
exercises the SAR, the amount of cash and the fair market value of any shares of common stock received will be ordinary income
to the participant and will be allowed as a deduction for federal income tax purposes to the Company, subject to limitations under
Section 162(m) of the Code. In addition, the Board of Directors or the Compensation Committee, may at any time, in its discretion,
declare any or all awards to be fully or partially exercisable and may discriminate among participants or among awards in exercising
such discretion.
Restricted Stock. Unless a participant
makes an election to accelerate recognition of the income to the date of grant, a participant receiving a restricted stock award
will not recognize income, and the Company will not be allowed a tax deduction, at the time the award is granted. When the restrictions
lapse, the participant will recognize ordinary income equal to the fair market value of the common stock, and the Company will
be entitled to a corresponding tax deduction at that time, subject to the limitations under Section 162(m) of the Code.
2018 Equity Incentive Plan
On March 9, 2018, our Board of Directors
adopted the Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan was approved
by our stockholders at the Annual Meeting of Stockholders held on June 6, 2018. Except with respect to awards then outstanding,
unless sooner terminated, the 2018 Plan will expire on the tenth anniversary of the date it was approved by stockholders and no
further awards may be granted after such date.
The 2018 Plan contains provisions that are
designed to protect our stockholders’ interests and to reflect strong corporate governance practices, including:
|
·
|
Stockholder approval is required for additional
shares. The 2018 Plan does not contain an annual “evergreen” provision that provides for automatic increases of
shares on an ongoing basis. The 2018 Plan authorizes a fixed number for our share reserve, so that stockholder approval is required
to issue any additional shares from the 2018 Plan once we have used all shares available for issuance. The 2018 Plan is not an
inducement plan, and therefore requires stockholder approval under the Nasdaq Stock Market Rules.
|
|
·
|
No discounted stock options or stock appreciation rights. All stock options and stock appreciation rights will have an exercise price equal to or greater than the fair market value of our common stock on the date the stock option or stock appreciation right is granted.
|
|
·
|
Repricing is not allowed without stockholder approval. The 2018 Plan prohibits the repricing or exchange of underwater stock options and stock appreciation rights without prior stockholder approval.
|
|
·
|
Reasonable share counting provisions. In general, when awards granted under the 2018 Plan lapse or are canceled, the shares reserved for those awards will be returned to the share reserve and be available for future awards. However, the 2018 Plan prohibits shares tendered or withheld to pay the exercise price of an award or for payment of taxes to be returned to our share reserve.
|
Administration. Our Board of Directors
has authorized our Compensation Committee to administer the 2018 Plan, although the Board of Directors also, from time to time,
participates in the administration of the 2018 Plan and the grant of options. The Compensation Committee has the authority to determine
the terms and conditions of any agreements evidencing any awards granted under the 2018 Plan and to adopt, alter and repeal rules,
guidelines and practices relating to the 2018 Plan. The Compensation Committee has full discretion to administer and interpret
the 2018 Plan and to adopt such rules, regulations and procedures as it deems necessary or advisable and to determine, among other
things, the time or times at which the awards may be exercised and whether and under what circumstances an award may be exercised.
Eligibility. Any current or prospective
employees, directors, officers, consultants or advisors of the Company or its affiliates who are selected by the Compensation Committee
are eligible for awards under the 2018 Plan. The Compensation Committee will have the sole and complete authority to determine
who will be granted an award under the 2018 Plan.
Number of Shares Authorized. Pursuant
to the 2018 Plan, we have reserved an aggregate of 6,000,000 shares of our common stock for issuance of awards to be granted thereunder.
All of the shares of our common stock reserved under the plan may be issued as incentive stock options under the 2018 Plan. The
maximum number of equity awards that may be awarded to the non-employee members of the Board of Directors for serving on the Board
of Directors, shall be an amount equal to the product of 50,000 times the number of non-employee members on the Board of Directors;
provided, that the foregoing limitation shall not apply in respect of any awards issued to a non-employee director in respect of
(i) any one-time equity grant upon a non-employee director’s initial appointment or election to the Board of Directors, or
(ii) equity grants for services provided to the Company other than services as a member of the Board of Directors. The total amount
of awards granted annually to the non-employee members of the Board of Directors may allocated amongst the non-employee members
of the Board of Directors in a manner determined by the Board of Directors. If any award granted under the 2018 Plan expires, terminates,
or is canceled or forfeited without being settled, vested or exercised, shares of our common stock subject to such award will again
be made available for future grants. Any shares that are surrendered or tendered to pay the exercise price of an award or to satisfy
withholding taxes owed, or any shares reserved for issuance, but not issued, with respect to settlement of a stock appreciation
right, will not again be available for grants under the 2018 Plan.
Change in Capitalization. If there
is a change in our capitalization in the event of a stock or extraordinary cash dividend, recapitalization, stock split, reverse
stock split, reorganization, merger, consolidation, split-up, split-off, spin-off, combination, repurchase or exchange of shares
of our common stock or other relevant change in capitalization or applicable law or circumstances, such that the Compensation Committee
determines that an adjustment to the terms of the 2018 Plan (or awards thereunder) is necessary or appropriate, then the Compensation
Committee shall make adjustments in a manner that it deems equitable. Such adjustments may be to the number of shares reserved
for issuance under the 2018 Plan, the number of shares covered by awards then outstanding under the 2018 Plan, the limitations
on awards under the 2018 Plan, or the exercise price of outstanding options, or such other equitable substitution or adjustments
as the Compensation Committee may determine appropriate.
Awards Available for Grant. The Compensation
Committee may grant awards of non-qualified stock options, incentive (qualified) stock options, stock appreciation rights (“SARs”),
restricted stock awards, restricted stock units, other stock-based awards, other cash-based awards or any combination of the foregoing.
Awards may be granted under the 2018 Plan in assumption of, or in substitution for, outstanding awards previously granted by an
entity acquired by the Company or with which the Company combines, which are referred to herein as “Substitute Awards.”
Stock Options. The Compensation
Committee will be authorized to grant options to purchase shares of our common stock that are either “qualified,”
meaning they are intended to satisfy the requirements of Section 422 of the Code for incentive stock options, or “non-qualified,”
meaning they are not intended to satisfy the requirements of Section 422 of the Code. All options granted under the 2018 Plan
shall be non-qualified unless the applicable award agreement expressly states that the option is intended to be an incentive stock
option. Options granted under the 2018 Plan will be subject to the terms and conditions established by the Compensation Committee.
Under the terms of the 2018 Plan, the exercise price of the options will not be less than the fair market value (or 110% of the
fair market value in the case of an incentive stock option granted to a 10% stockholder) of our common stock on the date of grant
(except with respect to Substitute Awards). Options granted under the 2018 Plan will be subject to such terms, including the exercise
price and the conditions and timing of exercise, as may be determined by the Compensation Committee and specified in the applicable
award agreement. The maximum term of an option granted under the 2018 Plan will be ten years from the date of grant (or five years
in the case of an incentive stock option granted to a 10% stockholder), provided that if the term of a non-qualified option would
expire at a time when trading in the shares of our common stock is prohibited by the Company’s insider trading policy, the
option’s term shall be extended automatically until the 30th day following the expiration of such prohibition (as long as
such extension shall not violate Section 409A of the Code). Payment in respect of the exercise of an option may be made in cash,
by check, by cash equivalent or by such other method as the Compensation Committee may permit in its sole discretion, including,
to the extent permitted by the Compensation Committee, (i) by delivery of shares of our common stock valued at the fair market
value on the date the option is exercised, provided that such shares are not subject to any pledge or other security interest,
(ii) by delivery of other property having a fair market value equal to the exercise price and all applicable required withholding
taxes, (iii) if there is a public market for the shares of our common stock at such time, by means of a broker-assisted cashless
exercise mechanism or (iv) by means of a “net exercise” procedure effected by withholding the minimum number of shares
otherwise deliverable in respect of an option that are needed to pay the exercise price and up to the maximum withholding taxes,
or any combination of the foregoing. In all events of cashless or net exercise, any fractional shares of common stock will be
settled in cash.
Stock Appreciation Rights. The Compensation
Committee will be authorized to award SARs under the 2018 Plan. SARs will be subject to the terms and conditions established by
the Compensation Committee. A SAR is a contractual right that allows a participant to receive, in the form of either cash, shares
or any combination of cash and shares, the appreciation, if any, in the value of a share over a certain period of time. An option
granted under the 2018 Plan may include SARs, and SARs may also be awarded to a participant independent of the grant of an option.
SARs granted in connection with an option shall be subject to terms similar to the option corresponding to such SARs, including
with respect to vesting and expiration. Except as otherwise provided by the Compensation Committee (in the case of Substitute Awards
or SARs granted in tandem with previously granted options), the strike price per share of our common stock underlying each SAR
shall not be less than 100% of the fair market value of such share, determined as of the date of grant and the maximum term of
a SAR granted under the 2018 Plan will be ten years from the date of grant.
Restricted Stock. The Compensation
Committee will be authorized to grant restricted stock under the 2018 Plan, which will be subject to the terms and conditions established
by the Compensation Committee. Restricted stock is common stock that is generally non-transferable and is subject to other restrictions
determined by the Compensation Committee for a specified period. Any accumulated dividends will be payable at the same time that
the underlying restricted stock vests.
Restricted Stock Unit Awards. The
Compensation Committee will be authorized to grant restricted stock unit awards, which will be subject to the terms and conditions
established by the Compensation Committee. A restricted stock unit award, once vested, may be settled in a number of shares of
our common stock equal to the number of units earned, in cash equal to the fair market value of the number of shares of our common
stock earned in respect of such restricted stock unit award or in a combination of the foregoing, at the election of the Compensation
Committee. Restricted stock units may be settled at the expiration of the period over which the units are to be earned or the Compensation
Committee may establish a program for deferred delivery, in compliance with Section 409A of the Code. To the extent provided in
an award agreement, the holder of outstanding restricted stock units shall be entitled to be credited with dividend equivalent
payments upon the payment by us of dividends on shares of our common stock, either in cash or, at the sole discretion of the Compensation
Committee, in shares of our common stock having a fair market value equal to the amount of such dividends (or a combination of
cash and shares), and interest may, at the sole discretion of the Compensation Committee, be credited on the amount of cash dividend
equivalents at a rate and subject to such terms as determined by the Compensation Committee, which accumulated dividend equivalents
(and interest thereon, if applicable) shall be payable at the same time that the underlying restricted stock units are settled.
Other Stock-Based Awards. The Compensation
Committee will be authorized to grant awards of unrestricted shares of our common stock, rights to receive grants of awards at
a future date, other awards denominated in shares of our common stock, or awards that provide for cash payments based in whole
or in part on the value of our common stock under such terms and conditions as the Compensation Committee may determine and as
set forth in the applicable award agreement.
Effect of a Change in Control. Unless
otherwise provided in an award agreement, or any applicable employment, consulting, change in control, severance or other agreement
between us and a participant, in the event of a change in control (as defined in the 2018 Plan), if a participant’s employment
or service is terminated by us other than for cause (and other than due to death or disability) within the 12-month period following
a change in control, then (i) all then-outstanding options and SARs held by such participant will become immediately exercisable
as of such participant’s date of termination with respect to all of the shares subject to such option or SAR; and/or (ii)
the restricted period (and any other conditions) shall expire as of such participant’s date of termination with respect to
all of the then-outstanding shares of restricted stock or restricted stock units held by such participant (including without limitation
a waiver of any applicable performance goals); provided that with respect to any award whose vesting or exercisability is otherwise
subject to the achievement of performance conditions, the portion of such award that shall become fully vested and immediately
exercisable shall be based on the assumed achievement of actual or target performance as determined by the Compensation Committee
and, unless otherwise determined by the Compensation Committee, prorated for the number of days elapsed from the grant date of
such award through the date of termination. In addition, the Compensation Committee may in its discretion and upon at least ten
days’ notice to the affected persons, cancel any outstanding award and pay the holders, in cash, securities or other property
(including of the acquiring or successor company), or any combination thereof, the value of such awards based upon the price per
share of the Company’s common stock received or to be received by other shareholders of the Company in connection with the
transaction (it being understood that any option or SAR having a per-share exercise price or strike price equal to, or in excess
of, the fair market value (as of the date specified by the Compensation Committee) of a share of the Company’s common stock
subject thereto may be canceled and terminated without payment or consideration therefor). Notwithstanding the above, the Compensation
Committee shall exercise such discretion over the timing of settlement of any award subject to Section 409A of the Code at the
time such award is granted.
Nontransferability. Each award may
be exercised during the participant’s lifetime by the participant or, if permissible under applicable law, by the participant’s
guardian or legal representative. No award may be assigned, alienated, pledged, attached, sold or otherwise transferred or encumbered
by a participant other than by will or by the laws of descent and distribution unless the Compensation Committee permits the award
to be transferred to a permitted transferee (as defined in the 2018 Plan).
Amendment. Our Board of Directors
may amend, suspend or terminate the 2018 Plan at any time, subject to stockholder approval if necessary to comply with any tax,
stock exchange rules, or other applicable regulatory requirement. No amendment, suspension or termination will materially and adversely
affect the rights of any participant or recipient of any award without the consent of the participant or recipient.
The Compensation Committee may, to the extent
consistent with the terms of any applicable award agreement, waive any conditions or rights under, amend any terms of, or alter,
suspend, discontinue, cancel or terminate, any award theretofore granted or the associated award agreement, prospectively or retroactively;
provided, that any such waiver, amendment, alteration, suspension, discontinuance, cancellation or termination that would materially
and adversely affect the rights of any participant with respect to any award theretofore granted will not to that extent be effective
without the consent of the affected participant; and provided further that, without stockholder approval, (i) no amendment or modification
may reduce the exercise price of any option or the strike price of any SAR, (ii) the Compensation Committee may not cancel any
outstanding option and replace it with a new option (with a lower exercise price) or cancel any SAR and replace it with a new SAR
(with a lower strike price) or, in each case, with another award or cash in a manner that would be treated as a repricing (for
compensation disclosure or accounting purposes), (iii) the Compensation Committee may not take any other action considered a repricing
for purposes of the stockholder approval rules of the applicable securities exchange on which our common shares are listed and
(iv) the Compensation Committee may not cancel any outstanding option or SAR that has a per-share exercise price or strike price
(as applicable) at or above the fair market value of a share of our common stock on the date of cancellation and pay any consideration
to the holder thereof. However, stockholder approval is not required with respect to clauses (i), (ii), (iii) and (iv) above with
respect to certain adjustments on changes in capitalization.
Certain Federal Income Tax Consequences of the 2018 Plan
Stock Options. Holders of incentive
stock options will generally incur no federal income tax liability at the time of grant or upon vesting or exercise of those options.
However, the spread at exercise will be an “item of tax preference,” which may give rise to “alternative minimum
tax” liability for the taxable year in which the exercise occurs. If the holder does not dispose of the shares before the
later of two years following the date of grant and one year following the date of exercise, the difference between the exercise
price and the amount realized upon disposition of the shares will constitute long-term capital gain or loss, as the case may be.
Assuming the holding period is satisfied, no deduction will be allowed to us for U.S. federal income tax purposes in connection
with the grant or exercise of the incentive stock option. If, within two years following the date of grant or within one year following
the date of exercise, the holder of shares acquired through the exercise of an incentive stock option disposes of those shares
(a “disqualifying disposition”), the participant will generally realize taxable compensation at the time of such disposition
equal to the difference between the exercise price and the lesser of the fair market value of the share on the date of exercise
or the amount realized on the subsequent disposition of the shares, and that amount will generally be deductible by us for U.S.
federal income tax purposes, subject to the possible limitations on deductibility under Sections 280G and 162(m) of the Code. Any
additional gain and any loss would be a capital gain or loss. The applicable capital gain tax rate will depend on the length of
the Participant’s share holding period measured from the exercise date. Finally, if an incentive stock option becomes first
exercisable in any one year for shares having an aggregate value in excess of $100,000 (based on the grant date value), the portion
of the incentive stock option in respect of those excess shares will be treated as a non-qualified stock option for federal income
tax purposes.
No income will be realized by a participant
upon grant or vesting of an option that does not qualify as an incentive stock option (“a non-qualified stock option”).
Upon the exercise of a non-qualified stock option, the participant will recognize ordinary compensation income in an amount equal
to the excess, if any, of the fair market value of the purchased shares on the date of exercise over the option exercise price,
and the participant’s tax basis will equal the sum of the compensation income recognized and the exercise price paid. We
will be able to deduct this same excess amount for U.S. federal income tax purposes, subject to the possible limitations on deductibility
under Sections 280G and 162(m) of the Code. In the event of a sale of shares received upon the exercise of a non-qualified stock
option, any appreciation or depreciation after the exercise date generally will be taxed as capital gain or loss and will be long-term
gain or loss if the holding period for such shares is more than one year.
SARs. No income will be realized
by a participant upon grant or vesting of a SAR. Upon the exercise of a SAR, the participant will recognize ordinary compensation
income in an amount equal to the fair market value of the payment received in respect of the SAR. We will be able to deduct this
same amount for U.S. federal income tax purposes, subject to the possible limitations on deductibility under Sections 280G and
162(m) of the Code.
Restricted Stock. A participant will
not be subject to tax upon the grant of an award of restricted stock unless the participant elects to be taxed on the date of grant
pursuant to Section 83(b) of the Code. On the date an award of restricted stock is no longer subject to a substantial risk of forfeiture
(i.e., the vesting date), the participant will have taxable compensation equal to the difference between the fair market value
of the shares on that date over the amount the participant paid for such shares, if any, unless the participant made an election
under Section 83(b) of the Code to be taxed on the date of grant. If the participant made an election under Section 83(b), the
participant will have taxable compensation on the date of grant equal to the difference between the fair market value of the shares
on the date of grant over the amount the participant paid for such shares, if any. If the election is made, the participant will
not be allowed a deduction for, or recoupment of, taxes paid on account of shares that fail to vest or on account of any subsequent
decrease in the value of the shares. (Special rules apply to the receipt and disposition of restricted shares received by officers
and directors who are subject to Section 16(b) of the Exchange Act). We will be able to deduct, in the same year as it is recognized
by the participant, the amount of taxable compensation to the participant for U.S. federal income tax purposes, subject to the
possible limitations on deductibility under Sections 280G and 162(m) of the Code.
Restricted Stock Units. A participant
will not be subject to tax upon the grant or vesting of a restricted stock unit award. Rather, upon the delivery of shares or cash
pursuant to a restricted stock unit award, the participant will have taxable compensation equal to the fair market value of the
number of shares (or the amount of cash) the participant actually receives with respect to the award. We will be able to deduct
the amount of taxable compensation to the participant for U.S. federal income tax purposes, subject to the possible limitations
on deductibility under Sections 280G and 162(m) of the Code.
Section 409A
Code Section 409A imposes complex rules
on nonqualified deferred compensation arrangements, including requirements with respect to elections to defer compensation and
the timing of payment of deferred amounts. Depending on how they are structured, certain equity-based awards may be subject to
Code Section 409A, while others are exempt. If an award is subject to Code Section 409A and a violation occurs, the compensation
is includible in income when no longer subject to a substantial risk of forfeiture and the participant may be subject to a 20%
penalty tax and, in some cases, interest penalties. The 2018 Plan and awards granted under the 2018 Plan are intended to be exempt
from or conform to the requirements of Code Section 409A.
Section 162(m) and the Company’s Deduction.
Generally, whenever a participant recognizes
ordinary income under the 2018 Plan, a corresponding deduction is available to the Company, provided that the Company complies
with certain reporting requirements. However, under Code Section 162(m), the Company will be denied a deduction for compensation
paid to certain senior executives that exceeds $1,000,000, unless the compensation is “performance-based compensation”
within the meaning of the Code.
Beginning January 1, 2018, with the passage
of the TCJA, this limitation will apply to the Company's Chief Executive Officer, Chief Financial Officer, the Company's three
next highest-paid executive officers, and anyone who was such a covered person starting with 2017. Prior to January 1, 2018, certain
performance-based compensation was excluded from the $1,000,000 deduction limit. Under the TCJA, beginning January 1, 2018 (with
an exception for certain grandfathered arrangements), the Company will be denied a deduction for any compensation exceeding $1,000,000.
Equity Compensation Plan Information
The following table summarizes, as of December
31, 2019, (i) the number of shares of our common stock that are issuable under our equity compensation plans upon the exercise
of outstanding options, and other rights, (ii) the weighted-average exercise price of such options and rights, and (iii) the number
of securities remaining available for future issuance under our equity compensation plans.
Plan Category
|
|
Number of
securities
to be issued
upon
exercise of
outstanding
options,
warrants and
rights
(a)
|
|
|
Weighted-
average
exercise
price of
outstanding options,
warrants
and rights
(b)
|
|
|
Number of securities
remaining available
for
future issuance under
equity compensation
plans (excluding
securities reflected
in column (a))
(c)
|
|
2018 Equity Incentive Plan
|
|
|
2,702,400
|
|
|
$
|
14.63
|
|
|
|
3,297,600
|
|
2014 Equity Incentive Plan
|
|
|
5,983,312
|
|
|
$
|
10.61
|
|
|
|
174,292
|
|
Equity compensation plans not approved by our stockholders: (1)
|
|
|
|
|
|
|
|
|
|
|
|
|
2010 Equity Compensation Plan
|
|
|
2,000
|
|
|
$
|
117.00
|
|
|
|
33,000
|
|
2011 Equity Incentive Plan
|
|
|
807,000
|
|
|
$
|
13.25
|
|
|
|
151,240
|
|
Total
|
|
|
9,494,712
|
|
|
$
|
12.00
|
|
|
|
3,656,132
|
|
|
(1)
|
Our Board of Directors adopted our 2010 Equity Compensation Plan and our 2011 Equity Incentive Plan. However, we did not submit either of those plans to our stockholders for their approval. Accordingly, while we have adopted these equity compensation plans, these plans are not stockholder-approved plans.
|
Equity Incentive Compensation Philosophy
We believe that successful long-term corporate
performance is more likely to be achieved with a corporate culture that encourages a long-term focus by our named executive officers
and other employees through the use of equity awards, the value of which depends on our stock performance. We established our 2014
Equity Incentive Plan and 2018 Equity Incentive Plan to provide all of our employees, including our named executive officers, with
incentives to help align our employees’ interests with the interests of our stockholders and to enable them to participate
in the long-term appreciation of our stockholder value. Additionally, equity awards provide an important retention tool for all
employees, as the awards generally are subject to vesting over an extended period of time based on continued service with us.
Typically, we grant equity awards upon an
employee’s hire. In addition, equity awards may also be granted for performance annually at, or soon after, the end of each
year, depending on position, performance and tenure at the Company. We normally grant stock options or stock awards to new employees
when they join our Company based upon their position with us and their relevant prior experience. Our Board of Directors has granted
our Chief Executive Officer the discretion to grant options to non-executive employees upon joining our Company, and to make grants
during each annual non-executive employee review cycle. Our Board of Directors has reviewed and approved both the total number
of shares that our Chief Executive Officer can grant under such options, and the range of shares subject to such grants based on
each employee’s position with the Company. Options are granted based on a combination of individual contributions to our
Company and on general corporate achievements, which may include the attainment of product development milestones (such as commencement
and completion of clinical trials) and attaining other annual corporate goals and objectives.
The awards granted by the Company generally
vest over the first three years of the ten-year option term (although some previously granted awards vest over four years), or
upon the achievement of certain milestones. Unless otherwise agreed to by us with respect to a termination without “cause”
or for “good reason,” vesting and exercise rights generally cease upon termination of employment, except in the case
of death (subject to a one-year limitation), disability or retirement. Prior to the exercise of an option, the holder has no rights
as a stockholder with respect to the shares subject to such option, including voting rights or the right to receive dividends or
dividend equivalents. In addition to the initial option grants, our Compensation Committee may grant additional options to retain
our employees and reward, or provide incentive for, the achievement of corporate goals and strong individual performance.
It is our policy to award stock options
at an exercise price equal to the closing price on the Nasdaq Global Market of our common stock on the date of the grant. For purposes
of determining the exercise price of stock options for newly hired employees, other than executive officers, the grant date is
deemed to be the first day of employment and the authority to make such a grant is delegated to our Chief Executive Officer. For
other employee stock option grants, the grant date is such date as is determined by the Compensation Committee when it approves
the stock option grant.
We have no program, practice or plan to
grant stock options, in coordination with the release of material nonpublic information. We also have not timed the release of
material nonpublic information for the purpose of affecting the value of stock options or other compensation, and we have no plan
to do so. We have no policy regarding the adjustment or recovery of stock option awards in connection with the restatement of our
financial statements, as our stock option awards have not been tied to the achievement of specific financial statement goals.
We do not take into consideration any amounts
realized by our named executive officers from prior stock option or stock awards in determining whether to grant new stock options,
restricted stock units or restricted stock awards
CERTAIN RELATIONSHIPS AND RELATED PARTY
TRANSACTIONS
Certain Relationships and Related Transactions
Other than employment agreements with our
named executive officers and other payments made to our named executive officers, all as described above under the section entitled
“Executive Compensation —Compensation of Executive Officers,” and compensation paid to directors as described
above in the section titled “Executive Compensation - Director Compensation,” the following is a description of all
transactions since January 1, 2017 to which we have been a party, and in which (i) the amounts involved exceeded or will exceed
$120,000, and (ii) our directors and named executive officers or holders of more than 5% of our common stock, or any member of
the immediate family of the foregoing persons or entities affiliated with them, had or will have a direct or indirect material
interest.
On September 8, 2017 we entered into a three-year
consulting agreement (the “Consulting Agreement”) with Iain Dukes, D. Phil, the Chairman of our Board of Directors.
Under the Consulting Agreement, Dr. Dukes agreed to consult with us regarding business development opportunities, licensing transactions
and technology acquisitions, and any such strategic initiatives appropriate for the Company that Dr. Dukes may identify. In consideration
for his services, we granted Dr. Dukes a ten-year, non-qualified stock option to purchase up to 150,000 shares of our common stock
at an exercise price of $7.30 per share (the closing trading price of the common stock on the Nasdaq Global Market on September
8, 2017). The stock option vests in 12 quarterly installments (with 1/12th of the option shares having vested on the date of grant).
The vesting of the stock option will accelerate, and the entire stock option will become fully vested upon the closing of a significant
licensing transaction, a material product acquisition, a material strategic transaction, or upon a Change of Control transaction.
A “Change of Control” is defined to mean: (1) a merger or consolidation or the sale or exchange by our of capital stock,
where our stockholders do not obtain or retain, directly or indirectly, at least a majority of the beneficial interest in the voting
stock or other voting equity of the surviving or acquiring corporation or other surviving or acquiring entity, in substantially
the same proportion as before such transaction; (2) any transaction or series of related transactions to which this Company is
a party in which in excess of fifty percent (50%) of our voting power is transferred; or (3) the sale or exchange of all or substantially
all of our assets, where our stockholders do not obtain or retain, directly or indirectly, at least a majority of the beneficial
interest in the voting stock or other voting equity of the corporation or other entity acquiring our assets, in substantially the
same proportion as before such transaction.
In July 2017, we filed a post-effective
amendment to a registration statement on Form S-3 to register the public sale of certain securities, including 446,433 shares owned
by General McPeak, a member of our Board of Directors.
Policies and Procedures for the Review and Approval of Transactions
with Related Persons
Our Audit Committee’s charter requires
the Audit Committee to review and approve any related-person transactions. In considering related-person transactions, our Audit
Committee considers the relevant available facts and circumstances, including, but not limited to, (i) the risks, costs and
benefits to us, (ii) the impact on a director’s independence in the event the related party is a director, immediate
family member of a director or an entity with which a director is affiliated, (iii) the terms of the transaction, (iv) the
availability of other sources for comparable services or products, and (v) the terms available to or from, as the case may
be, unrelated third parties or to or from employees generally. In the event a director has an interest in the proposed transaction,
the director must recuse himself or herself from the deliberations and approval. In determining whether to approve, ratify or reject
a related-person transaction, our Audit Committee evaluates whether, in light of known circumstances, the transaction is in, or
is not inconsistent with, our best interests and those of our stockholders.
Director Independence
Our Board of Directors has determined that
Dr. Countouriotis, General McPeak, Mr. Rothbaum, Mr. Maynard and Dr. Weiser qualify as “independent directors” as defined
under the applicable Nasdaq Stock Market Rules and the rules of the SEC, satisfy the independence criteria set forth in Rule 10A-3
under the Exchange Act, and have no material relationships with us (either directly or as a partner, stockholder or officer of
any entity) that are inconsistent with a finding of their independence as members of our Board of Directors. Our Board of Directors
has determined that Mr. Maynard, General McPeak and Dr. Weiser, the current members of our Audit Committee, also are “independent”
for purposes of service as the members of our Audit Committee.
Commitment to Corporate Responsibility
Iovance’s corporate responsibility
is fundamental to our long-term success, as well as our commitment to healthcare for critically ill cancer patients. It is also
now more than ever important to our stakeholders. We have a commitment to environmental, social and governance (“ESG”)
issues. We continue to improve our environmental sustainability by, among other programs, complying with our local and state recycling
programs and building and modifying facilities with the environment in mind. Further, we have a commitment to social issues, including
the diversity of our board, management and employees. It starts at the top, where we have two female directors, including a female
Chief Executive Officer. Lastly, our corporate governance principles are focused on ethics and transparency. We will continue to
focus on ESG issues during 2020.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT
The following table sets forth certain information
regarding the beneficial ownership of our common stock as of the Record Date by (i) each person who is known by us to own more
than 5% of the outstanding common stock; (ii) each of our directors and director nominees; (iii) each of our named executive officers
listed in the “Compensation of Executive Officers” table; and (iv) all of our current named executive officers and
directors as a group. This table is based upon information supplied by officers, directors and principal stockholders and Schedules
13D and 13G and amendments thereto filed with the SEC. Unless otherwise indicated below, to our knowledge, the persons and entities
named in the table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject
to community property laws where applicable. As of the Record Date, a total of 126,846,818 shares of common stock were outstanding,
a total of 194 shares of Series A Preferred, convertible into 97,000 shares of common stock, were outstanding, and a total of 3,581,119
shares of Series B Preferred, convertible into 3,581,119 shares of common stock, were outstanding. Our shares of Series A Preferred
and Series B Preferred do not have voting rights.
|
|
Common Stock
|
|
Name and Address of
Beneficial Owner
|
|
Number of
Shares
|
|
|
Percent of
Class (1)
|
|
5% and Greater Stockholders
|
|
|
|
|
|
|
|
|
The Vanguard Group Inc.
100 Vanguard Blvd.
Malvern, PA 19335 (2)
|
|
|
10,853,129
|
(2)
|
|
|
8.6
|
%
|
Perceptive Advisors LLC
Joseph Edelman
Perceptive Life Sciences Master Fund Ltd
51 Astor Place, 10th Floor
New York, NY 10003 (3)
|
|
|
10,417,887
|
(3)
|
|
|
8.2
|
%
|
BlackRock Inc.
55 East 52nd Street
New York, NY 10055 (4)
|
|
|
9,594,660
|
(4)
|
|
|
7.6
|
%
|
Avoro Capital Advisors LLC
110 Greene Street, Suite 800
New York, NY 10012 (5)
|
|
|
9,565,000
|
(5)
|
|
|
7.5
|
%
|
Quogue Capital LLC
101 Central Park West, Suite 1F
New York, New York 10019 (6)
|
|
|
9,000,000
|
(6)
|
|
|
7.1
|
%
|
T. Rowe Price Associates Inc.
100 E. Pratt Street
Baltimore, MD 21202 (7)
|
|
|
6,509,856
|
(7)
|
|
|
5.1
|
%
|
|
|
|
|
|
|
|
|
|
Named Executive Officers and Directors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Merrill A. McPeak
|
|
|
726,583
|
(8)
|
|
|
*
|
|
Michael Weiser, M.D., Ph.D.
|
|
|
237,632
|
(9)
|
|
|
*
|
|
Ryan D. Maynard
|
|
|
225,000
|
(10)
|
|
|
*
|
|
Maria Fardis, Ph.D.
|
|
|
1,343,074
|
(11)
|
|
|
1.1
|
%
|
Timothy E. Morris
|
|
|
270,541
|
(10)
|
|
|
*
|
|
Frederick G. Vogt, Ph.D., Esq.
|
|
|
323,400
|
(10)
|
|
|
*
|
|
Wayne P. Rothbaum
|
|
|
9,000,000
|
(12)
|
|
|
7.1
|
%
|
Iain Dukes, D. Phil.
|
|
|
442,000
|
(13)
|
|
|
*
|
|
Athena Countouriotis, M.D.
|
|
|
35,000
|
(13)
|
|
|
*
|
|
Friedrich Graf Finckenstein, M.D.
|
|
|
-
|
|
|
|
*
|
|
All directors, director nominees and current executive officers as a group (10 persons)
|
|
|
12,603,230
|
(14)
|
|
|
9.9
|
%
|
|
(1)
|
Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Shares of common stock subject to options, warrants and convertible securities currently exercisable or convertible, or exercisable or convertible within 60 days, are deemed outstanding, including for purposes of computing the percentage ownership of the person holding such option, or convertible security, but not for purposes of computing the percentage of any other holder.
|
|
(2)
|
Based on information disclosed in a Schedule 13G filed with the SEC on February 11, 2020 by The Vanguard Group, Inc., (“The Vanguard Group”) according to which The Vanguard Group beneficially owns 10,853,129 shares of our common stock, with sole voting power over 244,256 shares, shared voting power over 29,802 shares, sole dispositive power over 10,591,162 shares and shared dispositive power over 261,967 shares. Vanguard Fiduciary Trust Company, a wholly-owned subsidiary of The Vanguard Group, is the beneficial owner of 232,165 shares of our common stock as a result of its serving as investment manager of collective trust accounts, and Vanguard Investments Australia, Ltd., a wholly-owned subsidiary of The Vanguard Group, is the beneficial owner of 41,893 shares of our common stock as a result of its serving as investment manager of Australian investment offerings.
|
|
(3)
|
Based on information disclosed in a Schedule 13G filed with the SEC on February 14, 2020 by Perceptive Advisors LLC, according to which Perceptive Advisors LLC and Joseph Edelman beneficially own 9,411,396 shares, all of which are held by Perceptive Life Sciences Master Fund Ltd., a private investment fund to which Perceptive Advisors LLC serves as the investment manager. Mr. Edelman is the managing member of Perceptive Advisors LLC. Includes 97,000 shares of our common stock issuable upon the conversion of Series A Preferred shares and 909,491 shares of our common stock issuable upon the conversion of Series B Preferred Shares. Under the terms of the Series A Preferred and Series B Preferred shares, the holder does not have the right to convert the preferred stock to the extent that after giving effect to such exercise, the holder (together with its affiliates) would beneficially own in excess of 4.99% (which limit was increased to 9.99% upon notice by Perceptive Advisors LLC). Additionally, the beneficial ownership limitation for the Series B Preferred shares will not apply to the extent that the holder’s ownership was, immediately prior to such conversion, required to report, or exempt from reporting, his, her or its holdings and transactions relating to our securities pursuant to Section 16 of the Exchange Act.
|
|
(4)
|
Based on information disclosed in a Schedule 13G filed with the SEC on February 5, 2020 by BlackRock, Inc. (“BlackRock”), according to which BlackRock beneficially owns 9,594,660 shares of our common stock, with sole voting power over 9,401,515 shares and sole dispositive power over 9,594,660 shares. The registered holders of the referenced shares are funds and accounts under management by investment adviser subsidiaries of BlackRock. BlackRock is the ultimate parent holding company of such investment adviser entities.
|
|
(5)
|
Based on information disclosed in a Schedule 13G/A filed with the SEC on February 24, 2020 by (i) Avoro Capital Advisors LLC, a Delaware limited liability company (“Avoro”), formerly known as venBio Select Advisor LLC, which provides investment advisory and management services and has acquired the securities of the Issuer solely for investment purposes on behalf of Avoro Life Sciences Fund LLC, a Delaware limited liability company, and certain managed accounts and (ii) Behzad Aghazadeh, who serves as the portfolio manager and controlling person of Avoro. The number of shares beneficially owned consists of 8,826,029 shares of our common stock and 738,961 shares of our common stock issuable upon conversion of Series B Preferred shares. Under the terms of the Series B Preferred, the holder does not have the right to convert the preferred stock to the extent that after giving effect to such exercise, the holder (together with its affiliates) would beneficially own in excess of 4.99% (which limit was increased to 9.99% upon notice by Avoro). Additionally, the beneficial ownership limitation for the Series B Preferred shares will not apply to the extent that the holder’s ownership was, immediately prior to such conversion, required to report, or exempt from reporting, his, her or its holdings and transactions relating to our securities pursuant to Section 16 of the Exchange Act.
|
|
(6)
|
Based on information disclosed in a Schedule 13D/A filed with the SEC on December 7, 2018 by Quogue Capital LLC, the number of shares beneficially owned consists of 7,067,333 shares of our common stock and 1,932,667 shares of our common stock issuable upon conversion of Series B Preferred shares owned by Quogue Capital LLC. Mr. Rothbaum is the sole managing member of Quogue Capital LLC and may be deemed to beneficially own the shares owned by Quogue Capital LLC. Under the terms of the Series B Preferred shares, the holder does not have the right to convert the preferred stock or exercise the warrant to the extent that after giving effect to such exercise, the holder (together with its affiliates) would beneficially own in excess of 4.99% (which limit was increased to 9.99% upon notice by Mr. Rothbaum); provided, however, that the beneficial ownership limitation for the Series B Preferred shares will not apply to the extent that the holder’s ownership was, immediately prior to such conversion, required to report, or exempt from reporting, his, her or its holdings and transactions relating to our securities pursuant to Section 16 of the Exchange Act. Therefore, the 9.99% limitation does not apply to Mr. Rothbaum or Quogue Capital LLC.
|
|
(7)
|
Based on information disclosed in a Schedule 13G filed with the SEC on February 14, 2020 by T. Rowe Price Associates, Inc., (“T. Rowe Price”) according to which T. Rowe Price beneficially owns 6,509,856 shares of our common stock, with sole voting power over 894,859 shares and sole dispositive power over 6,509,856 shares.
|
|
(8)
|
Represents 456,583 shares of common stock and options to purchase 270,000 shares of common stock that are exercisable currently or within 60 days of the Record Date.
|
|
(9)
|
Represents 102,632 shares owned by Dr. Weiser and 135,000 options that are exercisable currently or within 60 days of the Record Date. Does not include 28,484 shares owned by Actin Capital Partners, LLC. Dr. Weiser holds a position in Actin Capital Partners, LLC but does not have voting or dispositive control over the 28,484 shares held by Actin Capital Partners, LLC, and thus disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.
|
|
(10)
|
Represents options to purchase shares of common stock that are exercisable currently or within 60 days of the Record Date.
|
|
(11)
|
Represents 294,935 shares owned and 7,639 shares of common stock that are issuable upon vesting of restricted stock units, and 1,040,500 options to purchase shares of common stock that are exercisable currently or within 60 days of the Record Date.
|
|
(12)
|
Represents the shares of common stock owned by Quogue Capital LLC described in footnote (6) above. Mr. Rothbaum is the sole managing member of Quogue Capital LLC and may be deemed to beneficially own the shares owned by Quogue Capital LLC.
|
|
(13)
|
Represents 12,000 shares of common stock and 430,000 options to purchase shares of common stock that are exercisable currently or within 60 days of the Record Date.
|
|
(14)
|
Includes 7,639 shares of common stock that are issuable upon vesting of restricted stock units and options to purchase 2,729,441 shares of common stock that are exercisable currently or within 60 days of the Record Date.
|
THE BOARD OF DIRECTORS RECOMMENDS A VOTE
“FOR” THE COMPENSATION OF THE COMPANY’S NAMED EXECUTIVE OFFICERS.
* * *
PROPOSAL NO.
3 - ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY
"SAY ON
PAY" VOTES
Under the Dodd-Frank
Wall Street Reform and Consumer Protection Act, the Company is required to include in this proxy statement and to present at the
Annual Meeting a non-binding stockholder vote on whether an advisory vote on executive compensation should be held annually, every
two years or every three years. The Board of Directors believes that an advisory “say on pay” vote on executive compensation
should be held annually, consistent with the Company’s past practices.
In
line with our past practices, and based on the results of our first say on frequency proposal in 2014, we believe it is in our
best interest to hold our say on pay vote on an annual basis, as we believe holding this vote annually provides an effective way
to obtain current information on stockholder sentiment about the Company’s executive compensation program. Additionally,
while the say on pay vote is a formal means for soliciting stockholder feedback, we welcome the opportunity to engage with stockholders
at any time.
Proposal No. 3,
commonly known as a “say on frequency” vote, gives stockholders the opportunity to endorse or not endorse the decision
of the Board of Directors to hold an advisory vote on executive compensation at each annual meeting of stockholders hereafter.
This proposal will be presented at the Annual Meeting as a resolution in substantially the following form:
RESOLVED, that
the stockholders approve the Company’s presentation at every annual meeting of stockholders hereafter of a proposal to approve
the compensation of the Company’s Named Executive Officers, as disclosed pursuant to the compensation disclosure rules of
the Securities and Exchange Commission in the compensation tables and related narrative disclosure in the Company’s proxy
statement for such annual meeting.
This vote will
not be binding on the Board of Directors and may not be construed as overruling a decision by the Board of Directors or creating
or implying any change to the fiduciary duties of the Board. The Compensation Committee and the Board may, however, take into account
the outcome of the vote when considering the frequency of future advisory votes on executive compensation.
Stockholders can
choose one of four choices for this Proposal on the proxy card: one year, two years, three years, or abstain. Stockholders are
not voting to approve or disapprove our Board’s recommendation.
THE
BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” HOLDING FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION ANNUALLY.
* * *
PROPOSAL NO. 4 - APPROVAL OF AN AMENDMENT
TO OUR 2018 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF THE COMPANY’S COMMON STOCK AUTHORIZED FOR ISSUANCE
THEREUNDER FROM 6,000,000 SHARES TO 14,000,000 SHARES
On March 9, 2018, our Board of Directors
adopted the 2018 Plan, which was approved by our stockholders at the Annual Meeting of Stockholders held on June 6, 2018, as described
above under Proposal No. 2. As originally adopted by the Board and our stockholders, the 2018 Plan authorized the issuance up to
an aggregate of 6,000,000 shares of our common stock. On March 24, 2020, the Board adopted an amendment to the 2018 Plan to increase
the total number of shares that can be issued under the 2018 Plan from 6,000,000 shares to 14,000,000 shares, subject to stockholder
approval of the amendment. This increase in total number of shares represents approximately 6.3% of our total shares of common
stock outstanding as of the Record Date.
As of the Record Date, under the 2018 Plan:
|
·
|
No shares of common stock had been issued upon exercise of stock options.
|
|
·
|
No shares of restricted stock have been issued or were outstanding.
|
|
·
|
There were 5,785,720 shares subject to issuance upon exercise of outstanding
options at a weighted average share price of $20.26 per share and a weighted average remaining life of 2.45 years.
|
|
·
|
There were 214,280 shares of common stock available for future issuance
under the 2018 Plan.
|
Since the 2018 Plan was adopted, we have
granted options for the purchase of an aggregate of 1,585,000 shares of common stock to current executive officers and directors
with grant date fair values ranging from $11.26 to $25.78 per share, and have granted to all our employees (excluding current executive
officers) as a group options to purchase an aggregate of 4,200,720 shares. The stock options granted to such employees have exercise
prices ranging from $9.51 to $35.99 per share.
At the time that the 2018 Plan was adopted,
our company had approximately 106 employees, including our executive officers. Since then, we have hired approximately 108 employees
to whom we granted stock options. We believe that incentive compensation in the form of options (and possibly restricted stock)
is critical to our success in remaining competitive and in attracting, hiring, motivating and retaining key personnel. The efforts
and skill of our employees and other personnel who provide services to our Company generate much of the growth and success of our
business. Our employees, consultants and directors understand that their stake in our Company will have value only if, working
together, we create value for our stockholders. Awards generally vest over a period of service with us or upon accomplishment of
performance objectives, giving the recipient an additional incentive to provide services over a number of years and build on past
performance.
As of December 31, 2019, our 2014 Plan and
2011 Plan, which are each summarized above under Proposal No. 2, had 174,292 and 151,240 shares of common stock available for issuance,
respectively.
Based on our current projected hiring goals,
which involve building our commercial team and commercial manufacturing staff, our management and Board has determined that we
will not have a sufficient number of securities available under the 2018 Plan, 2014 Plan, and 2011 Plan for future grants of options
or restricted stock to our new hires and to our existing employees unless we increase the shares available under the 2018 Plan.
Accordingly, based upon the advice of our compensation consultant, Haigh, and upon review and recommendation by the Compensation
Committee, on March 24, 2020, our Board approved an increase in the number of securities available for award grants under the 2018
Plan. We are hereby submitting the foregoing amendment of our 2018 Plan to our stockholders for their approval.
2018 Equity Incentive Plan as Amended
On March 9, 2018, our Board of Directors
adopted the 2018 Plan. The 2018 Plan was approved by our stockholders at the Annual Meeting of Stockholders held on June 6, 2018.
Except with respect to awards then outstanding, unless sooner terminated, the 2018 Plan will expire on the tenth anniversary of
the date it was approved by stockholders and no further awards may be granted after such date. On March 24, 2020, our Board adopted
an amendment to the 2018 Plan to increase the total number of shares that can be issued under the 2018 Plan from 6,000,000 shares
to 14,000,000 shares, subject to stockholder approval of the amendment. The 2018 Plan, as amended, is provided in Appendix A, where
the foregoing amendment is shown in blackline text.
The 2018 Plan, as amended, contains provisions
that are designed to protect our stockholders’ interests and to reflect strong corporate governance practices, including:
|
·
|
Stockholder approval is required for additional
shares. The 2018 Plan, as amended, does not contain an annual “evergreen” provision that provides for automatic
increases of shares on an ongoing basis. The 2018 Plan, as amended, authorizes a fixed number for our share reserve, so that stockholder
approval is required to issue any additional shares from the 2018 Plan once we have used all shares available for issuance. The
2018 Plan, as amended, is not an inducement plan, and therefore requires stockholder approval under the Nasdaq Stock Market Rules.
|
|
·
|
No discounted stock options or stock appreciation rights. All stock options and stock appreciation rights will have an exercise price equal to or greater than the fair market value of our common stock on the date the stock option or stock appreciation right is granted.
|
|
·
|
Repricing is not allowed without stockholder approval. The 2018 Plan, as amended, prohibits the repricing or exchange of underwater stock options and stock appreciation rights without prior stockholder approval.
|
|
·
|
Reasonable share counting provisions. In general, when awards granted under the 2018 Plan lapse or are canceled, the shares reserved for those awards will be returned to the share reserve and be available for future awards. However, the 2018 Plan, as amended, prohibits shares tendered or withheld to pay the exercise price of an award or for payment of taxes to be returned to our share reserve.
|
Administration. Our Board of Directors
has authorized our Compensation Committee to administer the 2018 Plan, as amended, although the Board of Directors also, from time
to time, participates in the administration of the 2018 Plan, as amended, and the grant of options. The Compensation Committee
has the authority to determine the terms and conditions of any agreements evidencing any awards granted under the 2018 Plan, as
amended, and to adopt, alter and repeal rules, guidelines and practices relating to the 2018 Plan, as amended. The Compensation
Committee has full discretion to administer and interpret the 2018 Plan, as amended, and to adopt such rules, regulations and procedures
as it deems necessary or advisable and to determine, among other things, the time or times at which the awards may be exercised
and whether and under what circumstances an award may be exercised.
Eligibility. Any current or prospective
employees, directors, officers, consultants or advisors of the Company or its affiliates who are selected by the Compensation Committee
are eligible for awards under the 2018 Plan, as amended. The Compensation Committee will have the sole and complete authority to
determine who will be granted an award under the 2018 Plan, as amended.
Number of Shares Authorized. Pursuant
to the 2018 Plan, as amended, we have reserved an aggregate of 14,000,000 shares of our common stock for issuance of awards to
be granted thereunder. All of the shares of our common stock reserved under the plan may be issued as incentive stock options under
the 2018 Plan, as amended. The maximum number of equity awards that may be awarded to the non-employee members of the Board of
Directors for serving on the Board of Directors, shall be an amount equal to the product of 50,000 times the number of non-employee
members on the Board of Directors; provided, that the foregoing limitation shall not apply in respect of any awards issued to a
non-employee director in respect of (i) any one-time equity grant upon a non-employee director’s initial appointment or election
to the Board of Directors, or (ii) equity grants for services provided to the Company other than services as a member of the Board
of Directors. The total amount of awards granted annually to the non-employee members of the Board of Directors may be allocated
amongst the non-employee members of the Board of Directors in a manner determined by the Board of Directors. If any award granted
under the 2018 Plan, as amended, expires, terminates, or is canceled or forfeited without being settled, vested or exercised, shares
of our common stock subject to such award will again be made available for future grants. Any shares that are surrendered or tendered
to pay the exercise price of an award or to satisfy withholding taxes owed, or any shares reserved for issuance, but not issued,
with respect to settlement of a stock appreciation right, will not again be available for grants under the 2018 Plan, as amended.
Change in Capitalization. If there
is a change in our capitalization in the event of a stock or extraordinary cash dividend, recapitalization, stock split, reverse
stock split, reorganization, merger, consolidation, split-up, split-off, spin-off, combination, repurchase or exchange of shares
of our common stock or other relevant change in capitalization or applicable law or circumstances, such that the Compensation Committee
determines that an adjustment to the terms of the 2018 Plan, as amended (or awards thereunder) is necessary or appropriate, then
the Compensation Committee shall make adjustments in a manner that it deems equitable. Such adjustments may be to the number of
shares reserved for issuance under the 2018 Plan, as amended, the number of shares covered by awards then outstanding under the
2018 Plan, as amended, the limitations on awards under the 2018 Plan, as amended, or the exercise price of outstanding options,
or such other equitable substitution or adjustments as the Compensation Committee may determine appropriate.
Awards Available for Grant. The Compensation
Committee may grant awards of non-qualified stock options, incentive (qualified) stock options, stock appreciation rights (“SARs”),
restricted stock awards, restricted stock units, other stock-based awards, other cash-based awards or any combination of the foregoing.
Awards may be granted under the 2018 Plan, as amended, in assumption of, or in substitution for, outstanding awards previously
granted by an entity acquired by the Company or with which the Company combines, which are referred to herein as “Substitute
Awards.”
Stock Options. The Compensation Committee
will be authorized to grant options to purchase shares of our common stock that are either “qualified,” meaning they
are intended to satisfy the requirements of Section 422 of the Code for incentive stock options, or “non-qualified,”
meaning they are not intended to satisfy the requirements of Section 422 of the Code. All options granted under the 2018 Plan,
as amended, shall be non-qualified unless the applicable award agreement expressly states that the option is intended to be an
incentive stock option. Options granted under the 2018 Plan, as amended, will be subject to the terms and conditions established
by the Compensation Committee. Under the terms of the 2018 Plan, as amended, the exercise price of the options will not be less
than the fair market value (or 110% of the fair market value in the case of an incentive stock option granted to a 10% stockholder)
of our common stock on the date of grant (except with respect to Substitute Awards). Options granted under the 2018 Plan, as amended,
will be subject to such terms, including the exercise price and the conditions and timing of exercise, as may be determined by
the Compensation Committee and specified in the applicable award agreement. The maximum term of an option granted under the 2018
Plan, as amended, will be ten years from the date of grant (or five years in the case of an incentive stock option granted to a
10% stockholder), provided that if the term of a non-qualified option would expire at a time when trading in the shares of our
common stock is prohibited by the Company’s insider trading policy, the option’s term shall be extended automatically
until the 30th day following the expiration of such prohibition (as long as such extension shall not violate Section 409A of the
Code). Payment in respect of the exercise of an option may be made in cash, by check, by cash equivalent or by such other method
as the Compensation Committee may permit in its sole discretion, including, to the extent permitted by the Compensation Committee,
(i) by delivery of shares of our common stock valued at the fair market value on the date the option is exercised, provided that
such shares are not subject to any pledge or other security interest, (ii) by delivery of other property having a fair market value
equal to the exercise price and all applicable required withholding taxes, (iii) if there is a public market for the shares of
our common stock at such time, by means of a broker-assisted cashless exercise mechanism or (iv) by means of a “net exercise”
procedure effected by withholding the minimum number of shares otherwise deliverable in respect of an option that are needed to
pay the exercise price and up to the maximum withholding taxes, or any combination of the foregoing. In all events of cashless
or net exercise, any fractional shares of common stock will be settled in cash.
Stock Appreciation Rights. The Compensation
Committee will be authorized to award SARs under the 2018 Plan, as amended. SARs will be subject to the terms and conditions established
by the Compensation Committee. A SAR is a contractual right that allows a participant to receive, in the form of either cash, shares
or any combination of cash and shares, the appreciation, if any, in the value of a share over a certain period of time. An option
granted under the 2018 Plan, as amended, may include SARs, and SARs may also be awarded to a participant independent of the grant
of an option. SARs granted in connection with an option shall be subject to terms similar to the option corresponding to such SARs,
including with respect to vesting and expiration. Except as otherwise provided by the Compensation Committee (in the case of Substitute
Awards or SARs granted in tandem with previously granted options), the strike price per share of our common stock underlying each
SAR shall not be less than 100% of the fair market value of such share, determined as of the date of grant and the maximum term
of a SAR granted under the 2018 Plan, as amended, will be ten years from the date of grant.
Restricted Stock. The Compensation
Committee will be authorized to grant restricted stock under the 2018 Plan, as amended, which will be subject to the terms and
conditions established by the Compensation Committee. Restricted stock is common stock that is generally non-transferable and is
subject to other restrictions determined by the Compensation Committee for a specified period. Any accumulated dividends will be
payable at the same time that the underlying restricted stock vests.
Restricted Stock Unit Awards. The
Compensation Committee will be authorized to grant restricted stock unit awards, which will be subject to the terms and conditions
established by the Compensation Committee. A restricted stock unit award, once vested, may be settled in a number of shares of
our common stock equal to the number of units earned, in cash equal to the fair market value of the number of shares of our common
stock earned in respect of such restricted stock unit award or in a combination of the foregoing, at the election of the Compensation
Committee. Restricted stock units may be settled at the expiration of the period over which the units are to be earned or the Compensation
Committee may establish a program for deferred delivery, in compliance with Section 409A of the Code. To the extent provided in
an award agreement, the holder of outstanding restricted stock units shall be entitled to be credited with dividend equivalent
payments upon the payment by us of dividends on shares of our common stock, either in cash or, at the sole discretion of the Compensation
Committee, in shares of our common stock having a fair market value equal to the amount of such dividends (or a combination of
cash and shares), and interest may, at the sole discretion of the Compensation Committee, be credited on the amount of cash dividend
equivalents at a rate and subject to such terms as determined by the Compensation Committee, which accumulated dividend equivalents
(and interest thereon, if applicable) shall be payable at the same time that the underlying restricted stock units are settled.
Other Stock-Based Awards. The Compensation
Committee will be authorized to grant awards of unrestricted shares of our common stock, rights to receive grants of awards at
a future date, other awards denominated in shares of our common stock, or awards that provide for cash payments based in whole
or in part on the value of our common stock under such terms and conditions as the Compensation Committee may determine and as
set forth in the applicable award agreement.
Effect of a Change in Control. Unless
otherwise provided in an award agreement, or any applicable employment, consulting, change in control, severance or other agreement
between us and a participant, in the event of a change in control (as defined in the 2018 Plan, as amended), if a participant’s
employment or service is terminated by us other than for cause (and other than due to death or disability) within the 12-month
period following a change in control, then (i) all then-outstanding options and SARs held by such participant will become immediately
exercisable as of such participant’s date of termination with respect to all of the shares subject to such option or SAR;
and/or (ii) the restricted period (and any other conditions) shall expire as of such participant’s date of termination with
respect to all of the then-outstanding shares of restricted stock or restricted stock units held by such participant (including
without limitation a waiver of any applicable performance goals); provided that with respect to any award whose vesting or exercisability
is otherwise subject to the achievement of performance conditions, the portion of such award that shall become fully vested and
immediately exercisable shall be based on the assumed achievement of actual or target performance as determined by the Compensation
Committee and, unless otherwise determined by the Compensation Committee, prorated for the number of days elapsed from the grant
date of such award through the date of termination. In addition, the Compensation Committee may in its discretion and upon at least
ten days’ notice to the affected persons, cancel any outstanding award and pay the holders, in cash, securities or other
property (including of the acquiring or successor company), or any combination thereof, the value of such awards based upon the
price per share of the Company’s common stock received or to be received by other shareholders of the Company in connection
with the transaction (it being understood that any option or SAR having a per-share exercise price or strike price equal to, or
in excess of, the fair market value (as of the date specified by the Compensation Committee) of a share of the Company’s
common stock subject thereto may be canceled and terminated without payment or consideration therefor). Notwithstanding the above,
the Compensation Committee shall exercise such discretion over the timing of settlement of any award subject to Section 409A of
the Code at the time such award is granted.
Nontransferability. Each award may
be exercised during the participant’s lifetime by the participant or, if permissible under applicable law, by the participant’s
guardian or legal representative. No award may be assigned, alienated, pledged, attached, sold or otherwise transferred or encumbered
by a participant other than by will or by the laws of descent and distribution unless the Compensation Committee permits the award
to be transferred to a permitted transferee (as defined in the 2018 Plan, as amended).
Amendment. Our Board of Directors
may amend, suspend or terminate the 2018 Plan, as amended, at any time, subject to stockholder approval if necessary to comply
with any tax, stock exchange rules, or other applicable regulatory requirement. No amendment, suspension or termination will materially
and adversely affect the rights of any participant or recipient of any award without the consent of the participant or recipient.
The Compensation Committee may, to the extent
consistent with the terms of any applicable award agreement, waive any conditions or rights under, amend any terms of, or alter,
suspend, discontinue, cancel or terminate, any award theretofore granted or the associated award agreement, prospectively or retroactively;
provided, that any such waiver, amendment, alteration, suspension, discontinuance, cancellation or termination that would materially
and adversely affect the rights of any participant with respect to any award theretofore granted will not to that extent be effective
without the consent of the affected participant; and provided further that, without stockholder approval, (i) no amendment or modification
may reduce the exercise price of any option or the strike price of any SAR, (ii) the Compensation Committee may not cancel any
outstanding option and replace it with a new option (with a lower exercise price) or cancel any SAR and replace it with a new SAR
(with a lower strike price) or, in each case, with another award or cash in a manner that would be treated as a repricing (for
compensation disclosure or accounting purposes), (iii) the Compensation Committee may not take any other action considered a repricing
for purposes of the stockholder approval rules of the applicable securities exchange on which our common shares are listed and
(iv) the Compensation Committee may not cancel any outstanding option or SAR that has a per-share exercise price or strike price
(as applicable) at or above the fair market value of a share of our common stock on the date of cancellation and pay any consideration
to the holder thereof. However, stockholder approval is not required with respect to clauses (i), (ii), (iii) and (iv) above with
respect to certain adjustments on changes in capitalization.
Certain Federal Income Tax Consequences of the 2018 Plan
as Amended
Stock Options. Holders of incentive
stock options will generally incur no federal income tax liability at the time of grant or upon vesting or exercise of those options.
However, the spread at exercise will be an “item of tax preference,” which may give rise to “alternative minimum
tax” liability for the taxable year in which the exercise occurs. If the holder does not dispose of the shares before the
later of two years following the date of grant and one year following the date of exercise, the difference between the exercise
price and the amount realized upon disposition of the shares will constitute long-term capital gain or loss, as the case may be.
Assuming the holding period is satisfied, no deduction will be allowed to us for U.S. federal income tax purposes in connection
with the grant or exercise of the incentive stock option. If, within two years following the date of grant or within one year following
the date of exercise, the holder of shares acquired through the exercise of an incentive stock option disposes of those shares
(a “disqualifying disposition”), the participant will generally realize taxable compensation at the time of such disposition
equal to the difference between the exercise price and the lesser of the fair market value of the share on the date of exercise
or the amount realized on the subsequent disposition of the shares, and that amount will generally be deductible by us for U.S.
federal income tax purposes, subject to the possible limitations on deductibility under Sections 280G and 162(m) of the Code. Any
additional gain and any loss would be a capital gain or loss. The applicable capital gain tax rate will depend on the length of
the Participant’s share holding period measured from the exercise date. Finally, if an incentive stock option becomes first
exercisable in any one year for shares having an aggregate value in excess of $100,000 (based on the grant date value), the portion
of the incentive stock option in respect of those excess shares will be treated as a non-qualified stock option for federal income
tax purposes.
No income will be realized by a participant
upon grant or vesting of an option that does not qualify as an incentive stock option (“a non-qualified stock option”).
Upon the exercise of a non-qualified stock option, the participant will recognize ordinary compensation income in an amount equal
to the excess, if any, of the fair market value of the purchased shares on the date of exercise over the option exercise price,
and the participant’s tax basis will equal the sum of the compensation income recognized and the exercise price paid. We
will be able to deduct this same excess amount for U.S. federal income tax purposes, subject to the possible limitations on deductibility
under Sections 280G and 162(m) of the Code. In the event of a sale of shares received upon the exercise of a non-qualified stock
option, any appreciation or depreciation after the exercise date generally will be taxed as capital gain or loss and will be long-term
gain or loss if the holding period for such shares is more than one year.
SARs. No income will be realized
by a participant upon grant or vesting of a SAR. Upon the exercise of a SAR, the participant will recognize ordinary compensation
income in an amount equal to the fair market value of the payment received in respect of the SAR. We will be able to deduct this
same amount for U.S. federal income tax purposes, subject to the possible limitations on deductibility under Sections 280G and
162(m) of the Code.
Restricted Stock. A participant will
not be subject to tax upon the grant of an award of restricted stock unless the participant elects to be taxed on the date of grant
pursuant to Section 83(b) of the Code. On the date an award of restricted stock is no longer subject to a substantial risk of forfeiture
(i.e., the vesting date), the participant will have taxable compensation equal to the difference between the fair market value
of the shares on that date over the amount the participant paid for such shares, if any, unless the participant made an election
under Section 83(b) of the Code to be taxed on the date of grant. If the participant made an election under Section 83(b), the
participant will have taxable compensation on the date of grant equal to the difference between the fair market value of the shares
on the date of grant over the amount the participant paid for such shares, if any. If the election is made, the participant will
not be allowed a deduction for, or recoupment of, taxes paid on account of shares that fail to vest or on account of any subsequent
decrease in the value of the shares. (Special rules apply to the receipt and disposition of restricted shares received by officers
and directors who are subject to Section 16(b) of the Exchange Act). We will be able to deduct, in the same year as it is recognized
by the participant, the amount of taxable compensation to the participant for U.S. federal income tax purposes, subject to the
possible limitations on deductibility under Sections 280G and 162(m) of the Code.
Restricted Stock Units. A participant
will not be subject to tax upon the grant or vesting of a restricted stock unit award. Rather, upon the delivery of shares or cash
pursuant to a restricted stock unit award, the participant will have taxable compensation equal to the fair market value of the
number of shares (or the amount of cash) the participant actually receives with respect to the award. We will be able to deduct
the amount of taxable compensation to the participant for U.S. federal income tax purposes, subject to the possible limitations
on deductibility under Sections 280G and 162(m) of the Code.
Section 409A
Code Section 409A imposes complex rules
on nonqualified deferred compensation arrangements, including requirements with respect to elections to defer compensation and
the timing of payment of deferred amounts. Depending on how they are structured, certain equity-based awards may be subject to
Code Section 409A, while others are exempt. If an award is subject to Code Section 409A and a violation occurs, the compensation
is includible in income when no longer subject to a substantial risk of forfeiture and the participant may be subject to a 20%
penalty tax and, in some cases, interest penalties. The 2018 Plan, as amended, and awards granted under the 2018 Plan, as amended,
are intended to be exempt from or conform to the requirements of Code Section 409A.
Section 162(m) and the Company’s Deduction
Generally, whenever a participant recognizes
ordinary income under the 2018 Plan, as amended, a corresponding deduction is available to the Company, provided that the Company
complies with certain reporting requirements. However, under Code Section 162(m), the Company will be denied a deduction for compensation
paid to certain senior executives that exceeds $1,000,000, unless the compensation is “performance-based compensation”
within the meaning of the Code.
Beginning January 1, 2018, with the passage
and signing of the Tax Cuts and Jobs Act (“TCJA”), this limitation will apply to the Company's Chief Executive Officer,
Chief Financial Officer, the Company's three next highest-paid executive officers, and anyone who was such a covered person starting
with 2017. Prior to January 1, 2018, certain performance-based compensation was excluded from the $1,000,000 deduction limit. Under
the TCJA, beginning January 1, 2018 (with an exception for certain grandfathered arrangements), the Company will be denied a deduction
for any compensation exceeding $1,000,000.
New Plan Benefits
Future Awards under
the 2018 Plan are granted in the discretion of the Compensation Committee, and therefore are not determinable. The following table
sets forth the number of stock option, restricted stock and restricted stock unit awards that have been granted under the 2018
Plan to our Named Executive Officers and the other individuals and groups indicated during the fiscal year ended December 31, 2019.
|
|
Stock Options
|
|
|
|
Average Exercise Price
|
|
|
Number of Awards
|
|
Name and Position
|
|
($)
|
|
|
(#)
|
|
Maria Fardis, Ph.D., Chief Executive Officer
|
|
|
11.26
|
|
|
|
400,000
|
|
Timothy E. Morris, Chief Financial Officer
|
|
|
11.26
|
|
|
|
100,000
|
|
Friedrich Graf Finckenstein, M.D., Chief Medical Officer
|
|
|
25.78
|
|
|
|
160,000
|
|
Frederick G. Vogt, Ph.D., Esq.
|
|
|
11.26
|
|
|
|
200,000
|
|
All Current Executive Officers as a Group
|
|
|
13.96 (1)
|
|
|
|
860,000
|
|
All Nonexecutive Directors as a Group
|
|
|
-
|
|
|
|
-
|
|
All Employees as a Group (Including Officers who are not Executive Officers)
|
|
|
14.72 (1)
|
|
|
|
3,047,900
|
|
|
(1)
|
Represents the weighted-average exercise price for the group.
|
Vote Required for Approval
We are asking our stockholders to approve
an amendment to Section 5(b) of the 2018 Plan to increase the total number of shares of common stock that may be issued under the
2018 Plan from 6,000,000 to 14,000,000. A copy of the 2018 Plan, with the proposed amendment highlighted in Section 5(b), is included
as Appendix A to this Proxy Statement.
Approval of the aforementioned amendment
to the 2018 Plan by the stockholders of the Company will require the affirmative vote of a majority of the shares of common stock
voted on the matter. Under Delaware law and our Bylaws, abstentions are counted as votes cast, and therefore have the same effect
as votes against approval of the amendment to the 2018 Plan.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE
“FOR” THE APPROVAL OF AN AMENDMENT TO OUR 2018 PLAN TO INCREASE THE NUMBER OF SHARES OF THE COMPANY’S COMMON
STOCK AUTHORIZED FOR ISSUANCE THEREUNDER FROM 6,000,000 SHARES TO 14,000,000 SHARES.
* * *
PROPOSAL NO. 5 - APPROVAL OF OUR 2020
EMPLOYEE STOCK PURCHASE PLAN
Overview
On March 24, 2020, our Board of Directors
adopted the 2020 Employee Stock Purchase Plan (the “2020 ESPP”), subject to stockholder approval. A total of 500,000
shares of our common stock are available for sale under our 2020 ESPP, based upon the advice of our compensation consultant, Haigh,
and upon review and recommendation by the Compensation Committee. In adopting the ESPP, our Board of Directors considered the benefits
of stock purchase plans, including the adoption of similar plans by most of the companies in our peer group, the recruitment benefits
of such plans, and the development of a stock ownership culture by our employees.
Summary
This section summarizes certain principal
features of the 2020 ESPP. The summary is qualified in its entirety by reference to the complete text of the 2020 ESPP. Stockholders
are urged to read the actual text of the 2020 ESPP in its entirety which is set forth in Appendix B to this proxy statement.
The 2020 ESPP authorizes the sale of an
aggregate of 500,000 shares of our common stock. Appropriate adjustments will be made in the number of authorized shares and in
outstanding purchase rights to prevent dilution or enlargement of participants’ rights in the event of a stock split or other
change in our capital structure. Shares subject to purchase rights which expire or are cancelled will again become available for
issuance under the 2020 ESPP.
The Compensation Committee will administer
the 2020 ESPP and have full authority to interpret the terms of the 2020 ESPP. The 2020 ESPP provides, subject to certain limitations,
for indemnification by us of any director, officer or employee against all reasonable expenses, including attorneys’ fees,
incurred in connection with any legal action arising from such person’s action or failure to act in administering the 2020
ESPP.
All of our employees, including our named
executive officers, are eligible to participate if they are customarily employed by us for at least 20 hours per week and more
than five months in any calendar year. Non-employee Directors are not eligible to participate in the 2020 ESPP. If any local laws
applicable to any of our non-United States employees require that participation in the 2020 ESPP be extended to additional classes
of employees or otherwise impose different terms or restrictions on their participation, those requirements may be satisfied through
separate offerings under the 2020 ESPP not intended to qualify under Section 423 of the Code, and such separate offerings will
be treated part of a “Non-423 Plan” component of the 2020 ESPP. Employees in certain jurisdictions having unfavorable
laws regarding stock purchase plans may be excluded from participating in the 2020 ESPP. As of December 31, 2019, we had 148 employees.
However, an employee may not be granted rights to purchase stock under our 2020 ESPP if such employee:
|
·
|
immediately
after the grant would own stock or options to purchase stock possessing 5.0% or more of the total combined voting power or value
of all classes of our capital stock; or
|
|
·
|
holds
rights to purchase stock under all of our employee stock purchase plans that would accrue at a rate that exceeds $25,000 worth
of our stock for each calendar year in which the right to be granted would be outstanding at any time.
|
Our 2020 ESPP is intended to qualify under
Section 423 of the Code and the 2020 ESPP shall be so construed. The 2020 ESPP will typically be implemented through two consecutive
six-month offering periods. The offering periods generally start on or about December 15th and June 15th of each year after an
enrollment period. The Compensation Committee may, in its discretion, modify the terms of future offering periods, including establishing
longer offering periods and providing for multiple purchase dates.
Our 2020 ESPP permits participants to purchase
common stock through payroll deductions of up to 20.0% of their eligible compensation, which includes a participant’s regular
and recurring straight time gross earnings and payments for overtime and shift premiums, but exclusive of sign-on bonuses, annual
or other incentive bonuses, commissions, profit-sharing distributions or other incentive-type payments, any contributions made
by us on the participant’s behalf to any employee benefit or welfare plan now or hereafter established (other than amounts
deferred pursuant to Section 401(k) or Section 125 of the Code), payments in lieu of notice, payments pursuant to a severance agreement,
termination pay, moving allowances, relocation payments, or any amounts directly or indirectly paid pursuant to the 2020 ESPP or
any other stock purchase, stock option or other stock-based compensation plan, or similar types of compensation.
Amounts deducted and accumulated from participant
compensation are used to purchase shares of our common stock at the end of each offering period. Under the terms of the 2020 ESPP,
the purchase price of the shares may be 85.0% of the lower of the fair market value of our common stock on the first trading day
of the offering period or on the last day of the offering period. Participants may end their participation at any time during an
offering period and will be paid their accrued payroll deductions that have not yet been used to purchase shares of common stock.
Participation ends automatically upon termination of employment with us.
Each participant in any offering will have
an option to purchase for each full month contained in the offering period a number of shares which shall be the lesser of (i)
the number of shares determined by dividing $2,083.33 by the fair market value of a share of our common stock on the first day
of the offering period or (ii) 250 shares, and except as limited in order to comply with Section 423 of the Code. Prior to the
beginning of any offering period, the Compensation Committee, as administrator of the 2020 ESPP, may alter the maximum number of
shares that may be purchased by any participant during the offering period or specify a maximum aggregate number of shares that
may be purchased by all participants in the offering period. If insufficient shares remain available under the plan to permit all
participants to purchase the number of shares to which they would otherwise be entitled, the administrator will make a pro rata
allocation of the available shares. Any amounts withheld from participants’ compensation in excess of the amounts used to
purchase shares will be refunded, without interest.
A participant may not transfer rights granted
under the 2020 ESPP other than by will, the laws of descent and distribution or as otherwise provided under the 2020 ESPP.
As further discussed below, in the event
of a change in control, an acquiring or successor corporation may assume our rights and obligations under outstanding purchase
rights or substitute substantially equivalent purchase rights. If the acquiring or successor corporation does not assume or substitute
for outstanding purchase rights, then the purchase date of the offering periods then in progress will be accelerated to a date
prior to the change in control.
Our 2020 ESPP will continue in effect until
terminated by the Compensation Committee. The Compensation Committee has the authority to amend, suspend or terminate our 2020
ESPP as described below.
Purpose
The purpose of the 2020
ESPP is to advance the interests of the Company and its stockholders by providing an incentive to attract, retain and reward our
eligible employees and by motivating such persons to contribute to the growth and profitability of the Company. The 2020 ESPP provides
such eligible employees with an opportunity to acquire a proprietary interest in the Company through the purchase of common stock.
Valuation
On
the Record Date, the fair market value per share of our common stock was $35.20, which was the closing price per share of our
common stock on such date.
New Plan Benefits
While all of our employees
employed by us for at least 20 hours per week who work more than five months in any calendar year will be eligible to participate
in the 2020 ESPP and could purchase as much $25,000 worth of our common stock in a particular year, the actual amount or value
of shares purchased by any given employee or group of employees is not determinable because it depends on the elections of each
employee who chooses to participate. Therefore, it is not possible to determine the benefits that will be received in the future
by participants in the 2020 ESPP or the benefits that would have been received by such participants if the 2020 ESPP had been in
effect in the year ended December 31, 2019. Therefore, a New Plan Benefits table has not been provided.
Participant Withdrawal
or Termination
A participant may withdraw
from the 2020 ESPP by signing and delivering to our office or representative designated by us a written or electronic notice of
withdrawal on a form provided by us for this purpose. Such withdrawal may be elected at any time prior to the end of an offering
period; provided, however, that if a participant withdraws from the 2020 ESPP after a purchase date, the withdrawal shall not affect
shares of common stock acquired by the participant on such purchase date. A participant who voluntarily withdraws from the 2020
ESPP is prohibited from resuming participation in the 2020 ESPP in the same offering from which he or she withdrew, but may participate
in any subsequent offering by again satisfying the requirements of the 2020 ESPP. We may impose, from time to time, a requirement
that the notice of withdrawal from the 2020 ESPP be on file with our office or representative designated by us for a reasonable
period prior to the effectiveness of the participant’s withdrawal.
Upon a participant’s
voluntary withdrawal from the 2020 ESPP, the participant’s accumulated 2020 ESPP account balance which has not been applied
toward the purchase of shares of common stock shall be refunded to the participant as soon as practicable after the withdrawal,
without the payment of any interest, and the participant’s interest in the 2020 ESPP and the offering shall terminate. Such
amounts to be refunded may not be applied to any other offering under the 2020 ESPP.
Change in Control
In the event of a “Change
in Control” (as defined in the 2020 ESPP) of the Company, the surviving, continuing, successor, or purchasing corporation
or parent thereof, as the case may be (the “Acquiring Corporation”), may, without the consent of any participant, assume
or continue our rights and obligations under outstanding purchase rights or substitute substantially equivalent purchase rights
for the Acquiring Corporation’s stock. If the Acquiring Corporation elects not to assume, continue or substitute for the
outstanding purchase rights, the purchase date of the then current offering period shall be accelerated to a date before the date
of the Change in Control specified by the Compensation Committee, but the number of shares of common stock subject to outstanding
purchase rights shall not be adjusted. All purchase rights which are neither assumed or continued by the Acquiring Corporation
in connection with the Change in Control nor exercised as of the date of the Change in Control shall terminate and cease to be
outstanding effective as of the date of the Change in Control.
Amendment or Termination
of the 2020 ESPP
The Compensation Committee,
as administrator of the 2020 ESPP, may at any time amend, suspend or terminate the 2020 ESPP, except that (a) no such amendment,
suspension or termination shall affect purchase rights previously granted under the 2020 ESPP unless expressly provided by the
Compensation Committee, and (b) no such amendment, suspension or termination may adversely affect a purchase right previously
granted under the 2020 ESPP without the consent of the participant, except to the extent permitted by the 2020 ESPP or as may be
necessary to qualify the 2020 ESPP as an employee stock purchase plan pursuant to Section 423 of the Code or to comply with
any applicable law, regulation or rule. In addition, an amendment to the 2020 ESPP must be approved by the stockholders of the
Company within twelve months of the adoption of such amendment if such amendment would authorize the sale of more shares than are
then authorized for issuance under the 2020 ESPP or would change the definition of the corporations that may be designated by the
Compensation Committee as “Participating Companies” (as defined in the 2020 ESPP). Notwithstanding the foregoing, in
the event that the Compensation Committee determines that continuation of the 2020 ESPP Plan or an offering would result in unfavorable
financial accounting consequences to us, the Compensation Committee may, in its discretion and without the consent of any participant,
including with respect to an offering period then in progress: (i) terminate the 2020 ESPP or any offering period, (ii) accelerate
the purchase date of any offering period, (iii) reduce the discount or the method of determining the purchase price in any
offering period (e.g., by determining the purchase price solely on the basis of the “Fair Market Value” (as defined
in the 2020 ESPP) on the purchase date), (iv) reduce the maximum number of shares of common stock that may be purchased in
any offering period, or (v) take any combination of the foregoing actions.
Federal Income Tax Consequences
Relating to the 2020 ESPP
The following is a summary
of the principal U.S. federal income tax consequences generally applicable to awards made to a U.S. employee under the 2020 ESPP.
It does not describe all federal tax consequences under the 2020 ESPP, nor does it describe state or local tax consequences.
The 2020 ESPP is intended
to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code. Amounts withheld from
pay under the 2020 ESPP are taxable income to participating employees in the year in which the amounts otherwise would have been
received, but the participating employees will not be required to recognize additional income for federal income tax purposes either
at the time the employee is deemed to have been granted a right to purchase common stock (on the first day of an offering period)
or when the right to purchase common stock is exercised (on the last day of the purchase period).
If the participating employee
holds the common stock purchased under the 2020 ESPP for at least two years after the first day of the offering period in which
the common stock was acquired (the “Grant Date”) and for at least one year after the date the common stock is purchased,
when the participating employee disposes of the common stock, he or she will recognize as ordinary income an amount equal to the
lesser of:
|
(i)
|
the excess of the fair market value of the common stock on the date of disposition over the price
paid for the common stock; or
|
|
(ii)
|
the fair market value of the common stock on the Grant Date multiplied by the discount percentage
for stock purchases under the 2020 ESPP. We may choose 15% or a lesser discount percentage, including a zero discount percentage.
|
If the participating employee
disposes of the common stock within two years after the Grant Date or within one year after the date the common stock is purchased,
he or she will recognize ordinary income equal to the fair market value of the common stock on the last day of the purchase period
in which the common stock was acquired less the amount paid for the common stock. The ordinary income recognition pertains to any
disposition of common stock acquired under the 2020 ESPP (such as by sale, exchange or gift).
Upon disposition of the
common stock acquired under the 2020 ESPP, any gain realized in excess of the amount reported as ordinary income will be reportable
by the participating employee as a capital gain, and any loss will be reportable as a capital loss. Amounts required to be reported
as ordinary income on the disposition of the common stock may be added to the purchase price in determining any remaining capital
gain or loss. Capital gain or loss will be long-term if the employee has satisfied the two-year holding period requirement described
above or, in any event, if the employee has held the common stock for at least one year. Otherwise, the capital gain or loss will
be short-term.
If the participating employee
satisfies the two-year holding period for common stock purchased under the 2020 ESPP, we will not receive any deduction for federal
income tax purposes with respect to that common stock or the right under which it was purchased. If the employee does not satisfy
the two-year holding period, we will be entitled to a deduction in an amount equal to the amount that is considered ordinary income.
Otherwise, the 2020 ESPP has no tax effect on the Company.
If the exercise of a purchase
right does not constitute an exercise pursuant to an “employee stock purchase plan” under section 423 of the Code,
the exercise of the purchase right will be treated as the exercise of a nonstatutory stock option. The participant would therefore
recognize ordinary income on the purchase date equal to the excess of the fair market value of the shares acquired over the purchase
price. Such income is subject to withholding of income and employment taxes. Any gain or loss recognized on a subsequent sale of
the shares, as measured by the difference between the sale proceeds and the sum of (i) the purchase price for such shares and (ii)
the amount of ordinary income recognized on the exercise of the purchase right, will be treated as a capital gain or loss, as the
case may be.
Vote Required for Approval
We are asking our stockholders to approve
the 2020 ESPP. A copy of the 2020 ESPP is included as Appendix B to this Proxy Statement.
Approval of the 2020 ESPP by the stockholders
of the Company will require the affirmative vote of a majority of the shares of common stock voted on the matter. Under Delaware
law and our Bylaws, abstentions are counted as votes cast, and therefore have the same effect as votes against approval of the
2020 ESPP.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE
“FOR” THE APPROVAL OF OUR 2020 EMPLOYEE STOCK PURCHASE PLAN
* * *
PROPOSAL NO. 6 - RATIFICATION OF APPOINTMENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Our Audit Committee appointed Marcum LLP
as our independent registered public accounting firm for 2020. Marcum LLP served as our independent registered public accounting
firm and audited our consolidated financial statements for our fiscal years ended December 31, 2019, 2018, 2017, and 2016. Representatives
of Marcum LLP are expected to be present at the Annual Meeting, will have an opportunity to make a statement if they so desire,
and will be available to respond to appropriate questions.
At the Annual Meeting, our stockholders
are being asked to ratify the appointment of Marcum LLP as our independent registered public accounting firm for our fiscal year
ending December 31, 2019. Our Audit Committee is submitting the appointment of Marcum LLP to our stockholders because we value
our stockholders’ views on our independent registered public accounting firm and as a matter of good corporate governance.
Notwithstanding this appointment of Marcum LLP as our independent registered public accounting firm, and even if our stockholders
ratify that appointment, our Audit Committee, in its discretion, may appoint another independent registered public accounting firm
at any time during our 2018 fiscal year if our Audit Committee believes that such a change would be in the best interests of our
Company and our stockholders.
If our stockholders do not ratify the appointment
of Marcum LLP, our Audit Committee may reconsider the appointment.
Fees Paid to the Independent Registered Public Accounting
Firm
The following table presents fees for professional
audit services and other services rendered to our Company by Marcum LLP for our fiscal years ended December 31, 2019 and 2018,
respectively.
|
|
2019
|
|
|
2018
|
|
|
|
|
|
|
|
|
Audit fees:
|
|
$
|
423,601
|
|
|
$
|
375,965
|
|
Audit related fees:
|
|
$
|
-
|
|
|
$
|
-
|
|
Tax fees:
|
|
$
|
-
|
|
|
$
|
-
|
|
All other fees:
|
|
$
|
-
|
|
|
$
|
-
|
|
Total
|
|
$
|
423,601
|
|
|
$
|
375,965
|
|
In the above table, “audit fees”
are fees for professional services for the audit of the Company’s financial statements included in its Annual Report on Form
10-K for the fiscal year ended December 31, 2019 and the fiscal year ended December 31, 2018, including internal control attestations,
and review of financial statements included in its quarterly reports on Form 10-Q and for services that are normally provided in
connection with regulatory filings and public offerings. “Audit-related fees” represent fees for professional services
for assurance and related services that are reasonably related to the performance of the audit or review of financial statements
and that are not reported under the “audit fees” category. “Tax fees” are fees for tax compliance, tax
advice and tax planning.
Our Audit Committee of our Board of Directors
considered whether the provision of the services described above for the fiscal years ended December 31, 2019 and 2018, is compatible
with maintaining the auditor’s independence. All audit and non-audit services that may be provided by our principal accountant
to us require pre-approval by the Audit Committee of our Board of Directors. Further, our auditor shall not provide those services
to us specifically prohibited by the SEC, including bookkeeping or other services related to the accounting records or financial
statements of the audit client; financial information systems design and implementation; appraisal or valuation services, fairness
opinion, or contribution-in-kind reports; actuarial services; internal audit outsourcing services; management functions; human
resources; broker-dealer, investment adviser, or investment banking services; legal services and expert services unrelated to the
audit; and any other service that the Public Company Accounting Oversight Board determines, by regulation, is impermissible.
Auditor Independence
In our fiscal year ended December 31, 2019,
there were no other professional services provided by Marcum LLP that would have required our audit committee to consider their
compatibility with maintaining the independence of Marcum LLP.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE
“FOR” THE RATIFICATION OF THE APPOINTMENT
OF MARCUM LLP
* * *
OTHER MATTERS
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Exchange Act requires
our Company’s executive officers and directors, and persons who own more than 10% of a registered class of our Company’s
equity securities, to file reports of ownership and changes in ownership with the SEC. Executive officers, directors and greater
than 10% stockholders are required by SEC regulations to furnish our Company with copies of all Section 16(a) forms they file.
SEC regulations require us to identify in
this proxy statement anyone who filed a required report late during the most recent fiscal year. Based solely on our review of
forms we received, or written representations from reporting persons stating that they were not required to file these forms, we
believe that during the fiscal year ended December 31, 2019, all filings required under Section 16(a) of the Exchange Act, were
filed in a timely manner, with the exception of monthly Forms 4 for our Chief Executive Officer that were required to be filed
to report shares disposed of by the Company in accordance with the terms of the grant of the Restricted Stock Units (“RSUs”)
dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement
of RSUs. Our Chief Executive Officer did not receive or sell any of the shares reported in these monthly Forms 4; these shares
were withheld and subsequently canceled by the Company in accordance with the foregoing. The grant of the RSUs was previously reported
in Table I of our Chief Executive Officer’s initial Form 4 reporting the acquisition of common stock pursuant to the June
1, 2016 grant.
Fiscal Year 2019 Annual Report and SEC Filings
Our financial statements for our fiscal
year ended December 31, 2019 are included in our 2019 Annual Report, which we will make available to stockholders at the same time
as this proxy statement. This proxy statement and our annual report are posted on our website at www.iovance.com and are also available
from the SEC at its website at www.sec.gov. You may also obtain a copy of our annual report without charge by sending a written
request to the Corporate Secretary, at Iovance Biotherapeutics, Inc., 999 Skyway Road, Suite 150, San Carlos, California 94070.
* * *
Our Board of Directors does not know of
any other matters to be presented at the Annual Meeting. If any additional matters are properly presented at the Annual Meeting,
the persons named in the enclosed proxy card will have discretion to vote the shares of our common stock they represent in accordance
with their own judgment on such matters.
It is important that your shares of our
common stock be represented at the Annual Meeting, regardless of the number of shares that you hold. You are, therefore, urged
to vote by telephone or by using the internet as instructed on the enclosed proxy card or execute and return, at your earliest
convenience, the enclosed proxy card in the envelope that has also been provided.
|
THE BOARD OF DIRECTORS
San Carlos, California
April 27, 2020
|
APPENDIX A
IOVANCE BIOTHERAPEUTICS, INC.
2018 EQUITY INCENTIVE PLAN AS AMENDED
1. Purpose. The Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (as amended from time to time, the “Plan”)
is intended to help Iovance Biotherapeutics, Inc., a Delaware corporation (including any successor thereto, the “Company”),
and its Affiliates attract and retain key personnel by providing them the opportunity to acquire an equity interest in the Company
or other incentive compensation measured by reference to the value of Common Stock and to align the interests of key personnel
with those of the Company’s stockholders.
2. Effective Date; Duration. The Plan will become effective, if at all, upon the date (the “Effective Date”)
that the Plan is approved by the stockholders of the Company. The expiration date of the Plan, on and after which date no Awards
may be granted, shall be the tenth anniversary of the Effective Date; provided, however, that such expiration shall not affect
Awards then outstanding, and the terms and conditions of the Plan shall continue to apply to such Awards.
3. Definitions. When used herein, the following capitalized terms shall have the meanings indicated, and their plural
forms shall have the pluralized forms of their meanings indicated:
(a)
“Affiliate” means any person or entity that directly or indirectly controls, is controlled by, or is
under common control with, the Company. The term “control” (including, with correlative meaning, the terms “controlled
by” and “under common control with”), as applied to any person or entity, means the possession, directly or indirectly,
of the power to direct or cause the direction of the management and policies of such person or entity, whether through the ownership
of voting or other securities, by contract or otherwise.
(b)
“Award” means any Incentive Stock Option, Nonqualified Stock Option, Stock Appreciation Right, Restricted
Stock, Restricted Stock Unit, or Other Stock-Based Award granted under the Plan.
(c)
“Award Agreement” means the agreement (whether in written or electronic form) or other instrument or
document evidencing any Award granted under the Plan.
(d)
“Beneficial Ownership” has the meaning set forth in Rule 13d-3 promulgated under Section 13 of the Exchange
Act.
(e)
“Board” means the Board of Directors of the Company.
(f)
“Cause” in the case of a particular Award, unless the applicable Award Agreement states otherwise, (i)
shall have the meaning given such term (or term of similar import) in any employment, consulting, change-in-control, severance
or any other agreement between the Participant and the Company or any of its Affiliates, or severance plan in which the Participant
is eligible to participate, in either case in effect at the time of the Participant’s termination of employment or service
with the Company and its Affiliates, or (ii) if “cause” (or term of similar import) is not defined in, or in the absence
of, any such employment, consulting, change-in-control, severance or any other agreement between the Participant and the Company
or any of its Affiliates, or severance plan in which the Participant is eligible to participate, means: (A) the Participant’s
conviction of, or entry of a plea of no contest to (x) a felony or (y) a misdemeanor involving moral turpitude, (B) the Participant’s
gross negligence or willful misconduct, or a willful failure to attempt in good faith to substantially perform his or her duties
(other than due to physical illness or incapacity), (C) the Participant’s material breach of a material provision of any
employment agreement, consulting agreement, directorship agreement or similar services agreement or offer letter between the Participant
and the Company or any of its Affiliates, or any non-competition, non-disclosure or non-solicitation agreement with the Company
or any of its Affiliates, (D) the Participant’s material violation of any written policies adopted by the Company or any
of its Affiliates governing the conduct of persons performing services on behalf of the Company or any of its Affiliates, (E) the
Participant’s obtaining any material improper personal benefit as result of breach by the Participant of any covenant or
agreement (including a breach by the Participant of the Company’s code of ethics or a material breach by the Participant
of other written policies furnished to the Participant relating to personal investment transactions) of which the Participant was
or should have been aware, (F) the Participant’s fraud or misappropriation, embezzlement or material misuse of funds or property
belonging to the Company or any of its Affiliates, (G) the Participant’s use of alcohol or drugs that materially interferes
with the performance of his or her duties, or (H) willful or reckless misconduct in respect of the Participant’s obligations
to the Company or its Affiliates or other acts of misconduct by the Participant occurring during the course of the Participant’s
employment or service that in either case results in or could reasonably be expected to result in material damage to the property,
business or reputation of the Company or its Affiliates. Notwithstanding anything to the contrary herein, and except where provided
otherwise by an applicable agreement, if, within six (6) months following a Participant’s termination of employment or service
for any reason other than by the Company for Cause, the Company determines that such Participant’s termination of employment
or service could have been for Cause, such Participant’s termination of employment or service will be deemed to have been
for Cause for all purposes, and such Participant will be required to disgorge to the Company all amounts received under this Plan,
any Award Agreement or otherwise that would not have been payable to such Participant had such termination of employment or service
been by the Company for Cause. The determination of whether Cause exists shall be made by the Committee in its sole discretion.
(g) “Change in Control” means, in the case of a particular Award, unless the applicable Award Agreement (or
any employment, consulting, change-in-control, severance or other agreement between the Participant and the Company or any of its
Affiliates) states otherwise, the first to occur of any of the following events:
(i)
the acquisition by any Person or related “group” (as such term is used in Section 13(d) and Section 14(d) of
the Exchange Act) of Persons, or Persons acting jointly or in concert, of Beneficial Ownership (including control or direction)
of 50% or more (on a fully diluted basis) of either (A) the then-outstanding shares of Common Stock, including Common Stock issuable
upon the exercise of options or warrants, the conversion of convertible stock or debt, and the exercise of any similar right to
acquire such Common Stock (the “Outstanding Company Common Stock”), or (B) the combined voting power of the
then-outstanding voting securities of the Company entitled to vote in the election of directors (the “Outstanding Company
Voting Securities”), but excluding any acquisition by the Company or any of its Affiliates or by any employee benefit
plan sponsored or maintained by the Company or any of its Affiliates;
(ii)
a change in the composition of the Board such that members of the Board during any consecutive 12-month period (the “Incumbent
Directors”) cease to constitute a majority of the Board. Any person becoming a director through election or nomination
for election approved by a valid vote of at least two thirds of the Incumbent Directors shall be deemed an Incumbent Director;
provided, however, that no individual becoming a director as a result of an actual or threatened election contest, as such terms
are used in Rule 14a-12 of Regulation 14A promulgated under the Exchange Act, or as a result of any other actual or threatened
solicitation of proxies or consents by or on behalf of any person other than the Board, shall be deemed an Incumbent Director;
(iii)
the approval by the stockholders of the Company of a plan of complete dissolution or liquidation of the Company; and
(iv)
the consummation of a reorganization, recapitalization, merger, amalgamation, consolidation, statutory share exchange or
similar form of corporate transaction involving the Company (a “Business Combination”), or sale, transfer or
other disposition of all or substantially all of the business or assets of the Company to an entity that is not an Affiliate of
the Company (a “Sale”), unless immediately following such Business Combination or Sale: (A) more than 50%
of the total voting power of the entity resulting from such Business Combination or the entity that acquired all or substantially
all of the business or assets of the Company in such Sale (in either case, the “Surviving Company”), or the
ultimate parent entity that has Beneficial Ownership of sufficient voting power to elect a majority of the board of directors (or
analogous governing body) of the Surviving Company (the “Parent Company”), is represented by the Outstanding
Company Voting Securities that were outstanding immediately prior to such Business Combination or Sale (or, if applicable, is represented
by shares into which the Outstanding Company Voting Securities were converted pursuant to such Business Combination or Sale), and
such voting power among the holders thereof is in substantially the same proportion as the voting power of the Outstanding Company
Voting Securities among the holders thereof immediately prior to the Business Combination or Sale, (B) no Person (other than any
employee benefit plan sponsored or maintained by the Surviving Company or the Parent Company) is or becomes the beneficial owner,
directly or indirectly, of 50% or more of the total voting power of the outstanding voting securities eligible to elect members
of the board of directors (or the analogous governing body) of the Parent Company (or, if there is no Parent Company, the Surviving
Company), and (C) at least a majority of the members of the board of directors (or the analogous governing body) of the Parent
Company (or, if there is no Parent Company, the Surviving Company) following the consummation of the Business Combination or Sale
were Board members at the time of the Board’s approval of the execution of the initial agreement providing for such Business
Combination or Sale.
(h)
“Code” means the U.S. Internal Revenue Code of 1986, as amended, and any successor thereto. References
to any section of the Code shall be deemed to include any regulations or other interpretative guidance under such section, and
any amendments or successors thereto.
(i)
“Committee” means the Compensation Committee of the Board or a subcommittee thereof if required with
respect to actions taken to comply with Rule 16b-3 promulgated under the Exchange Act in respect of Awards or, if no such Compensation
Committee or subcommittee thereof exists, or if the Board otherwise takes action hereunder on behalf of the Committee, the Board.
(j)
“Common Stock” means the common stock of the Company, par value $0.000041666 per share (and any stock
or other securities into which such common stock may be converted or into which it may be exchanged).
(k)
“Disability” means cause for termination of the Participant’s employment or service due to a determination
that the Participant is disabled in accordance with a long-term disability insurance program maintained by the Company or a determination
by the U.S. Social Security Administration that the Participant is totally disabled.
(l)
“$” shall refer to the United States dollars.
(m)
“Eligible Director” means a director who satisfies the conditions set forth in Section 4(a) of the Plan.
(n)
“Eligible Person” means any (i) individual employed by the Company or a Subsidiary; provided, however,
that no such employee covered by a collective bargaining agreement shall be an Eligible Person, (ii) director or officer of the
Company or a Subsidiary, (iii) consultant or advisor to the Company or an Affiliate who may be offered securities registrable on
Form S-8 under the Securities Act, or (iv) prospective employee, director, officer, consultant or advisor who has accepted an offer
of employment or service from the Company or its Subsidiaries (and would satisfy the provisions of clause (i), (ii) or (iii) above
once such individual begins employment with or providing services to the Company or a Subsidiary).
(o)
“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended, and any successor thereto.
References to any section of (or rule promulgated under) the Exchange Act shall be deemed to include any rules, regulations or
other interpretative guidance under such section or rule, and any amendments or successors thereto.
(p)
“Exercise Price” has the meaning set forth in Section 7(b) of the Plan.
(q)
“Fair Market Value” means, (i) with respect to Common Stock on a given date, (x) if the Common Stock
is listed on a national securities exchange, the closing sales price of a share of Common Stock reported on such exchange on such
date, or if there is no such sale on that date, then on the last preceding date on which such a sale was reported, or (y) if the
Common Stock is not listed on any national securities exchange, the amount determined by the Committee in good faith to be the
fair market value of the Common Stock, or (ii) with respect to any other property on any given date, the amount determined by the
Committee in good faith to be the fair market value of such other property as of such date.
(r)
“Incentive Stock Option” means an Option that is designated by the Committee as an incentive stock option
as described in Section 422 of the Code and otherwise meets the requirements set forth in the Plan.
(s)
“Immediate Family Members” has the meaning set forth in Section 14(b)(ii) of the Plan.
(t)
“Indemnifiable Person” has the meaning set forth in Section 4(e) of the Plan.
(u)
“NASDAQ” means The NASDAQ Stock Market.
(v)
“Nonqualified Stock Option” means an Option that is not designated by the Committee as an Incentive Stock
Option.
(w)
“Option” means an Award granted under Section 7 of the Plan.
(x)
“Option Period” has the meaning set forth in Section 7(c) of the Plan.
(y)
“Other Stock-Based Award” means an Award granted under Section 10 of the Plan.
(z)
“Participant” has the meaning set forth in Section 6 of the Plan.
(aa)
“Permitted Transferee” has the meaning set forth in Section 14(b)(ii) of the Plan.
(bb)
“Person” has the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections
13(d) and 14(d) thereof, except that such term shall not include (i) the Company or any of its Subsidiaries, (ii) a trustee or
other fiduciary holding securities under an employee benefit plan of the Company or any of its Affiliates, (iii) an underwriter
temporarily holding securities pursuant to an offering of such securities, or (iv) a corporation owned, directly or indirectly,
by the stockholders of the Company in substantially the same proportions as their ownership of Common Stock of the Company.
(cc)
“Released Unit” has the meaning set forth in Section 9(d)(ii) of the Plan.
(dd)
“Restricted Period” has the meaning set forth in Section 9(a) of the Plan.
(ee)
“Restricted Stock” means an Award of Common Stock, subject to certain specified restrictions, granted
under Section 9 of the Plan.
(ff)
“Restricted Stock Unit” means an Award of an unfunded and unsecured promise to deliver shares of Common
Stock, cash, other securities or other property, subject to certain specified restrictions, granted under Section 9 of the Plan.
(gg)
“SAR Period” has the meaning set forth in Section 8(c) of the Plan.
(hh)
“Securities Act” means the U.S. Securities Act of 1933, as amended, and any successor thereto. Reference
in the Plan to any section of (or rule promulgated under) the Securities Act shall be deemed to include any rules, regulations
or other interpretative guidance under such section or rule, and any amendments or successor provisions to such section, rules,
regulations or other interpretive guidance.
(ii)
“Strike Price” has the meaning set forth in Section 8(b) of the Plan.
(jj)
“Stock Appreciation Right” or “SAR” means an Award granted under Section 8 of the
Plan.
(kk)
“Subsidiary” means any corporation or other entity a majority of whose outstanding voting stock or voting
power is beneficially owned directly or indirectly by the Company.
(ll)
“Substitute Awards” has the meaning set forth in Section 5(e) of the Plan.
4. Administration.
(a)
The Plan shall be administered by the Committee or, in the Board's sole discretion, by the Board. Subject to the terms of
the Plan, the Committee (or the Board) shall have the sole and plenary authority to (i) designate Participants, (ii) determine
the type, size, and terms and conditions of Awards to be granted and to grant such Awards, (iii) determine the method by which
an Award may be settled, exercised, canceled, forfeited, suspended, or repurchased by the Company, (iv) determine the circumstances
under which the delivery of cash, property or other amounts payable with respect to an Award may be deferred, either automatically
or at the Participant’s or Committee’s election, (v) interpret, administer, reconcile any inconsistency in, correct
any defect in and supply any omission in the Plan and any Award granted under the Plan, (vi) establish, amend, suspend, or waive
any rules and regulations and appoint such agents as the Committee shall deem appropriate for the proper administration of the
Plan, (vii) accelerate the vesting, delivery or exercisability of, or payment for or lapse of restrictions on, or waive any condition
in respect of, Awards, and (viii) make any other determination and take any other action that the Committee deems necessary or
desirable for the administration of the Plan or to comply with any applicable law. To the extent required to comply with the provisions
of Rule 16b-3 promulgated under the Exchange Act (if applicable and if the Board is not acting as the Committee under the Plan),
or any exception or exemption under applicable securities laws or the applicable NASDAQ rules or the rules of any other securities
exchange or inter-dealer quotation service on which the Common Stock is listed or quoted, as applicable, it is intended that each
member of the Committee shall, at the time such member takes any action with respect to an Award under the Plan, be (1) a “non-employee
director” within the meaning of Rule 16b-3 promulgated under the Exchange Act or (2) an “independent director”
under NASDAQ rules or the rules of any other securities exchange or inter-dealer quotation service on which the Common Stock is
listed or quoted, or a person meeting any similar requirement under any successor rule or regulation (“Eligible Director”).
However, the fact that a Committee member shall fail to qualify as an Eligible Director shall not invalidate any Award granted
or action taken by the Committee that is otherwise validly granted or taken under the Plan.
(b)
The Committee may delegate all or any portion of its responsibilities and powers to any persons selected by it, except for
grants of Awards to persons who are non-employee members of the Board or are otherwise subject to Section 16 of the Exchange Act.
Any such delegation may be revoked by the Committee at any time.
(c)
As further set forth in Section 14(f) of the Plan, the Committee shall have the authority to amend the Plan and Awards to
the extent necessary to permit participation in the Plan by Eligible Persons who are located outside of the United States on terms
and conditions comparable to those afforded to Eligible Persons located within the United States; provided, however, that no such
action shall be taken without stockholder approval if such approval is required by applicable securities laws or regulation or
NASDAQ rules or the rules of any other securities exchange or inter-dealer quotation service on which the Common Stock is listed
or quoted.
(d)
Unless otherwise expressly provided in the Plan, all designations, determinations, interpretations, and other decisions
regarding the Plan or any Award or any documents evidencing Awards granted pursuant to the Plan shall be within the sole discretion
of the Committee, may be made at any time and shall be final, conclusive and binding upon all persons and entities, including,
without limitation, the Company, any Affiliate, any Participant, any holder or beneficiary of any Award, and any stockholder of
the Company.
(e)
No member of the Board or the Committee, nor any employee or agent of the Company (each such person, an “Indemnifiable
Person”), shall be liable for any action taken or omitted to be taken or any determination made with respect to the Plan
or any Award hereunder (unless constituting fraud or a willful criminal act or willful criminal omission). Each Indemnifiable Person
shall be indemnified and held harmless by the Company against and from any loss, cost, liability, or expense (including attorneys’
fees) that may be imposed upon or incurred by such Indemnifiable Person in connection with or resulting from any action, suit or
proceeding to which such Indemnifiable Person may be involved as a party, witness or otherwise by reason of any action taken or
omitted to be taken or determination made under the Plan or any Award Agreement and against and from any and all amounts paid by
such Indemnifiable Person with the Company’s approval (not to be unreasonably withheld), in settlement thereof, or paid by
such Indemnifiable Person in satisfaction of any judgment in any such action, suit or proceeding against such Indemnifiable Person,
and the Company shall advance to such Indemnifiable Person any such expenses promptly upon written request (which request shall
include an undertaking by the Indemnifiable Person to repay the amount of such advance if it shall ultimately be determined as
provided below that the Indemnifiable Person is not entitled to be indemnified); provided, that the Company shall have the right,
at its own expense, to assume and defend any such action, suit or proceeding, and once the Company gives notice of its intent to
assume the defense, the Company shall have sole control over such defense with counsel of recognized standing of the Company’s
choice. The foregoing right of indemnification shall not be available to an Indemnifiable Person to the extent that a final judgment
or other final adjudication (in either case not subject to further appeal) binding upon such Indemnifiable Person determines that
the acts or omissions or determinations of such Indemnifiable Person giving rise to the indemnification claim resulted from such
Indemnifiable Person’s fraud or willful criminal act or willful criminal omission or that such right of indemnification is
otherwise prohibited by law or by the Company’s certificate of incorporation or by-laws. The foregoing right of indemnification
shall not be exclusive of or otherwise supersede any other rights of indemnification to which such Indemnifiable Persons may be
entitled under the Company’s certificate of incorporation or by-laws, as a matter of law, individual indemnification agreement
or contract or otherwise, or any other power that the Company may have to indemnify such Indemnifiable Persons or hold them harmless.
(f)
The Board may at any time and from time to time grant Awards and administer the Plan with respect to such Awards. In any
such case, the Board shall have all the authority granted to the Committee under the Plan.
5.
Grant of Awards; Shares Subject to the Plan; Limitations.
(a)
Awards. The Committee may grant Awards to one or more Eligible Persons.
(b)
Share Limits. Subject to Section 11 of the Plan and subsection (e): (i) no more than 14,000,0006,000,000
shares of Common Stock may be reserved for issuance and delivered in the aggregate pursuant to Awards granted under the Plan (the
“Share Pool”); (ii) no more than 14,000,0006,000,000 shares of Common Stock may be delivered
pursuant to the exercise of Incentive Stock Options granted under the Plan; and (iii) the maximum number of Awards that may
be granted collectively in any single fiscal year to the non-employee members of the Board for serving on the Board, shall be an
amount equal to the product of 50,000 times the number of non-employee members on the Board; provided, that the foregoing limitation
shall not apply in respect of any Awards issued to a non-employee director in respect of (i) any one-time equity grant upon a non-employee
director’s initial appointment or election to the Board, or (ii) equity grants for services provided to the Company other
than services as a member of the Board. The total amount of Awards granted annually to the non-employee members of the Board may
allocated amongst the non-employee members of the Board in a manner determined by the Board.
(c)
Share Counting. The Share Pool shall be reduced, on the date of grant, by the relevant number of shares of Common
Stock for each Award granted under the Plan that is valued by reference to a share of Common Stock; provided that Awards that are
valued by reference to shares of Common Stock but are required to be paid in cash pursuant to their terms shall not reduce the
Share Pool. If and to the extent that Awards originating from the Share Pool terminate, expire, or are canceled, forfeited, exchanged,
or surrendered without having been exercised, vested, or settled, the shares of Common Stock subject to such Awards shall again
be available for Awards under the Share Pool. Notwithstanding the foregoing, the following shares of Common Stock shall not become
available for issuance under the Plan: (i) shares of Common Stock tendered by Participants, or withheld by the Company, as full
or partial payment to the Company upon the exercise of Stock Options granted under the Plan; (ii) shares of Common Stock reserved
for issuance upon the grant of Stock Appreciation Rights, to the extent that the number of reserved shares of Common Stock exceeds
the number of shares of Common Stock actually issued upon the exercise of the Stock Appreciation Rights; and (iii) shares of Common
Stock withheld by, or otherwise remitted to, the Company to satisfy a Participant’s tax withholding obligations upon the
lapse of restrictions on, settlement of, or exercise of Awards granted under the Plan.
(d)
Source of Shares. Shares of Common Stock delivered by the Company in settlement of Awards may be authorized and unissued
shares, shares held in the treasury of the Company, shares purchased on the open market or by private purchase, or a combination
of the foregoing.
(e)
Substitute Awards. The Committee may grant Awards in assumption of, or in substitution for, outstanding awards previously
granted by the Company or any Affiliate or an entity directly or indirectly acquired by the Company or with which the Company combines
(“Substitute Awards”), and such Substitute Awards shall not be counted against the aggregate number of shares
of Common Stock available for Awards; provided, that Substitute Awards issued or intended as “incentive stock options”
within the meaning of Section 422 of the Code shall be counted against the aggregate number of Incentive Stock Options available
under the Plan.
6. Eligibility. Participation shall be limited to Eligible Persons who have been selected by the Committee and who have
entered into an Award Agreement with respect to an Award granted to them under the Plan (each such Eligible Person, a “Participant”).
7. Options.
(a)
Generally. Each Option shall be subject to the conditions set forth in the Plan and in the applicable Award Agreement.
All Options granted under the Plan shall be Nonqualified Stock Options unless the Award Agreement expressly states otherwise. Incentive
Stock Options shall be granted only subject to and in compliance with Section 422 of the Code, and only to Eligible Persons who
are employees of the Company or of a parent or subsidiary of the Company (within the meaning of Sections 424(e) and 424(f) of the
Code). If for any reason an Option intended to be an Incentive Stock Option (or any portion thereof) shall not qualify as an Incentive
Stock Option, then, to the extent of such nonqualification, such Option or portion thereof shall be regarded as a Nonqualified
Stock Option properly granted under the Plan.
(b)
Exercise Price. The exercise price (“Exercise Price”) per share of Common Stock for each Option
(that is not a Substitute Award) shall not be less than 100% of the Fair Market Value of such share, determined as of the date
of grant. Any modification to the Exercise Price of an outstanding Option shall be subject to the prohibition on repricing set
forth in Section 13(b).
(c)
Vesting, Exercise and Expiration. The Committee shall determine the manner and timing of vesting, exercise and expiration
of Options. The period between the date of grant and the scheduled expiration date of the Option (“Option Period”)
shall not exceed ten years, unless the Option Period (other than in the case of an Incentive Stock Option) would expire at a time
when trading in the shares of Common Stock is prohibited by the Company’s insider-trading policy or a Company-imposed “blackout
period,” in which case the Option Period shall be extended automatically until the 30th day following the expiration of such
prohibition (so long as such extension shall not violate Section 409A of the Code). The Committee may accelerate the vesting and/or
exercisability of any Option, which acceleration shall not affect any other terms and conditions of such Option.
(d)
Method of Exercise and Form of Payment. No shares of Common Stock shall be delivered pursuant to any exercise of
an Option until the Participant has paid the Exercise Price to the Company in full, and an amount equal to any U.S. federal, state
and local income and employment taxes and non-U.S. income and employment taxes, social contributions and any other tax-related
items required to be withheld. Options may be exercised by delivery of written or electronic notice of exercise to the Company
or its designee (including a third-party administrator) in accordance with the terms of the Option and the Award Agreement accompanied
by payment of the Exercise Price and such applicable taxes. The Exercise Price and delivery of all applicable required withholding
taxes shall be payable (i) in cash, by check or cash equivalent, or (ii) by such other method as elected by the Participant and
that the Committee may permit, in its sole discretion, including without limitation: (A) shares of Common Stock valued at the Fair
Market Value at the time the Option is exercised (including, pursuant to procedures approved by the Committee, by means of attestation
of ownership of a sufficient number of shares of Common Stock in lieu of actual delivery of such shares to the Company) or any
combination of the foregoing; provided, that such shares of Common Stock are not subject to any pledge or other security interest;
(B) in the form of other property having a Fair Market Value on the date of exercise equal to the Exercise Price and all applicable
required withholding taxes; (C) if there is a public market for the shares of Common Stock at such time, by means of a broker-assisted
“cashless exercise” pursuant to which the Company or its designee (including third-party administrators) is delivered
a copy of irrevocable instructions to a stockbroker to sell the shares of Common Stock otherwise deliverable upon the exercise
of the Option and to deliver promptly to the Company an amount equal to the Exercise Price and all applicable required withholding
taxes against delivery of the shares of Common Stock to settle the applicable trade; or (D) by means of a “net exercise”
procedure effected by withholding the minimum number of shares of Common Stock otherwise deliverable in respect of an Option that
are needed to pay for the Exercise Price and up to the maximum required withholding taxes. In all events of cashless or net exercise,
any fractional shares of Common Stock shall be settled in cash.
(e)
Notification upon Disqualifying Disposition of an Incentive Stock Option. Each Participant awarded an Incentive Stock
Option under the Plan shall notify the Company in writing immediately after the date on which the Participant makes a disqualifying
disposition of any Common Stock acquired pursuant to the exercise of such Incentive Stock Option. A disqualifying disposition is
any disposition (including, without limitation, any sale) of such Common Stock before the later of (i) two years after the date
of grant of the Incentive Stock Option and (ii) one year after the date of exercise of the Incentive Stock Option. The Company
may, if determined by the Committee and in accordance with procedures established by the Committee, retain possession, as agent
for the applicable Participant, of any Common Stock acquired pursuant to the exercise of an Incentive Stock Option until the end
of the period described in the preceding sentence, subject to complying with any instruction from such Participant as to the sale
of such Common Stock.
(f)
Compliance with Laws. Notwithstanding the foregoing, in no event shall the Participant be permitted to exercise an
Option in a manner that the Committee determines would violate the Sarbanes-Oxley Act of 2002, or any other applicable law or the
applicable rules and regulations of the Securities and Exchange Commission or the applicable rules and regulations of any securities
exchange or inter-dealer quotation service on which the Common Stock of the Company is listed or quoted.
(g)
Incentive Stock Option Grants to 10% Stockholders. Notwithstanding anything to the contrary in this Section 7, if
an Incentive Stock Option is granted to a Participant who owns stock representing more than ten percent of the voting power of
all classes of stock of the Company or of a parent or subsidiary of the Company (within the meaning of Sections 424(e) and 424(f)
of the Code), the Option Period shall not exceed five years from the date of grant of such Option and the Exercise Price shall
be at least 110% of the Fair Market Value (on the date of grant) of the shares subject to the Option.
(h)
$100,000 Per Year Limitation for Incentive Stock Options. To the extent that the aggregate Fair Market Value (determined
as of the date of grant) of shares of Common Stock for which Incentive Stock Options are exercisable for the first time by any
Participant during any calendar year (under all plans of the Company) exceeds $100,000, such excess Incentive Stock Options shall
be treated as Nonqualified Stock Options.
8. Stock Appreciation Rights (SARs).
(a)
Generally. Each SAR shall be subject to the conditions set forth in the Plan and the Award Agreement. Any Option
granted under the Plan may include a tandem SAR. The Committee also may award SARs independent of any Option.
(b)
Strike Price. The strike price (“Strike Price”) per share of Common Stock for each SAR shall not
be less than 100% of the Fair Market Value of such share, determined as of the date of grant; provided, however, that a SAR granted
in tandem with (or in substitution for) an Option previously granted shall have a Strike Price equal to the Exercise Price of the
corresponding Option. Any modification to the Strike Price of an outstanding SAR shall be subject to the prohibition on repricing
set forth in Section 13(b).
(c)
Vesting and Expiration. A SAR granted in tandem with an Option shall vest and become exercisable and shall expire
according to the same vesting schedule and expiration provisions as the corresponding Option. A SAR granted independently of an
Option shall vest and become exercisable and shall expire in such manner and on such date or dates determined by the Committee
and shall expire after such period, not to exceed ten years, as may be determined by the Committee (the “SAR Period”);
provided, however, that notwithstanding any vesting or exercisability dates set by the Committee, the Committee may accelerate
the vesting and/or exercisability of any SAR, which acceleration shall not affect the terms and conditions of such SAR other than
with respect to vesting and/or exercisability. If the SAR Period would expire at a time when trading in the shares of Common Stock
is prohibited by the Company’s insider trading policy or a Company-imposed “blackout period,” the SAR Period
shall be automatically extended until the 30th day following the expiration of such prohibition (so long as such extension shall
not violate Section 409A of the Code).
(d)
Method of Exercise. SARs may be exercised by delivery of written or electronic notice of exercise to the Company
or its designee (including a third-party administrator) in accordance with the terms of the Award, specifying the number of SARs
to be exercised and the date on which such SARs were awarded.
(e)
Payment. Upon the exercise of a SAR, the Company shall pay to the holder thereof an amount equal to the number of
shares subject to the SAR that are being exercised multiplied by the excess, if any, of the Fair Market Value of one share of Common
Stock on the exercise date over the Strike Price, less an amount equal to any U.S. federal, state and local income and employment
taxes and non-U.S. income and employment taxes, social contributions and any other tax-related items required to be withheld. The
Company shall pay such amount in cash, in shares of Common Stock valued at Fair Market Value as determined on the date of exercise,
or any combination thereof, as determined by the Committee. Any fractional shares of Common Stock shall be settled in cash.
9. Restricted Stock and Restricted Stock Units.
(a)
Generally. Each Restricted Stock and Restricted Stock Unit Award shall be subject to the conditions set forth in
the Plan and the applicable Award Agreement. The Committee shall establish restrictions applicable to Restricted Stock and Restricted
Stock Units, including the period over which the restrictions shall apply (the “Restricted Period”), and the
time or times at which Restricted Stock or Restricted Stock Units shall become vested (which, for the avoidance of doubt, may include
service- and/or performance-based vesting conditions). Subject to such rules, approvals, and conditions as the Committee may impose
from time to time, an Eligible Person who is a non-employee director may elect to receive all or a portion of such Eligible Person’s
cash director fees and other cash director compensation payable for director services provided to the Company by such Eligible
Person in any fiscal year, in whole or in part, in the form of Restricted Stock Units. The Committee may accelerate the vesting
and/or the lapse of any or all of the restrictions on Restricted Stock and Restricted Stock Units which acceleration shall not
affect any other terms and conditions of such Awards. No share of Common Stock shall be issued at the time an Award of Restricted
Stock Units is made, and the Company will not be required to set aside a fund for the payment of any such Award.
(b)
Stock Certificates; Escrow or Similar Arrangement. Upon the grant of Restricted Stock, the Committee shall cause
share(s) of Common Stock to be registered in the name of the Participant and held in book-entry form subject to the Company’s
directions. The Committee may also cause a stock certificate registered in the name of the Participant to be issued. In such event,
the Committee may provide that such certificates shall be held by the Company or in escrow rather than delivered to the Participant
pending vesting and release of restrictions, in which case the Committee may require the Participant to execute and deliver to
the Company or its designee (including third-party administrators) (i) an escrow agreement satisfactory to the Committee, if applicable,
and (ii) the appropriate stock power (endorsed in blank) with respect to the Restricted Stock. If the Participant shall fail to
execute and deliver the escrow agreement and blank stock power within the amount of time specified by the Committee, the Award
shall be null and void. Subject to the restrictions set forth in this Section 9 and the Award Agreement, the Participant shall
have the rights and privileges of a stockholder as to such Restricted Stock, including without limitation the right to vote such
Restricted Stock.
(c)
Restrictions; Forfeiture. Restricted Stock and Restricted Stock Units awarded to the Participant shall be subject
to forfeiture until the expiration of the Restricted Period and the attainment of any other vesting criteria established by the
Committee, and shall be subject to the restrictions on transferability set forth in the Award Agreement. In the event of any forfeiture,
all rights of the Participant to such Restricted Stock (or as a stockholder with respect thereto), and to such Restricted Stock
Units, as applicable, including to any dividends and/or dividend equivalents that may have been accumulated and withheld during
the Restricted Period in respect thereof, shall terminate without further action or obligation on the part of the Company. The
Committee shall have the authority to remove any or all of the restrictions on the Restricted Stock and Restricted Stock Units
whenever it may determine that, by reason of changes in applicable laws or other changes in circumstances arising after the date
of grant of the Restricted Stock Award or Restricted Stock Unit Award, such action is appropriate.
(d)
Delivery of Restricted Stock and Settlement of Restricted Stock Units.
(i)
Upon the expiration of the Restricted Period with respect to any shares of Restricted Stock and the attainment of any other
vesting criteria, the restrictions set forth in the applicable Award Agreement shall be of no further force or effect, except as
set forth in the Award Agreement. If an escrow arrangement is used, upon such expiration the Company shall deliver to the Participant
or such Participant’s beneficiary (via book-entry notation or, if applicable, in stock certificate form) the shares of Restricted
Stock with respect to which the Restricted Period has expired (rounded down to the nearest full share). Dividends, if any, that
may have been withheld by the Committee and attributable to the Restricted Stock shall be distributed to the Participant in cash
or in shares of Common Stock having a Fair Market Value (on the date of distribution) (or a combination of cash and shares of Common
Stock) equal to the amount of such dividends, upon the release of restrictions on the Restricted Stock.
(ii)
Unless otherwise provided by the Committee in an Award Agreement, upon the expiration of the Restricted Period and the attainment
of any other vesting criteria established by the Committee, with respect to any outstanding Restricted Stock Units, the Company
shall deliver to the Participant, or such Participant’s beneficiary (via book-entry notation or, if applicable, in stock
certificate form), one share of Common Stock (or other securities or other property, as applicable) for each such outstanding Restricted
Stock Unit that has not then been forfeited and with respect to which the Restricted Period has expired and any other such vesting
criteria are attained (“Released Unit”); provided, however, that the Committee may elect to (A) pay cash or
part cash and part Common Stock in lieu of delivering only shares of Common Stock in respect of such Released Units or (B) establish
a program for deferred delivery of Common Stock (or cash or part Common Stock and part cash, as the case may be) beyond the expiration
of the Restricted Period in compliance with Section 409A of the Code. If a cash payment is made in lieu of delivering shares of
Common Stock, the amount of such payment shall be equal to the Fair Market Value of the Common Stock as of the date on which the
shares of Common Stock would have otherwise been delivered to the Participant in respect of such Restricted Stock Units.
(iii)
To the extent provided in an Award Agreement, the holder of outstanding Restricted Stock Units shall be entitled to be credited
with dividend equivalent payments (upon the payment by the Company of dividends on shares of Common Stock) either in cash or, if
determined by the Committee, in shares of Common Stock having a Fair Market Value equal to the amount of such dividends as of the
date of payment (or a combination of cash and shares of Common Stock) (and interest may, if determined by the Committee, be credited
on the amount of cash dividend equivalents at a rate and subject to such terms as determined by the Committee), which accumulated
dividend equivalents (and interest thereon, if applicable) shall be payable at the same time as the underlying Restricted Stock
Units are settled (in the case of Restricted Stock Units, following the release of restrictions on such Restricted Stock Units),
and if such Restricted Stock Units are forfeited, the holder thereof shall have no right to such dividend equivalent payments.
(e) Legends on Restricted Stock. Each certificate representing Restricted Stock awarded under the Plan, if any, shall
bear a legend substantially in the form of the following in addition to any other information the Company deems appropriate until
the lapse of all restrictions with respect to such Common Stock:
TRANSFER OF THIS CERTIFICATE AND THE SHARES REPRESENTED HEREBY
IS RESTRICTED PURSUANT TO THE TERMS OF THE IOVANCE BIOTHERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN AND A RESTRICTED STOCK AWARD
AGREEMENT, DATED AS OF, BETWEEN IOVANCE BIOTHERAPEUTICS, INC. AND. A COPY OF SUCH PLAN AND AWARD AGREEMENT IS ON FILE AT THE PRINCIPAL
EXECUTIVE OFFICES OF IOVANCE BIOTHERAPEUTICS, INC.
10. Other Stock-Based Awards. The Committee may issue unrestricted Common Stock, rights to receive future grants of Awards,
or other Awards denominated in Common Stock (including performance shares or performance units), or Awards that provide for cash
payments based in whole or in part on the value or future value of shares of Common Stock under the Plan to Eligible Persons, alone
or in tandem with other Awards, in such amounts as the Committee shall from time to time determine (“Other Stock-Based
Awards”). Each Other Stock-Based Award shall be evidenced by an Award Agreement, which may include conditions including,
without limitation, the payment by the Participant of the Fair Market Value of such shares of Common Stock on the date of grant.
11. Changes in Capital Structure and Similar Events. In the event of (a) any dividend (other than regular cash dividends)
or other distribution (whether in the form of cash, shares of Common Stock, other securities or other property), recapitalization,
stock split, reverse stock split, reorganization, merger, amalgamation, consolidation, split-up, split-off, spin-off, combination,
repurchase or exchange of shares of Common Stock or other securities of the Company, issuance of warrants or other rights to acquire
shares of Common Stock or other securities of the Company, or other similar corporate transaction or event (including, without
limitation, a Change in Control) that affects the shares of Common Stock, or (b) unusual or nonrecurring events (including, without
limitation, a Change in Control) affecting the Company, any Affiliate, or the financial statements of the Company or any Affiliate,
or changes in applicable rules, rulings, regulations or other requirements of any governmental body or securities exchange or inter-dealer
quotation service, accounting principles or law, such that in any case an adjustment is determined by the Committee to be necessary
or appropriate, then the Committee shall make any such adjustments in such manner as it may deem equitable, including without limitation
any or all of the following:
(i)
adjusting any or all of (A) the number of shares of Common Stock or other securities of the Company (or number and kind
of other securities or other property) that may be delivered in respect of Awards or with respect to which Awards may be granted
under the Plan (including, without limitation, adjusting any or all of the limitations under Section 5 of the Plan) and (B) the
terms of any outstanding Award, including, without limitation, (1) the number of shares of Common Stock or other securities of
the Company (or number and kind of other securities or other property) subject to outstanding Awards or to which outstanding Awards
relate, (2) the Exercise Price or Strike Price with respect to any Award and/or (3) any applicable performance measures;
(ii)
providing for a substitution or assumption of Awards (or awards of an acquiring company), accelerating the delivery, vesting
and/or exercisability of, lapse of restrictions and/or other conditions on, or termination of, Awards or providing for a period
of time (which shall not be required to be more than ten (10) days) for Participants to exercise outstanding Awards prior to the
occurrence of such event (and any such Award not so exercised shall terminate or become no longer exercisable upon the occurrence
of such event); and
(iii)
cancelling any one or more outstanding Awards (or awards of an acquiring company) and causing to be paid to the holders
thereof, in cash, shares of Common Stock, other securities or other property, or any combination thereof, the value of such Awards,
if any, as determined by the Committee (which if applicable may be based upon the price per share of Common Stock received or to
be received by other stockholders of the Company in such event), including without limitation, in the case of an outstanding Option
or SAR, a cash payment in an amount equal to the excess, if any, of the Fair Market Value (as of a date specified by the Committee)
of the shares of Common Stock subject to such Option or SAR over the aggregate Exercise Price or Strike Price of such Option or
SAR, respectively (it being understood that, in such event, any Option or SAR having a per-share Exercise Price or Strike Price
equal to, or in excess of, the Fair Market Value (as of the date specified by the Committee) of a share of Common Stock subject
thereto may be canceled and terminated without any payment or consideration therefor);
provided, however, that the Committee shall make an equitable
or proportionate adjustment to outstanding Awards to reflect any “equity restructuring” (within the meaning of the
Financial Accounting Standards Codification Topic 718 (or any successor pronouncement thereto)). Except as otherwise determined
by the Committee, any adjustment in Incentive Stock Options under this Section 11 (other than any cancellation of Incentive Stock
Options) shall be made only to the extent not constituting a “modification” within the meaning of Section 424(h)(3)
of the Code, and any adjustments under this Section 11 shall be made in a manner that does not adversely affect the exemption provided
pursuant to Rule16b-3 promulgated under the Exchange Act. The Company shall give each Participant notice of an adjustment hereunder
and, upon notice, such adjustment shall be conclusive and binding for all purposes. In anticipation of the occurrence of any event
listed in the first sentence of this Section 11, for reasons of administrative convenience, the Committee in its sole discretion
may refuse to permit the exercise of any Award during a period of up to 30 days prior to, and/or up to 30 days after, the anticipated
occurrence of any such event.
12. Effect
of Change in Control. Except to the extent otherwise provided in an Award Agreement, or any applicable employment,
consulting, change-in-control, severance or other agreement between the Participant and the Company or an Affiliate, in the
event of a Change in Control, notwithstanding any provision of the Plan to the contrary:
(a)
If the Participant’s employment with or service to the Company or an Affiliate is terminated by the Company or Affiliate
without Cause (and other than due to death or Disability) on or within 12 months following a Change in Control, all Options and
SARs held by such Participant shall automatically become immediately exercisable with respect to 100% of the shares subject to
such Options and SARs, and that the Restricted Period (and any other conditions) shall expire immediately with respect to 100%
of the shares of Restricted Stock and Restricted Stock Units and any other Awards held by such Participant (including a waiver
of any applicable performance goals); provided, that if the vesting or exercisability of any Award would otherwise be subject to
the achievement of performance conditions, the portion of such Award that shall become fully vested and immediately exercisable
shall be based on the assumed achievement of actual or target performance as determined by the Committee and, unless otherwise
determined by the Committee, prorated for the number of days elapsed from the grant date of such Award through the date of termination.
(b)
In addition, the Committee may upon at least ten (10) days’ advance notice to the affected Participants, cancel any
outstanding Award and pay to the holders thereof, in cash, securities or other property (including of the acquiring or successor
company), or any combination thereof, the value of such Awards based upon the price per share of Common Stock received or to be
received by other stockholders of the Company in the event (it being understood that any Option or SAR having a per-share Exercise
Price or Strike Price equal to, or in excess of, the Fair Market Value (as of the date specified by the Committee) of a share of
Common Stock subject thereto may be canceled and terminated without any payment or consideration therefor). Notwithstanding the
above, the Committee shall exercise such discretion over the timing of settlement of any Award subject to Code Section 409A at
the time such Award is granted.
To the extent practicable, the provisions
of this Section 12 shall occur in a manner and at a time that allows affected Participants the ability to participate in the Change
in Control transaction with respect to the Common Stock subject to their Awards.
13. Amendments and Termination.
(a)
Amendment and Termination of the Plan. The Board may amend, alter, suspend, discontinue, or terminate the Plan or
any portion thereof at any time; provided, that no such amendment, alteration, suspension, discontinuation or termination shall
be made without stockholder approval if such approval is necessary to comply with any tax or regulatory requirement applicable
to the Plan (including, without limitation, as necessary to comply with any applicable rules or requirements of NASDAQ or of any
other securities exchange or inter-dealer quotation service on which the shares of Common Stock is listed or quoted, for changes
in GAAP to new accounting standards); and provided, further, that any such amendment, alteration, suspension, discontinuance or
termination that would materially and adversely affect the rights of any Participant or any holder or beneficiary of any Award
theretofore granted shall not to that extent be effective without the consent of the affected Participant, holder or beneficiary,
unless the Committee determines that such amendment, alteration, suspension, discontinuance or termination is either required or
advisable in order for the Company, the Plan or the Award to satisfy any applicable law or regulation. Notwithstanding the foregoing,
no amendment shall be made to the last proviso of Section 13(b) without stockholder approval.
(b)
Amendment of Award Agreements. The Committee may, to the extent not inconsistent with the terms of any applicable
Award Agreement or the Plan, waive any conditions or rights under, amend any terms of, or alter, suspend, discontinue, cancel or
terminate, any Award theretofore granted or the associated Award Agreement, prospectively or retroactively (including after the
Participant’s termination of employment or service with the Company); provided, that any such waiver, amendment, alteration,
suspension, discontinuance, cancellation or termination that would materially and adversely affect the rights of any Participant
with respect to any Award theretofore granted shall not to that extent be effective without the consent of the affected Participant
unless the Committee determines that such waiver, amendment, alteration, suspension, discontinuance, cancellation or termination
is either required or advisable in order for the Company, the Plan or the Award to satisfy any applicable law or regulation; and
provided, further, that except as otherwise permitted under Section 11 of the Plan, if (i) the Committee reduces the Exercise Price
of any Option or the Strike Price of any SAR, (ii) the Committee cancels any outstanding Option or SAR and replaces it with a new
Option or SAR (with a lower Exercise Price or Strike Price, as the case may be) or other Award or cash in a manner that would either
(A) be reportable on the Company’s proxy statement or Form 10-K (if applicable) as Options that have been “repriced”
(as such term is used in Item 402 of Regulation S-K promulgated under the Exchange Act), or (B) result in any “repricing”
for financial statement reporting purposes (or otherwise cause the Award to fail to qualify for equity accounting treatment), (iii)
the Committee takes any other action that is considered a “repricing” for purposes of the stockholder approval rules
of the applicable securities exchange or inter-dealer quotation service on which the Common Stock is listed or quoted, or (iv)
the Committee cancels any outstanding Option or SAR that has a per-share Exercise Price or Strike Price (as applicable) at or above
the Fair Market Value of a share of Common Stock on the date of cancellation, and pays any consideration to the holder thereof,
whether in cash, securities, or other property, or any combination thereof, then, in the case of the immediately preceding clauses
(i) through (iv), any such action shall not be effective without stockholder approval.
14. General.
(a) Award Agreements; Other Agreements. Each Award under the Plan shall be evidenced by an Award Agreement, which shall
be delivered to the Participant and shall specify the terms and conditions of the Award and any rules applicable thereto. In the
event of any conflict between the terms of the Plan and any Award Agreement or employment, change-in-control, severance or other
agreement in effect with the Participant, the term of the Plan shall control.
(b) Nontransferability.
(i)
Each Award shall be exercisable only by the Participant during the Participant’s lifetime, or, if permissible under
applicable law, by the Participant’s legal guardian or representative. No Award may be assigned, alienated, pledged, attached,
sold or otherwise transferred or encumbered by the Participant other than by will or by the laws of descent and distribution, and
any such purported assignment, alienation, pledge, attachment, sale, transfer or encumbrance shall be void and unenforceable against
the Company or an Affiliate; provided, that the designation of a beneficiary shall not constitute an assignment, alienation, pledge,
attachment, sale, transfer or encumbrance.
(ii)
Notwithstanding the foregoing, the Committee may permit Awards (other than Incentive Stock Options) to be transferred by
the Participant, without consideration, subject to such rules as the Committee may adopt, to (A) any person who is a “family
member” of the Participant, as such term is used in the instructions to Form S-8 under the Securities Act or any successor
form of registration statements promulgated by the Securities and Exchange Commission (collectively, the “Immediate Family
Members”); (B) a trust solely for the benefit of the Participant or the Participant’s Immediate Family Members;
(C) a partnership or limited liability company whose only partners or stockholders are the Participant and the Participant’s
Immediate Family Members; or (D) any other transferee as may be approved either (1) by the Board or the Committee, or (2) as provided
in the applicable Award Agreement; (each transferee described in clause (A), (B), (C) or (D) above is hereinafter referred to as
a “Permitted Transferee”); provided, that the Participant gives the Committee advance written notice describing
the terms and conditions of the proposed transfer and the Committee notifies the Participant in writing that such a transfer would
comply with the requirements of the Plan.
(iii)
The terms of any Award transferred in accordance with the immediately preceding paragraph shall apply to the Permitted Transferee,
and any reference in the Plan, or in any applicable Award Agreement, to the Participant shall be deemed to refer to the Permitted
Transferee, except that (A) Permitted Transferees shall not be entitled to transfer any Award, other than by will or the laws of
descent and distribution; (B) Permitted Transferees shall not be entitled to exercise any transferred Option unless there shall
be in effect a registration statement on an appropriate form covering the shares of Common Stock to be acquired pursuant to the
exercise of such Option if the Committee determines, consistent with any applicable Award Agreement, that such a registration statement
is necessary or appropriate; (C) the Committee or the Company shall not be required to provide any notice to a Permitted Transferee,
whether or not such notice is or would otherwise have been required to be given to the Participant under the Plan or otherwise;
(D) the consequences of the termination of the Participant’s employment by, or services to, the Company or an Affiliate under
the terms of the Plan and the applicable Award Agreement shall continue to be applied with respect to the transferred Award, including,
without limitation, that an Option shall be exercisable by the Permitted Transferee only to the extent, and for the periods, specified
in the Plan and the applicable Award Agreement; and (E) any non-competition, non-solicitation, non-disparagement, non-disclosure,
or other restrictive covenants contained in any Award Agreement or other agreement between the Participant and the Company or any
Affiliate shall continue to apply to the Participant and the consequences of the violation of such covenants shall continue to
be applied with respect to the transferred Award, including without limitation the clawback and forfeiture provisions of Section
14(v) of the Plan.
(c) Dividends and Dividend Equivalents. The Committee may provide the Participant with dividends or dividend equivalents
as part of an Award, payable in cash, shares of Common Stock, other securities, other Awards or other property, on a current or
deferred basis, on such terms and conditions as may be determined by the Committee, including, without limitation, payment directly
to the Participant, withholding of such amounts by the Company subject to vesting of the Award or reinvestment in additional shares
of Common Stock, Restricted Stock or other Awards; provided, that no dividends or dividend equivalents shall be payable (i) in
respect of outstanding Options or SARs or (ii) in respect of any other Award unless and until the Participant vests in such underlying
Award; provided, further, that dividend equivalents may be accumulated in respect of unearned Awards and paid as soon as administratively
practicable, but no more than 60 days, after such Awards are earned and become payable or distributable (and the right to any such
accumulated dividends or dividend equivalents shall be forfeited upon the forfeiture of the Award to which such dividends or dividend
equivalents relate).
(d) Tax Withholding.
(i)
The Participant shall be required to pay to the Company or any Affiliate, and the Company or any Affiliate shall have the
right (but not the obligation) and is hereby authorized to withhold, from any cash, shares of Common Stock, other securities or
other property deliverable under any Award or from any compensation or other amounts owing to the Participant, the amount (in cash,
Common Stock, other securities or other property) of any required withholding taxes (up to the maximum permissible withholding
amounts) in respect of an Award, its exercise, or any payment or transfer under an Award or under the Plan and to take such other
action that the Committee or the Company deem necessary to satisfy all obligations for the payment of such withholding taxes.
(ii)
Without limiting the generality of paragraph (i) above, the Committee may permit the Participant to satisfy, in whole or
in part, the foregoing withholding liability by (A) payment in cash, (B) the delivery of shares of Common Stock (which shares are
not subject to any pledge or other security interest) owned by the Participant having a Fair Market Value on such date equal to
such withholding liability or (C) having the Company withhold from the number of shares of Common Stock otherwise issuable or deliverable
pursuant to the exercise or settlement of the Award a number of shares with a Fair Market Value on such date equal to such withholding
liability. In addition, subject to any requirements of applicable law, the Participant may also satisfy the tax withholding obligations
by other methods, including selling shares of Common Stock that would otherwise be available for delivery, provided that the Board
or the Committee has specifically approved such payment method in advance.
(e) No Claim to Awards; No Rights to Continued Employment, Directorship or Engagement. No employee, director of the Company,
consultant providing service to the Company or an Affiliate, or other person, shall have any claim or right to be granted an Award
under the Plan or, having been selected for the grant of an Award, to be selected for a grant of any other Award. There is no obligation
for uniformity of treatment of Participants or holders or beneficiaries of Awards. The terms and conditions of Awards and the Committee’s
determinations and interpretations with respect thereto need not be the same with respect to each Participant and may be made selectively
among Participants, whether or not such Participants are similarly situated. Neither the Plan nor any action taken hereunder shall
be construed as giving any Participant any right to be retained in the employ or service of the Company or an Affiliate, or to
continue in the employ or the service of the Company or an Affiliate, nor shall it be construed as giving any Participant who is
a director any rights to continued service on the Board.
(f) International Participants. With respect to Participants who reside or work outside of the United States, the Committee
may amend the terms of the Plan or appendices thereto, or outstanding Awards, with respect to such Participants, in order to conform
such terms with or accommodate the requirements of local laws, procedures or practices or to obtain more favorable tax or other
treatment for the Participant, the Company or its Affiliates. Without limiting the generality of this subsection, the Committee
is specifically authorized to adopt rules, procedures and sub-plans with provisions that limit or modify rights on death, disability,
retirement or other terminations of employment, available methods of exercise or settlement of an Award, payment of income, social
insurance contributions or payroll taxes, withholding procedures and handling of any stock certificates or other indicia of ownership
that vary with local requirements. The Committee may also adopt rules, procedures or sub-plans applicable to particular Affiliates
or locations.
(g) Beneficiary Designation. The Participant’s beneficiary shall be the Participant’s spouse (or domestic
partner if such status is recognized by the Company and in such jurisdiction), or if the Participant is otherwise unmarried at
the time of death, the Participant’s estate, except to the extent that a different beneficiary is designated in accordance
with procedures that may be established by the Committee from time to time for such purpose. Notwithstanding the foregoing, in
the absence of a beneficiary validly designated under such Committee-established procedures and/or applicable law who is living
(or in existence) at the time of death of a Participant residing or working outside the United States, any required distribution
under the Plan shall be made to the executor or administrator of the estate of the Participant, or to such other individual as
may be prescribed by applicable law.
(h) Termination of Employment or Service. The Committee, in its sole discretion, shall determine the effect of all matters
and questions related to the termination of employment of or service of a Participant. Except as otherwise provided in an Award
Agreement, or any employment, consulting, change-in-control, severance or other agreement between the Participant and the Company
or an Affiliate, unless determined otherwise by the Committee: (i) neither a temporary absence from employment or service due to
illness, vacation or leave of absence (including, without limitation, a call to active duty for military service through a Reserve
or National Guard unit) nor a transfer from employment or service with the Company to employment or service with an Affiliate (or
vice versa) shall be considered a termination of employment or service with the Company or an Affiliate; and (ii) if the Participant’s
employment with the Company or its Affiliates terminates, but such Participant continues to provide services with the Company or
its Affiliates in a non-employee capacity (including as a non-employee director) (or vice versa), such change in status shall not
be considered a termination of employment or service with the Company or an Affiliate for purposes of the Plan.
(i) No Rights as a Stockholder. Except as otherwise specifically provided in the Plan or any Award Agreement, no person
shall be entitled to the privileges of ownership in respect of shares of Common Stock that are subject to Awards hereunder until
such shares have been issued or delivered to that person.
(j) Government and Other Regulations.
(i)
Nothing in the Plan shall be deemed to authorize the Committee or Board or any members thereof to take any action contrary
to applicable law or regulation, or Nasdaq rules or the rules of any other securities exchange or inter-dealer quotation service
on which the Common Stock is listed or quoted.
(ii)
The obligation of the Company to settle Awards in Common Stock or other consideration shall be subject to all applicable
laws, rules, and regulations, and to such approvals by governmental agencies as may be required. Notwithstanding any terms or conditions
of any Award to the contrary, the Company shall be under no obligation to offer to sell or to sell, and shall be prohibited from
offering to sell or selling, any shares of Common Stock pursuant to an Award unless such shares have been properly registered for
sale pursuant to the Securities Act with the Securities and Exchange Commission or unless the Company has received an opinion of
counsel, satisfactory to the Company, that such shares may be offered or sold without such registration pursuant to and in compliance
with the terms of an available exemption. The Company shall be under no obligation to register for sale under the Securities Act
any of the shares of Common Stock to be offered or sold under the Plan. The Committee shall have the authority to provide that
all shares of Common Stock or other securities of the Company or any Affiliate delivered under the Plan shall be subject to such
stop-transfer orders and other restrictions as the Committee may deem advisable under the Plan, the applicable Award Agreement,
U.S. federal securities laws, or the rules, regulations and other requirements of the U.S. Securities and Exchange Commission,
any securities exchange or inter-dealer quotation service upon which such shares or other securities of the Company are then listed
or quoted and any other applicable federal, state, local or non-U.S. laws, rules, regulations and other requirements, and, without
limiting the generality of Section 9 of the Plan, the Committee may cause a legend or legends to be put on any such certificates
of Common Stock or other securities of the Company or any Affiliate delivered under the Plan to make appropriate reference to such
restrictions or may cause such Common Stock or other securities of the Company or any Affiliate delivered under the Plan in book-entry
form to be held subject to the Company’s instructions or subject to appropriate stop-transfer orders. Notwithstanding any
provision in the Plan to the contrary, the Committee reserves the right to add any additional terms or provisions to any Award
granted under the Plan that it in its sole discretion deems necessary or advisable in order that such Award complies with the legal
requirements of any governmental entity to whose jurisdiction the Award is subject.
(iii)
The Committee may cancel an Award or any portion thereof if it determines that legal or contractual restrictions and/or
blockage and/or other market considerations would make the Company’s acquisition of shares of Common Stock from the public
markets, the Company’s issuance of Common Stock to the Participant, the Participant’s acquisition of Common Stock from
the Company and/or the Participant’s sale of Common Stock to the public markets illegal, impracticable or inadvisable. If
the Committee determines to cancel all or any portion of an Award in accordance with the foregoing, unless prevented by applicable
laws, the Company shall pay to the Participant an amount equal to the excess of (A) the aggregate Fair Market Value of the shares
of Common Stock subject to such Award or portion thereof canceled (determined as of the applicable exercise date, or the date that
the shares would have been vested or delivered, as applicable), over (B) the aggregate Exercise Price or Strike Price (in the case
of an Option or SAR, respectively) or any amount payable as a condition of delivery of shares of Common Stock (in the case of any
other Award). Such amount shall be delivered to the Participant as soon as practicable following the cancellation of such Award
or portion thereof.
(k) Section 83(b) Elections. If a Participant, in connection with the acquisition of shares of Common Stock under the
Plan, makes an election under Section 83(b) of the Code, the Participant shall notify the Company of such election within ten days
after filing notice of the election with the Internal Revenue Service, in addition to any filing and notification required pursuant
to Section 83(b) of the Code.
(l) Payments to Persons Other Than Participants. If the Committee shall find that any person to whom any amount is payable
under the Plan is unable to care for such person’s affairs because of illness or accident, or is a minor, or has died, then
any payment due to such person or such person’s estate (unless a prior claim therefor has been made by a duly appointed legal
representative or a beneficiary designation form has been filed with the Company) may, if the Committee so directs the Company,
be paid to such person’s spouse, child, or relative, or an institution maintaining or having custody of such person, or any
other person deemed by the Committee to be a proper recipient on behalf of such person otherwise entitled to payment. Any such
payment shall be a complete discharge of the liability of the Committee and the Company therefor.
(m) Nonexclusivity of the Plan. Neither the adoption of the Plan by the Board nor the submission of the Plan to the stockholders
of the Company for approval shall be construed as creating any limitations on the power of the Board to adopt such other incentive
arrangements as it may deem desirable, including, without limitation, the granting of stock options or awards otherwise than under
the Plan, and such arrangements may be either applicable generally or only in specific cases.
(n) No Trust or Fund Created. This Plan and Awards hereunder are intended to be unfunded for tax purposes and for purposes
of the Employee Retirement Income Security Act of 1974, as amended, and shall be construed and interpreted in accordance with such
intent. Neither the Plan nor any Award shall create or be construed to create a trust or separate fund of any kind or a fiduciary
relationship between the Company or any Affiliate, on the one hand, and the Participant or other person or entity, on the other
hand. No provision of the Plan or any Award shall require the Company, for the purpose of satisfying any obligations under the
Plan, to purchase assets or place any assets in a trust or other entity to which contributions are made or to otherwise segregate
any assets, nor shall the Company maintain separate bank accounts, books, records or other evidence of the existence of a segregated
or separately maintained or administered fund for such purposes. Participants shall have no rights under the Plan other than as
unsecured general creditors of the Company.
(o) Reliance on Reports. Each member of the Committee and each member of the Board (and each such member’s respective
designees) shall be fully justified in acting or failing to act, as the case may be, and shall not be liable for having so acted
or failed to act in good faith, in reliance upon any report made by the independent registered public accounting firm of the Company
or any of its Affiliates or any other information furnished in connection with the Plan by any agent or advisor of the Company
or the Committee or the Board.
(p) Relationship to Other Benefits. No payment under the Plan shall be taken into account in determining any benefits
under any pension, retirement, profit sharing, group insurance or other benefit plan of the Company except as otherwise specifically
provided in such other plan.
(q) Purchase for Investment. Whether or not the Options and shares covered by the Plan have been registered under the
Securities Act, each person exercising an Option under the Plan or acquiring shares under the Plan may be required by the Company
to give a representation in writing that such person is acquiring such shares for investment and not with a view to, or for sale
in connection with, the distribution of any part thereof. The Company will endorse any necessary legend referring to the foregoing
restriction upon the certificate or certificates representing any shares issued or transferred to the Participant upon the exercise
of any Option granted under the Plan.
(r) Governing Law. The Plan shall be governed by and construed in accordance with the laws of the State of Delaware,
without regard to principles of conflicts of laws thereof, or principles of conflicts of laws of any other jurisdiction that could
cause the application of the laws of any jurisdiction other than the State of Delaware.
(s) Severability. If any provision of the Plan or any Award or Award Agreement is or becomes or is deemed to be invalid,
illegal, or unenforceable in any jurisdiction or as to any person or entity or Award, or would disqualify the Plan or any Award
under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to the applicable
laws, or if it cannot be construed or deemed amended without, in the determination of the Committee, materially altering the intent
of the Plan or the Award, such provision shall be construed or deemed stricken as to such jurisdiction, person or entity or Award,
and the remainder of the Plan and any such Award shall remain in full force and effect.
(t) Obligations Binding on Successors. The obligations of the Company under the Plan shall be binding upon any successor
corporation or organization resulting from the merger, consolidation or other reorganization of the Company, or upon any successor
corporation or organization succeeding to all or substantially all of the assets and business of the Company.
(u) Section 409A of the Code.
(i)
It is intended that the Plan be exempt from or comply with Section 409A of the Code, and all provisions of the Plan shall
be construed and interpreted in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A of
the Code. Each Participant is solely responsible and liable for the satisfaction of all taxes and penalties that may be imposed
on or in respect of such Participant in connection with the Plan or any other plan maintained by the Company, including any taxes
and penalties under Section 409A of the Code, and neither the Company nor any Affiliate shall have any obligation to indemnify
or otherwise hold such Participant or any beneficiary harmless from any or all of such taxes or penalties. With respect to any
Award that is considered “deferred compensation” subject to Section 409A of the Code, references in the Plan to “termination
of employment” (and substantially similar phrases) shall mean “separation from service” within the meaning of
Section 409A of the Code. For purposes of Section 409A of the Code, each of the payments that may be made in respect of any Award
granted under the Plan is designated as a separate payment.
(ii)
Notwithstanding anything in the Plan to the contrary, if the Participant is a “specified employee” within the
meaning of Section 409A(a)(2)(B)(i) of the Code, no payments or deliveries in respect of any Awards that are payable on account
of the Participant’s “separation from service” and that are “deferred compensation” subject to Section
409A of the Code shall be made to such Participant prior to the date that is six months after the date of such Participant’s
“separation from service” within the meaning of Section 409A of the Code or, if earlier, the Participant’s date
of death. All such delayed payments or deliveries will be paid or delivered (without interest) in a single lump sum on the earliest
date permitted under Section 409A of the Code that is also a business day.
(iii)
In the event that the timing of payments in respect of any Award that would otherwise be considered “deferred compensation”
subject to Section 409A of the Code would be accelerated upon the occurrence of (A) a Change in Control, no such acceleration shall
be permitted unless the event giving rise to the Change in Control satisfies the definition of a change in the ownership or effective
control of a corporation, or a change in the ownership of a substantial portion of the assets of a corporation pursuant to Section
409A of the Code and any Treasury Regulations promulgated thereunder or (B) a Disability, no such acceleration shall be permitted
unless the Disability also satisfies the definition of “disability” pursuant to Section 409A of the Code and any Treasury
Regulations promulgated thereunder.
(v) Clawback/Forfeiture. Notwithstanding anything to the contrary contained herein, to the extent required by applicable
law (including, without limitation, Section 304 of the Sarbanes-Oxley Act and Section 954 of the Dodd-Frank Wall Street Reform
and Consumer Protection Act and any rules or regulations promulgated thereunder) and/or the rules and regulations of NASDAQ or
any other securities exchange or inter-dealer quotation service on which the Common Stock is listed or quoted, Awards shall be
subject (including on a retroactive basis) to clawback, forfeiture or similar requirements (and such requirements shall be deemed
incorporated by reference into all outstanding Award Agreements).
(w) No Representations or Covenants with Respect to Tax Qualification. Although the Company may endeavor to (i) qualify
an Award for favorable U.S. or non-U.S. tax treatment or (ii) avoid adverse tax treatment, the Company makes no representation
to that effect and expressly disavows any covenant to maintain favorable or avoid unfavorable tax treatment. The Company shall
be unconstrained in its corporate activities without regard to the potential negative tax impact on holders of Awards under the
Plan.
(x) No Interference. The existence of the Plan, any Award Agreement, and the Awards granted hereunder shall not affect
or restrict in any way the right or power of the Company, the Board, the Committee, or the stockholders of the Company to make
or authorize any adjustment, recapitalization, reorganization, or other change in the Company’s capital structure or its
business, any merger or consolidation of the Company, any issue of stock or of options, warrants, or rights to purchase stock or
of bonds, debentures, or preferred or prior preference stocks whose rights are superior to or affect the Common Stock or the rights
thereof or that are convertible into or exchangeable for Common Stock, or the dissolution or liquidation of the Company or any
Affiliate, or any sale or transfer of all or any part of their assets or business, or any other corporate act or proceeding, whether
of a similar character or otherwise.
(y) Expenses; Titles and Headings. The expenses of administering the Plan shall be borne by the Company and its Affiliates.
The titles and headings of the sections in the Plan are for convenience of reference only, and in the event of any conflict, the
text of the Plan, rather than such titles or headings shall control.
* * *
As adopted by the Board of Directors of the Company on March
9, 2018, as adopted by the stockholders of the Company on June 6, 2018, and as amended by the Board of Directors of the Company
on March 24, 2020.
APPENDIX B
IOVANCE BIOTHERAPEUTICS, INC.
2020 EMPLOYEE STOCK PURCHASE PLAN
1. Establishment, Purpose and Term of Plan.
1.1 Establishment. The Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan (the “Plan”)
is hereby established effective as of ________, 2020, the date of its approval by the stockholders of the Company (the “Effective
Date”).
1.2 Purpose. The purpose of the Plan is to advance the interests of the Company and its stockholders by providing an
incentive to attract, retain and reward Eligible Employees of the Participating Company Group and by motivating such persons to
contribute to the growth and profitability of the Participating Company Group. The Plan provides such Eligible Employees with an
opportunity to acquire a proprietary interest in the Company through the purchase of Stock. The Company intends that the Plan qualify
as an “employee stock purchase plan” under Section 423 of the Code (including any amendments or replacements of
such section), and the Plan shall be so construed.
1.3 Term of Plan. The Plan shall continue in effect until its termination by the Committee.
2. Definitions and Construction.
2.1 Definitions. Any term not expressly defined in the Plan but defined for purposes of Section 423 of the Code
shall have the same definition herein. Whenever used herein, the following terms shall have their respective meanings set forth
below:
(a) “Board” means the Board of Directors of the Company.
(b) “Change in Control” means the occurrence of any one or a combination of the following:
(i)
any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the “beneficial
owner” (as such term is defined in Rule 13d-3 promulgated under the Exchange Act), directly or indirectly, of securities
of the Company representing more than fifty percent (50%) of the total Fair Market Value or total combined voting power of the
Company’s then-outstanding securities entitled to vote generally in the election of Directors; provided, however, that a
Change in Control shall not be deemed to have occurred if such degree of beneficial ownership results from any of the following:
(A) an acquisition by any person who on the Effective Date is the beneficial owner of more than fifty percent (50%) of such
voting power, (B) any acquisition directly from the Company, including, without limitation, pursuant to or in connection with
a public offering of securities, (C) any acquisition by the Company, (D) any acquisition by a trustee or other fiduciary
under an employee benefit plan of a Participating Company or (E) any acquisition by an entity owned directly or indirectly
by the stockholders of the Company in substantially the same proportions as their ownership of the voting securities of the Company;
or
(ii)
an Ownership Change Event or series of related Ownership Change Events (collectively, a “Transaction”)
in which the stockholders of the Company immediately before the Transaction do not retain immediately after the Transaction direct
or indirect beneficial ownership of more than fifty percent (50%) of the total combined voting power of the outstanding securities
entitled to vote generally in the election of Directors or, in the case of an Ownership Change Event described in Section 2.1(p)(iii),
the entity to which the assets of the Company were transferred (the “Transferee”), as the case may be; or
(iii)
approval by the stockholders of a plan of complete liquidation or dissolution of the Company;
provided, however, that a Change in Control shall
be deemed not to include a transaction described in subsections (i) or (ii) of this Section 2.1(b) in which a majority of
the members of the board of directors of the continuing, surviving or successor entity, or parent thereof, immediately after such
transaction is comprised of Incumbent Directors.
For purposes of the preceding sentence, indirect beneficial
ownership shall include, without limitation, an interest resulting from ownership of the voting securities of one or more corporations
or other business entities which own the Company or the Transferee, as the case may be, either directly or through one or more
subsidiary corporations or other business entities. The Committee shall determine whether multiple acquisitions of the voting securities
of the Company and/or multiple Ownership Change Events are related and to be treated in the aggregate as a single Change in Control,
and its determination shall be final, binding and conclusive.
(c) “Code” means the Internal Revenue Code of 1986, as amended, and any applicable regulations promulgated
thereunder.
(d) “Committee” means the Compensation Committee and such other committee or subcommittee of the Board, if
any, duly appointed to administer the Plan and having such powers in each instance as shall be specified by the Board. If, at any
time, there is no committee of the Board then authorized or properly constituted to administer the Plan, the Board shall exercise
all of the powers of the Committee granted herein, and, in any event, the Board may in its discretion exercise any or all of such
powers.
(e) “Company” means Iovance Biotherapeutics, Inc., a Delaware corporation, or any successor corporation thereto.
(f) “Compensation” means, with respect to any Offering Period, regular base wages or salary, overtime payments,
shift premiums and payments for paid time off, calculated before deduction of (i) any income or employment tax withholdings or
(ii) any amounts deferred pursuant to Section 401(k) or Section 125 of the Code. Compensation shall be limited to such amounts
actually payable in cash or deferred during the Offering Period. Compensation shall not include (i) sign-on bonuses, annual or
other incentive bonuses, commissions, profit-sharing distributions or other incentive-type payments, (ii) any contributions made
by a Participating Company on the Participant’s behalf to any employee benefit or welfare plan now or hereafter established
(other than amounts deferred pursuant to Section 401(k) or Section 125 of the Code), (iii) payments in lieu of notice, payments
pursuant to a severance agreement, termination pay, moving allowances, relocation payments, or (iv) any amounts directly or indirectly
paid pursuant to the Plan or any other stock purchase, stock option or other stock-based compensation plan, or any other compensation
not expressly included by this Section.
(g)
“Eligible Employee” means an Employee who meets the requirements set forth in Section 5 for eligibility
to participate in the Plan.
(h)
“Employee” means a person treated as an employee of a Participating Company for purposes of Section 423
of the Code. A Participant shall be deemed to have ceased to be an Employee either upon an actual termination of employment or
upon the corporation employing the Participant ceasing to be a Participating Company. For purposes of the Plan, an individual shall
not be deemed to have ceased to be an Employee while on any military leave, sick leave, or other bona fide leave of absence approved
by the Company of ninety (90) days or less. If an individual’s leave of absence exceeds ninety (90) days, the individual
shall be deemed to have ceased to be an Employee on the ninety-first (91st) day of such leave unless the individual’s right
to reemployment with the Participating Company Group is guaranteed either by statute or by contract.
(i)
“Fair Market Value” means, as of any date:
(i)
If, on such date, the Stock is listed or quoted on a national or regional securities exchange or quotation system, the closing
price of a share of Stock as quoted on the national or regional securities exchange or quotation system constituting the primary
market for the Stock, as reported in The Wall Street Journal or such other source as the Company deems reliable. If the relevant
date does not fall on a day on which the Stock has traded on such securities exchange or quotation system, the date on which the
Fair Market Value is established shall be the last day on which the Stock was so traded or quoted prior to the relevant date, or
such other appropriate day as determined by the Committee, in its discretion.
(ii)
If, on the relevant date, the Stock is not then listed on a national or regional securities exchange or quotation system,
the Fair Market Value of a share of Stock shall be as determined in good faith by the Committee.
(j)
“Incumbent Director” means a director who either (i) is a member of the Board as of the Effective
Date or (ii) is elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the
Incumbent Directors at the time of such election or nomination (but excluding a director who was elected or nominated in connection
with an actual or threatened proxy contest relating to the election of directors of the Company).
(k)
“Non-United States Offering” means a separate Offering covering Eligible Employees of one or more Participating
Companies whose Eligible Employees are subject to a prohibition under applicable law on payroll deductions, as described in Section 11.1(b).
(l)
“Offering” means an offering of Stock pursuant to the Plan, as provided in Section 6.
(m)
“Offering Date” means, for any Offering Period, the first day of such Offering Period.
(n)
“Offering Period” means a period, established by the Committee in accordance with Section 6, during
which an Offering is outstanding.
(o)
“Officer” means any person designated by the Board as an officer of the Company.
(p)
“Ownership Change Event” means the occurrence of any of the following with respect to the Company: (i)
the direct or indirect sale or exchange in a single or series of related transactions by the stockholders of the Company of securities
of the Company representing more than fifty percent (50%) of the total combined voting power of the Company’s then outstanding
securities entitled to vote generally in the election of Directors; (ii) a merger or consolidation in which the Company is a party;
or (iii) the sale, exchange, or transfer of all or substantially all of the assets of the Company (other than a sale, exchange
or transfer to one or more subsidiaries of the Company).
(q)
“Parent Corporation” means any present or future “parent corporation” of the Company, as
defined in Section 424(e) of the Code.
(r)
“Participant” means an Eligible Employee who has become a participant in an Offering Period in accordance
with Section 7 and remains a participant in accordance with the Plan.
(s)
“Participating Company” means the Company and any Parent Corporation or Subsidiary Corporation designated
by the Committee as a corporation the Employees of which may, if Eligible Employees, participate in the Plan. The Committee shall
have the discretion to determine from time to time which Parent Corporations or Subsidiary Corporations shall be Participating
Companies. The Committee shall designate from time to time and set forth in Exhibit A to this Plan those Participating Companies
whose Eligible Employees may participate in the Plan.
(t)
“Participating Company Group” means, at any point in time, the Company and all other corporations collectively
which are then Participating Companies.
(u)
“Purchase Date” means, for any Offering Period, the last day of such Offering Period, or, if so determined
by the Committee, the last day of each Purchase Period occurring within such Offering Period.
(v)
“Purchase Period” means a period, established by the Committee in accordance with Section 6, included
within an Offering Period and on the final date of which outstanding Purchase Rights are exercised.
(w)
“Purchase Price” means the price at which a share of Stock may be purchased under the Plan, as determined
in accordance with Section 9.
(x)
“Purchase Right” means an option granted to a Participant pursuant to the Plan to purchase such shares
of Stock as provided in Section 8, which the Participant may or may not exercise during the Offering Period in which such
option is outstanding. Such option arises from the right of a Participant to withdraw any payroll deductions or other funds accumulated
on behalf of the Participant and not previously applied to the purchase of Stock under the Plan, and to terminate participation
in the Plan at any time during an Offering Period.
(y)
“Securities Act” means the Securities Act of 1933, as amended.
(z)
“Stock” means the common stock of the Company, as adjusted from time to time in accordance with Section 4.2.
(aa)
“Subscription Agreement” means a written or electronic agreement, in such form as specified by the Company,
stating an Employee’s election to participate in the Plan and authorizing payroll deductions under the Plan from the Employee’s
Compensation or other method of payment authorized by the Committee pursuant to Section 11.1(b).
(bb)
“Subscription Date” means the last business day prior to the Offering Date of an Offering Period or such
earlier date as the Company shall establish.
(cc)
“Subsidiary Corporation” means any present or future “subsidiary corporation” of the Company,
as defined in Section 424(f) of the Code.
2.2 Construction. Captions and titles contained herein are for convenience only and shall not affect the meaning or interpretation
of any provision of the Plan. Except when otherwise indicated by the context, the singular shall include the plural and the plural
shall include the singular. Use of the term “or” is not intended to be exclusive, unless the context clearly requires
otherwise.
3. Administration.
3.1 Administration by the Committee. The Plan shall be administered by the Committee. All questions of interpretation
of the Plan, of any form of agreement or other document employed by the Company in the administration of the Plan, or of any Purchase
Right shall be determined by the Committee, and such determinations shall be final, binding and conclusive upon all persons having
an interest in the Plan or the Purchase Right, unless fraudulent or made in bad faith. Subject to the provisions of the Plan, the
Committee shall determine all of the relevant terms and conditions of Purchase Rights; provided, however, that all Participants
granted Purchase Rights pursuant to an Offering shall have the same rights and privileges within the meaning of Section 423(b)(5)
of the Code. Any and all actions, decisions and determinations taken or made by the Committee in the exercise of its discretion
pursuant to the Plan or any agreement thereunder (other than determining questions of interpretation pursuant to the second sentence
of this Section 3.1) shall be final, binding and conclusive upon all persons having an interest therein. All expenses incurred
in connection with the administration of the Plan shall be paid by the Company.
3.2 Authority of Officers. Any Officer shall have the authority to act on behalf of the Company with respect to any matter,
right, obligation, determination or election that is the responsibility of or that is allocated to the Company herein, provided
that the Officer has apparent authority with respect to such matter, right, obligation, determination or election.
3.3 Power to Adopt Sub-Plans or Varying Terms with Respect to Non-U.S. Employees. The Committee shall have the power,
in its discretion, to adopt one or more sub-plans of the Plan as the Committee deems necessary or desirable to comply with the
laws or regulations, tax policy, accounting principles or custom of foreign jurisdictions applicable to employees of a subsidiary
business entity of the Company, provided that any such sub-plan shall not be within the scope of an “employee stock purchase
plan” within the meaning of Section 423 of the Code. Any of the provisions of any such sub-plan may supersede the provisions
of this Plan, other than Section 4. Except as superseded by the provisions of a sub-plan, the provisions of this Plan shall
govern such sub-plan. Alternatively and in order to comply with the laws of a foreign jurisdiction, the Committee shall have the
power, in its discretion, to grant Purchase Rights in an Offering to citizens or residents of a non-U.S. jurisdiction (without
regard to whether they are also citizens of the United States or resident aliens) that provide terms which are less favorable than
the terms of Purchase Rights granted under the same Offering to Employees resident in the United States.
3.4 Power to Establish Separate Offerings with Varying Terms. The Committee shall have the power, in its discretion,
to establish separate, simultaneous or overlapping Offerings having different terms and conditions and to designate the Participating
Company or Companies that may participate in a particular Offering, provided that each Offering shall individually comply with
the terms of the Plan and the requirements of Section 423(b)(5) of the Code that all Participants granted Purchase Rights
pursuant to such Offering shall have the same rights and privileges within the meaning of such section.
3.5 Policies and Procedures Established by the Company. Without regard to whether any Participant’s Purchase Right
may be considered adversely affected, the Company may, from time to time, consistent with the Plan and the requirements of Section 423
of the Code, establish, change or terminate such rules, guidelines, policies, procedures, limitations, or adjustments as deemed
advisable by the Company, in its discretion, for the proper administration of the Plan, including, without limitation, (a) a
minimum payroll deduction amount required for participation in an Offering, (b) a limitation on the frequency or number of
changes permitted in the rate of payroll deduction during an Offering, (c) an exchange ratio applicable to amounts withheld
or paid in a currency other than United States dollars, (d) a payroll deduction greater than or less than the amount designated
by a Participant in order to adjust for the Company’s delay or mistake in processing a Subscription Agreement or in otherwise
effecting a Participant’s election under the Plan or as advisable to comply with the requirements of Section 423 of
the Code, and (e) determination of the date and manner by which the Fair Market Value of a share of Stock is determined for
purposes of administration of the Plan. All such actions by the Company shall be taken consistent with the requirements under Section 423(b)(5)
of the Code that all Participants granted Purchase Rights pursuant to an Offering shall have the same rights and privileges within
the meaning of such section, except as otherwise permitted by Section 3.3 and the regulations under Section 423 of the
Code.
3.6 Indemnification. In addition to such other rights of indemnification as they may have as members of the Board or
the Committee or as officers or employees of the Participating Company Group, to the extent permitted by applicable law, members
of the Board or the Committee and any officers or employees of the Participating Company Group to whom authority to act for the
Board, the Committee or the Company is delegated shall be indemnified by the Company against all reasonable expenses, including
attorneys’ fees, actually and necessarily incurred in connection with the defense of any action, suit or proceeding, or in
connection with any appeal therein, to which they or any of them may be a party by reason of any action taken or failure to act
under or in connection with the Plan, or any right granted hereunder, and against all amounts paid by them in settlement thereof
(provided such settlement is approved by independent legal counsel selected by the Company) or paid by them in satisfaction of
a judgment in any such action, suit or proceeding, except in relation to matters as to which it shall be adjudged in such action,
suit or proceeding that such person is liable for gross negligence, bad faith or intentional misconduct in duties; provided, however,
that within sixty (60) days after the institution of such action, suit or proceeding, such person shall offer to the Company, in
writing, the opportunity at its own expense to handle and defend the same.
4. Shares Subject to Plan.
4.1 Maximum Number of Shares Issuable. Subject to adjustment as provided in Sections 4.2, the maximum aggregate
number of shares of Stock that may be issued under the Plan shall be 500,000 and shall consist of authorized but unissued or reacquired
shares of Stock, or any combination thereof. If an outstanding Purchase Right for any reason expires or is terminated or canceled,
the shares of Stock allocable to the unexercised portion of that Purchase Right shall again be available for issuance under the
Plan.
4.2 Adjustments for Changes in Capital Structure. Subject to any required action by the stockholders of the Company and
the requirements of Section 424 of the Code to the extent applicable, in the event of any change in the Stock effected without
receipt of consideration by the Company, whether through merger, consolidation, reorganization, reincorporation, recapitalization,
reclassification, stock dividend, stock split, reverse stock split, split-up, split-off, spin-off, combination of shares, exchange
of shares, or similar change in the capital structure of the Company, or in the event of payment of a dividend or distribution
to the stockholders of the Company in a form other than Stock (excepting regular, periodic cash dividends) that has a material
effect on the Fair Market Value of shares of Stock, appropriate and proportionate adjustments shall be made in the number and kind
of shares subject to the Plan, the Annual Increase, the limit on the shares which may be purchased by any Participant during an
Offering (as described in Sections 8.1 and 8.2) and each Purchase Right, and in the Purchase Price in order to prevent dilution
or enlargement of Participants’ rights under the Plan. For purposes of the foregoing, conversion of any convertible securities
of the Company shall not be treated as “effected without receipt of consideration by the Company.” If a majority of
the shares which are of the same class as the shares that are subject to outstanding Purchase Rights are exchanged for, converted
into, or otherwise become (whether or not pursuant to an Ownership Change Event) shares of another corporation (the “New
Shares”), the Committee may unilaterally amend the outstanding Purchase Rights to provide that such Purchase Rights are
for New Shares. In the event of any such amendment, the number of shares subject to, and the exercise price per share of, the outstanding
Purchase Rights shall be adjusted in a fair and equitable manner as determined by the Committee, in its discretion. Any fractional
share resulting from an adjustment pursuant to this Section shall be rounded down to the nearest whole number, and in no event
may the Purchase Price be decreased to an amount less than the par value, if any, of the stock subject to the Purchase Right. The
adjustments determined by the Committee pursuant to this Section 4.2 shall be final, binding and conclusive.
5. Eligibility.
5.1 Employees Eligible to Participate. Each Employee of a Participating Company is eligible to participate in the Plan
and shall be deemed an Eligible Employee, except the following:
(a)
Any Employee who is customarily employed by the Participating Company Group for twenty (20) hours or less per week; or
(b)
Any Employee who is customarily employed by the Participating Company Group for not more than five (5) months in any calendar
year.
5.2 Exclusion of Certain Stockholders. Notwithstanding any provision of the Plan to the contrary, no Employee shall be
treated as an Eligible Employee and granted a Purchase Right under the Plan if, immediately after such grant, the Employee would
own, or hold options to purchase, stock of the Company or of any Parent Corporation or Subsidiary Corporation possessing five percent
(5%) or more of the total combined voting power or value of all classes of stock of such corporation, as determined in accordance
with Section 423(b)(3) of the Code. For purposes of this Section 5.2, the attribution rules of Section 424(d) of
the Code shall apply in determining the stock ownership of such Employee.
5.3 Determination by Company. The Company shall determine in good faith and in the exercise of its discretion whether
an individual has become or has ceased to be an Employee or an Eligible Employee and the effective date of such individual’s
attainment or termination of such status, as the case may be. For purposes of an individual’s participation in or other rights,
if any, under the Plan as of the time of the Company’s determination of whether or not the individual is an Employee, all
such determinations by the Company shall be final, binding and conclusive as to such rights, if any, notwithstanding that the Company
or any court of law or governmental agency subsequently makes a contrary determination as to such individual’s status as
an Employee.
6. Offerings.
The Plan shall be implemented by sequential
Offerings of approximately six (6) months’ duration or such other duration as the Committee shall determine. Offering Periods
shall commence on or about the fifteenth (15th) days of June and December each year and end on or about the fourteenth (14th) day
of the next December and June, respectively, occurring thereafter. Notwithstanding the foregoing, the Committee may establish additional
or alternative concurrent, sequential or overlapping Offering Periods, a different duration for one or more Offering Periods or
different commencing or ending dates for such Offering Periods; provided, however, that no Offering Period may have a duration
exceeding twenty-seven (27) months. If the Committee shall so determine in its discretion, each Offering Period may consist of
two (2) or more consecutive Purchase Periods having such duration as the Committee shall specify, and the last day of each such
Purchase Period shall be a Purchase Date. If the first or last day of an Offering Period or a Purchase Period is not a day on which
the principal stock exchange or quotation system on which the Stock is then listed is open for trading, the Company shall specify
the trading day that will be deemed the first or last day, as the case may be, of the Offering Period or Purchase Period.
7. Participation in the Plan.
7.1 Initial Participation. An Eligible Employee may become a Participant in an Offering Period by delivering a properly
completed written or electronic Subscription Agreement to the Company office or representative designated by the Company (including
a third-party administrator designated by the Company) not later than the close of business on the Subscription Date established
by the Company for that Offering Period. An Eligible Employee who does not deliver a properly completed Subscription Agreement
in the manner permitted or required on or before the Subscription Date for an Offering Period shall not participate in the Plan
for that Offering Period or for any subsequent Offering Period unless the Eligible Employee subsequently delivers a properly completed
Subscription Agreement to the appropriate Company office or representative on or before the Subscription Date for such subsequent
Offering Period. An Employee who becomes an Eligible Employee after the Offering Date of an Offering Period shall not be eligible
to participate in that Offering Period but may participate in any subsequent Offering Period provided the Employee is still an
Eligible Employee as of the Offering Date of such subsequent Offering Period.
7.2 Continued Participation. A Participant shall automatically participate in the next Offering Period commencing immediately
after the final Purchase Date of each Offering Period in which the Participant participates provided that the Participant remains
an Eligible Employee on the Offering Date of the new Offering Period and has not either (a) withdrawn from the Plan pursuant
to Section 12.1, or (b) terminated employment or otherwise ceased to be an Eligible Employee as provided in Section 13.
A Participant who may automatically participate in a subsequent Offering Period, as provided in this Section, is not required to
deliver any additional Subscription Agreement for the subsequent Offering Period in order to continue participation in the Plan.
However, a Participant may deliver a new Subscription Agreement for a subsequent Offering Period in accordance with the procedures
set forth in Section 7.1 if the Participant desires to change any of the elections contained in the Participant’s then
effective Subscription Agreement.
8. Right to Purchase Shares.
8.1 Grant of Purchase Right. Except as otherwise provided below, on the Offering Date of each Offering Period, each Participant
in such Offering Period shall be granted automatically a Purchase Right consisting of an option to purchase the lesser of (a) that
number of whole shares of Stock determined by dividing the Dollar Limit (determined as provided below) by the Fair Market Value
of a share of Stock on such Offering Date or (b) the Share Limit (determined as provided below). The Committee may, in its discretion
and prior to the Offering Date of any Offering Period, (i) change the method of, or any of the foregoing factors in, determining
the number of shares of Stock subject to Purchase Rights to be granted on such Offering Date, or (ii) specify a maximum aggregate
number of shares that may be purchased by all Participants in an Offering or on any Purchase Date within an Offering Period. No
Purchase Right shall be granted on an Offering Date to any person who is not, on such Offering Date, an Eligible Employee. For
the purposes of this Section, the “Dollar Limit” shall be determined by multiplying $2,083.33 by the
number of months (rounded to the nearest whole month) in the Offering Period and rounding to the nearest whole dollar, and the
“Share Limit” shall be determined by multiplying 250 shares by the number of months (rounded to the nearest
whole month) in the Offering Period and rounding to the nearest whole share.
8.2 Calendar Year Purchase Limitation. Notwithstanding any provision of the Plan to the contrary, no Participant shall
be granted a Purchase Right which permits his or her right to purchase shares of Stock under the Plan to accrue at a rate which,
when aggregated with such Participant’s rights to purchase shares under all other employee stock purchase plans of a Participating
Company intended to meet the requirements of Section 423 of the Code, exceeds Twenty-Five Thousand Dollars ($25,000) in Fair
Market Value (or such other limit, if any, as may be imposed by the Code) for each calendar year in which such Purchase Right is
outstanding at any time. For purposes of the preceding sentence, the Fair Market Value of shares purchased during a given Offering
Period shall be determined as of the Offering Date for such Offering Period. The limitation described in this Section shall be
applied in conformance with Section 423(b)(8) of the Code and the regulations thereunder.
9. Purchase
Price.
The Purchase Price at which each share of
Stock may be acquired in an Offering Period upon the exercise of all or any portion of a Purchase Right shall be established by
the Committee; provided, however, that the Purchase Price on each Purchase Date shall not be less than eighty-five percent (85%)
of the lesser of (a) the Fair Market Value of a share of Stock on the Offering Date of the Offering Period or (b) the
Fair Market Value of a share of Stock on the Purchase Date. Subject to adjustment as provided by the Plan and unless otherwise
provided by the Committee, the Purchase Price for each Offering Period shall be eighty-five percent (85%) of the lesser of (a) the
Fair Market Value of a share of Stock on the Offering Date of the Offering Period or (b) the Fair Market Value of a share
of Stock on the Purchase Date.
10. Accumulation of Purchase Price through Payroll Deduction.
Except as provided in Section 11.1(b)
with respect to a Non-United States Offering, shares of Stock acquired pursuant to the exercise of all or any portion of a Purchase
Right may be paid for only by means of payroll deductions from the Participant’s Compensation accumulated during the Offering
Period for which such Purchase Right was granted, subject to the following:
10.1
Amount of Payroll Deductions. Except as otherwise provided herein, the amount to be deducted under the Plan from
a Participant’s Compensation on each pay day during an Offering Period shall be determined by the Participant’s Subscription
Agreement. The Subscription Agreement shall set forth the percentage of the Participant’s Compensation to be deducted on
each pay day during an Offering Period in whole percentages of not less than one percent (1%) (except as a result of an election
pursuant to Section 10.3 to stop payroll deductions effective following the first pay day during an Offering) or more than
twenty percent (20%). The Committee may change the foregoing limits on payroll deductions effective as of any Offering Date.
10.2
Commencement of Payroll Deductions. Payroll deductions shall commence on the first pay day following the Offering
Date and shall continue to the end of the Offering Period unless sooner altered or terminated as provided herein.
10.3
Election to Decrease or Stop Payroll Deductions. During an Offering Period, a Participant may elect to decrease the
rate of or to stop deductions from his or her Compensation by delivering to the Company office or representative designated by
the Company (including a third-party administrator designated by the Company) an amended Subscription Agreement authorizing such
change on or before the “Change Notice Date.” The “Change Notice Date” shall be a date prior to
the beginning of the first pay period for which such election is to be effective as established by the Company from time to time
and announced to the Participants. A Participant who elects, effective following the first pay day of an Offering Period, to decrease
the rate of his or her payroll deductions to zero percent (0%) shall nevertheless remain a Participant in such Offering Period
unless the Participant withdraws from the Plan as provided in Section 12.1.
10.4
Administrative Suspension of Payroll Deductions. The Company may, in its discretion, suspend a Participant’s
payroll deductions under the Plan as the Company deems advisable to avoid accumulating payroll deductions in excess of the amount
that could reasonably be anticipated to purchase the maximum number of shares of Stock permitted (a) under the Participant’s
Purchase Right or (b) during a calendar year under the limit set forth in Section 8.2. Unless the Participant has either
withdrawn from the Plan as provided in Section 12.1 or has ceased to be an Eligible Employee, suspended payroll deductions
shall be resumed at the rate specified in the Participant’s then effective Subscription Agreement either (i) at the
beginning of the next Offering Period if the reason for suspension was clause (a) in the preceding sentence, or (ii) at the
beginning of the next Offering Period having a first Purchase Date that falls within the subsequent calendar year if the reason
for suspension was clause (b) in the preceding sentence.
10.5 Participant Accounts. Individual bookkeeping accounts shall be maintained for each Participant. All payroll deductions
from a Participant’s Compensation (and other amounts received from a non-United States Participant pursuant to Section 11.1(b))
shall be credited to such Participant’s Plan account and shall be deposited with the general funds of the Company. All such
amounts received or held by the Company may be used by the Company for any corporate purpose.
10.6 No Interest Paid. Interest shall not be paid on sums deducted from a Participant’s Compensation pursuant to
the Plan or otherwise credited to the Participant’s Plan account.
11. Purchase of Shares.
11.1 Exercise of Purchase Right.
(a)
Generally. Except as provided in Section 11.1(b), on each Purchase Date of an Offering Period, each Participant
who has not withdrawn from the Plan and whose participation in the Offering has not otherwise terminated before such Purchase Date
shall automatically acquire pursuant to the exercise of the Participant’s Purchase Right the number of whole shares of Stock
determined by dividing (a) the total amount of the Participant’s payroll deductions accumulated in the Participant’s
Plan account during the Offering Period and not previously applied toward the purchase of Stock by (b) the Purchase Price. However,
in no event shall the number of shares purchased by the Participant during an Offering Period exceed the number of shares subject
to the Participant’s Purchase Right. No shares of Stock shall be purchased on a Purchase Date on behalf of a Participant
whose participation in the Offering or the Plan has terminated before such Purchase Date.
(b)
Purchase by Non-United States Participants for Whom Payroll Deductions Are Prohibited by Applicable Law. Notwithstanding
Section 11.1(a), where payroll deductions on behalf of Participants who are citizens or residents of countries other than
the United States (without regard to whether they are also citizens of the United States or resident aliens) are prohibited by
applicable law, the Committee may establish a separate Offering (a “Non-United States Offering”) covering all
Eligible Employees of one or more Participating Companies subject to such prohibition on payroll deductions. The Non-United States
Offering shall provide another method for payment of the Purchase Price with such terms and conditions as shall be administratively
convenient and comply with applicable law. On each Purchase Date of the Offering Period applicable to a Non-United States Offering,
each Participant who has not withdrawn from the Plan and whose participation in such Offering Period has not otherwise terminated
before such Purchase Date shall automatically acquire pursuant to the exercise of the Participant’s Purchase Right a number
of whole shares of Stock determined in accordance with Section 11.1(a) to the extent of the total amount of the Participant’s
Plan account balance accumulated during the Offering Period in accordance with the method established by the Committee and not
previously applied toward the purchase of Stock. However, in no event shall the number of shares purchased by a Participant during
such Offering Period exceed the number of shares subject to the Participant’s Purchase Right. The Company shall refund to
a Participant in a Non-United States Offering in accordance with Section 11.4 any excess Purchase Price payment received from
such Participant.
11.2 Pro Rata Allocation of Shares. If the number of shares of Stock which might be purchased by all Participants on a
Purchase Date exceeds the number of shares of Stock remaining available for issuance under the Plan or the maximum aggregate number
of shares of Stock that may be purchased on such Purchase Date pursuant to a limit established by the Committee pursuant to Section 8.1,
the Company shall make a pro rata allocation of the shares available in as uniform a manner as practicable and as the Company determines
to be equitable. Any fractional share resulting from such pro rata allocation to any Participant shall be disregarded.
11.3 Delivery of Title to Shares. Subject to any governing rules or regulations, as soon as practicable after each Purchase
Date, the Company shall issue or cause to be issued to or for the benefit of each Participant the shares of Stock acquired by the
Participant on such Purchase Date by means of one or more of the following: (a) by delivering to the Participant evidence
of book entry shares of Stock credited to the account of the Participant, (b) by depositing such shares of Stock for the benefit
of the Participant with any broker with which the Participant has an account relationship, or (c) by delivering such shares
of Stock to the Participant in certificate form.
11.4 Return of Plan Account Balance. Any cash balance remaining in a Participant’s Plan account following any Purchase
Date shall be refunded to the Participant as soon as practicable after such Purchase Date. However, if the cash balance to be returned
to a Participant pursuant to the preceding sentence is less than the amount that would have been necessary to purchase an additional
whole share of Stock on such Purchase Date, the Company may retain the cash balance in the Participant’s Plan account to
be applied toward the purchase of shares of Stock in the subsequent Purchase Period or Offering Period.
11.5 Tax Withholding. At the time a Participant’s Purchase Right is exercised, in whole or in part, or at the time
a Participant disposes of some or all of the shares of Stock he or she acquires under the Plan, the Participant shall make adequate
provision for the federal, state, local and foreign taxes (including social insurance), if any, required to be withheld by any
Participating Company upon exercise of the Purchase Right or upon such disposition of shares, respectively. A Participating Company
may, but shall not be obligated to, withhold from the Participant’s compensation the amount necessary to meet such withholding
obligations.
11.6 Expiration of Purchase Right. Any portion of a Participant’s Purchase Right remaining unexercised after the
end of the Offering Period to which the Purchase Right relates shall expire immediately upon the end of the Offering Period.
11.7 Provision of Reports and Stockholder Information to Participants. Each Participant who has exercised all or part
of his or her Purchase Right shall receive, as soon as practicable after the Purchase Date, a report of such Participant’s
Plan account setting forth the total amount credited to his or her Plan account prior to such exercise, the number of shares of
Stock purchased, the Purchase Price for such shares, the date of purchase and the cash balance, if any, remaining immediately after
such purchase that is to be refunded or retained in the Participant’s Plan account pursuant to Section 11.4. The report
required by this Section may be delivered in such form and by such means, including by electronic transmission, as the Company
may determine. In addition, each Participant shall be provided information concerning the Company equivalent to that information
provided generally to the Company’s common stockholders.
12. Withdrawal from Plan.
12.1 Voluntary Withdrawal from the Plan. A Participant may withdraw from the Plan by signing and delivering to the Company
office or representative designated by the Company (including a third-party administrator designated by the Company) a written
or electronic notice of withdrawal on a form provided by the Company for this purpose. Such withdrawal may be elected at any time
prior to the end of an Offering Period; provided, however, that if a Participant withdraws from the Plan after a Purchase Date,
the withdrawal shall not affect shares of Stock acquired by the Participant on such Purchase Date. A Participant who voluntarily
withdraws from the Plan is prohibited from resuming participation in the Plan in the same Offering from which he or she withdrew,
but may participate in any subsequent Offering by again satisfying the requirements of Sections 5 and 7.1. The Company may
impose, from time to time, a requirement that the notice of withdrawal from the Plan be on file with the Company office or representative
designated by the Company for a reasonable period prior to the effectiveness of the Participant’s withdrawal.
12.2 Return of Plan Account Balance. Upon a Participant’s voluntary withdrawal from the Plan pursuant to Section 12.1,
the Participant’s accumulated Plan account balance which has not been applied toward the purchase of shares of Stock shall
be refunded to the Participant as soon as practicable after the withdrawal, without the payment of any interest, and the Participant’s
interest in the Plan and the Offering shall terminate. Such amounts to be refunded in accordance with this Section may not be applied
to any other Offering under the Plan.
13. Termination of Employment or Eligibility.
Upon a Participant’s ceasing, prior
to a Purchase Date, to be an Employee of the Participating Company Group for any reason, including retirement, disability or death,
or upon the failure of a Participant to remain an Eligible Employee, the Participant’s participation in the Plan shall terminate
immediately. In such event, the Participant’s Plan account balance which has not been applied toward the purchase of shares
of Stock shall, as soon as practicable, be returned to the Participant or, in the case of the Participant’s death, to the
Participant’s beneficiary designated in accordance with Section 20, if any, or legal representative, and all of the
Participant’s rights under the Plan shall terminate. Interest shall not be paid on sums returned pursuant to this Section 13.
A Participant whose participation has been so terminated may again become eligible to participate in the Plan by satisfying the
requirements of Sections 5 and 7.1.
14. Effect of Change in Control on Purchase Rights.
In the event of a Change in Control, the surviving,
continuing, successor, or purchasing corporation or parent thereof, as the case may be (the “Acquiring Corporation”),
may, without the consent of any Participant, assume or continue the Company’s rights and obligations under outstanding Purchase
Rights or substitute substantially equivalent purchase rights for the Acquiring Corporation’s stock. If the Acquiring Corporation
elects not to assume, continue or substitute for the outstanding Purchase Rights, the Purchase Date of the then current Offering
Period shall be accelerated to a date before the date of the Change in Control specified by the Committee, but the number of shares
of Stock subject to outstanding Purchase Rights shall not be adjusted. All Purchase Rights which are neither assumed or continued
by the Acquiring Corporation in connection with the Change in Control nor exercised as of the date of the Change in Control shall
terminate and cease to be outstanding effective as of the date of the Change in Control.
15. Nontransferability of Purchase Rights.
Neither payroll deductions or other amounts
credited to a Participant’s Plan account nor a Participant’s Purchase Right may be assigned, transferred, pledged or
otherwise disposed of in any manner other than as provided by the Plan or by will or the laws of descent and distribution. (A beneficiary
designation pursuant to Section 20 shall not be treated as a disposition for this purpose.) Any such attempted assignment,
transfer, pledge or other disposition shall be without effect, except that the Company may treat such act as an election to withdraw
from the Plan as provided in Section 12.1. A Purchase Right shall be exercisable during the lifetime of the Participant only
by the Participant.
16. Compliance with Securities Law.
The issuance of shares under the Plan shall
be subject to compliance with all applicable requirements of federal, state and foreign law with respect to such securities. A
Purchase Right may not be exercised if the issuance of shares upon such exercise would constitute a violation of any applicable
federal, state or foreign securities laws or other law or regulations or the requirements of any securities exchange or market
system upon which the Stock may then be listed. In addition, no Purchase Right may be exercised unless (a) a registration
statement under the Securities Act shall at the time of exercise of the Purchase Right be in effect with respect to the shares
issuable upon exercise of the Purchase Right, or (b) in the opinion of legal counsel to the Company, the shares issuable upon
exercise of the Purchase Right may be issued in accordance with the terms of an applicable exemption from the registration requirements
of the Securities Act. The inability of the Company to obtain from any regulatory body having jurisdiction the authority, if any,
deemed by the Company’s legal counsel to be necessary to the lawful issuance and sale of any shares under the Plan shall
relieve the Company of any liability in respect of the failure to issue or sell such shares as to which such requisite authority
shall not have been obtained. As a condition to the exercise of a Purchase Right, the Company may require the Participant to satisfy
any qualifications that may be necessary or appropriate, to evidence compliance with any applicable law or regulation, and to make
any representation or warranty with respect thereto as may be requested by the Company.
17. Rights as a Stockholder and Employee.
A Participant shall have no rights as a stockholder
by virtue of the Participant’s participation in the Plan until the date of the issuance of the shares of Stock purchased
pursuant to the exercise of the Participant’s Purchase Right (as evidenced by the appropriate entry on the books of the Company
or of a duly authorized transfer agent of the Company). No adjustment shall be made for dividends, distributions or other rights
for which the record date is prior to the date such shares are issued, except as provided in Section 4.2. Nothing herein shall
confer upon a Participant any right to continue in the employ of the Participating Company Group or interfere in any way with any
right of the Participating Company Group to terminate the Participant’s employment at any time.
18. Notification of Disposition of Shares.
The Company may require the Participant to
give the Company prompt notice of any disposition of shares of Stock acquired by exercise of a Purchase Right. The Company may
require that until such time as a Participant disposes of shares of Stock acquired upon exercise of a Purchase Right, the Participant
shall hold all such shares in the Participant’s name until the later of two years after the date of grant of such Purchase
Right or one year after the date of exercise of such Purchase Right. The Company may direct that the certificates evidencing shares
of Stock acquired by exercise of a Purchase Right refer to such requirement to give prompt notice of disposition.
19. Legends.
The Company may at any time place legends
or other identifying symbols referencing any applicable federal, state or foreign securities law restrictions or any provision
convenient in the administration of the Plan on some or all of the certificates representing shares of Stock issued under the Plan.
The Participant shall, at the request of the Company, promptly present to the Company any and all certificates representing shares
acquired pursuant to a Purchase Right in the possession of the Participant in order to carry out the provisions of this Section.
Unless otherwise specified by the Company, legends placed on such certificates may include but shall not be limited to the following:
“THE SHARES EVIDENCED BY THIS CERTIFICATE
WERE ISSUED BY THE CORPORATION TO THE REGISTERED HOLDER UPON THE PURCHASE OF SHARES UNDER AN EMPLOYEE STOCK PURCHASE PLAN AS DEFINED
IN SECTION 423 OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED. THE TRANSFER AGENT FOR THE SHARES EVIDENCED HEREBY SHALL
NOTIFY THE CORPORATION IMMEDIATELY OF ANY TRANSFER OF THE SHARES BY THE REGISTERED HOLDER HEREOF. THE REGISTERED HOLDER SHALL HOLD
ALL SHARES PURCHASED UNDER THE PLAN IN THE REGISTERED HOLDER’S NAME (AND NOT IN THE NAME OF ANY NOMINEE).”
20. Designation of Beneficiary.
20.1
Designation Procedure. Subject to local laws and procedures, a Participant may file a written designation of a beneficiary
who is to receive (a) shares and cash, if any, from the Participant’s Plan account if the Participant dies subsequent to
a Purchase Date but prior to delivery to the Participant of such shares and cash, or (b) cash, if any, from the Participant’s
Plan account if the Participant dies prior to the exercise of the Participant’s Purchase Right. If a married Participant
designates a beneficiary other than the Participant’s spouse, the effectiveness of such designation may be subject to the
consent of the Participant’s spouse. A Participant may change his or her beneficiary designation at any time by written notice
to the Company.
20.2
Absence of Beneficiary Designation. If a Participant dies without an effective designation pursuant to Section 20.1
of a beneficiary who is living at the time of the Participant’s death, the Company shall deliver any shares or cash credited
to the Participant’s Plan account to the Participant’s legal representative or as otherwise required by applicable
law.
21. Notices.
All notices or other communications by a Participant
to the Company under or in connection with the Plan shall be deemed to have been duly given when received in the form specified
by the Company at the location, or by the person, designated by the Company for the receipt thereof.
22. Amendment or Termination of the Plan.
The Committee may at any time amend, suspend
or terminate the Plan, except that (a) no such amendment, suspension or termination shall affect Purchase Rights previously
granted under the Plan unless expressly provided by the Committee, and (b) no such amendment, suspension or termination may
adversely affect a Purchase Right previously granted under the Plan without the consent of the Participant, except to the extent
permitted by the Plan or as may be necessary to qualify the Plan as an employee stock purchase plan pursuant to Section 423
of the Code or to comply with any applicable law, regulation or rule. In addition, an amendment to the Plan must be approved by
the stockholders of the Company within twelve (12) months of the adoption of such amendment if such amendment would authorize the
sale of more shares than are then authorized for issuance under the Plan or would change the definition of the corporations that
may be designated by the Committee as Participating Companies. Notwithstanding the foregoing, in the event that the Committee determines
that continuation of the Plan or an Offering would result in unfavorable financial accounting consequences to the Company, the
Committee may, in its discretion and without the consent of any Participant, including with respect to an Offering Period then
in progress: (i) terminate the Plan or any Offering Period, (ii) accelerate the Purchase Date of any Offering Period,
(iii) reduce the discount or the method of determining the Purchase Price in any Offering Period (e.g., by determining the
Purchase Price solely on the basis of the Fair Market Value on the Purchase Date), (iv) reduce the maximum number of shares
of Stock that may be purchased in any Offering Period, or (v) take any combination of the foregoing actions.
* * *
IN WITNESS WHEREOF, the undersigned Secretary
of the Company certifies that the foregoing sets forth the Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan as duly
adopted by the Board on March 24, 2020.
|
/s/ Frederick G. Vogt
|
|
Frederick G. Vogt, Corporate Secretary
|
EXHIBIT A
Participating Companies
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics Manufacturing LLC
Iovance Biotherapeutics GmbH
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2023 to Apr 2024